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Abstract 
  Regulation of insulin secretion from the pancreatic β-cell and glucagon secretion from the α-cell is 
vital for the control of normal glucose homeostasis. Dysfunction may lead to some forms of 
Diabetes. Liver kinase B1 (LKB1) is a tumour suppressor that is mutated in the premalignant disorder 
Peutz-Jeghers Syndrome (PJS). PJS is characterised by the formation of polyps in the gastrointestinal 
tract. LKB1 exerts its biological effect via direct phosphorylation of AMP-activated protein kinase 
(AMPK) and related kinases. 
  The incretin hormones glucagon-like-peptide 1 (GLP-1), secreted from proglucagon-expressing 
enteroendocrine L-cells, is involved in the regulation of appetite and glucose homeostasis. 
Therefore, GLP-1 is considered of therapeutic value in the treatment of Type 2 Diabetes. Both LKB1 
and AMPK have been shown to play some role in insulin secretion. However, the role of LKB1 and 
AMPK in proglucagon-expressing cells in regulating GLP-1 secretion and glucose homeostasis has yet 
to be studied in vivo. 
In this study, we investigate how LKB1 contributes to insulin secretion in pancreatic β-cells by 
deleting LKB1 using a β-cell selective Ins1Cre promoter in mice. I also explore the roles of LKB1 and 
AMPKα1α2 in proglucagon-expressing cells including enteroendocrine L-cells of the gut and 
pancreatic α-cells using a proglucagon specific iGluCre promoter.  
Deletion of LKB1 in β-cells resulted in two opposing effects. (1) Glucose tolerance and β-cell mass 
were increased and (2) the cytosolic ATP/ADP and Ca2+ response to glucose was impaired. Despite 
these effects, insulin secretion in vitro remained unaffected. Moreover, deletion of LKB1 resulted in 
amplification of a glutamate-induced signalling pathway. Therefore, ablation of LKB1 amplifies other 
pathways which compensates for impairments in cytosolic and mitochondrial function. 
Deletion of LKB1 in proglucagon-expressing cells has no effect on GLP-1 secretion or glucose 
homeostasis but result in the development of large gastro-duodenal polyps. On the other hand, 
deletion of AMPK from these cells improves glucose tolerance as well as L-cell mass and GLP-1 
secretion. 
Therefore, both LKB1 and AMPK play roles in normal insulin secretion. Targeting inhibition of these 
kinases in β- and L-cells may thus provide a new therapeutic strategy in some forms of Type 2 
Diabetes.
  Table of Contents 
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Chapter 1 
Introduction 
1.1 The Pancreas  
 
1.1.1 The endocrine pancreas 
  The pancreas is a glandular organ vital for nutrient metabolism and digestion. It has both exo- and 
endocrine functions [1] and consists of acinar and ductal cells. The acinar cells secrete enzymes such 
as amylase, trypsin and carboxypeptidase-A to catalyse the breakdown of carbohydrates, lipids and 
proteins [2]. The endocrine pancreas functions independently of exocrine cells and is responsible for 
the regulation of glucose homeostasis by releasing hormones such as insulin, glucagon and 
somatostatin into the blood stream.  The endocrine pancreas is made up of cells (α-, β-, δ-, PP- and ξ-
cells, discussed in more detail later) residing in small clusters known as the islets of Langerhans [3]. 
 
1.1.2 The development of the pancreas 
    During development, the pancreas first becomes morphologically evident on the 26th day after 
gestation in humans and on the 9th day in mice as the epithelial buds emerge, overlaying the dorsal 
aspect of the endodermal gut tube in the duodenal anlage of the foregut [4]. As this is happening, 
the pancreatic buds, which are surrounded by mesenchymal cells,  continue to enlongate and 
change their shape forming branched tubular structures; this process is known as the primary 
transition [5]. 
  The secondary transition lasts from the 12th day of embryogenesis in mouse and the 37th day of 
embryogenesis in humans until birth. The endocrine cell number greatly expands, especially the β-
cells, and rapid branching morphogenesis will occur. As well as this, gene expression in acinar 
enzyme increases and large amounts of rough endoplasmic reticulum (ER) and zymogen granules will 
form [1]. At this stage, endocrine, acinar and ductal cells become fully differentiated [3]. The 
development of the pancreas during embryogenesis is illustrated in Figure 1.1. 
  Disturbances in pancreatic development, though rare, may result in alterations in exocrine or 
endocrine pancreas. Developmental abnormalities in the pancreas are most likely to occur during 
morphogenesis of the foregut or due to mutations of genes such as regulatory factor X (RFX)6, 
Pancreatic duodenum homobox-1 (PDX1) and pancreas transcription factor 1 alpha subunit (PTF1A) 
[6]. 
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Figure 1.1 - Overview of organogenesis of the pancreas 
(A)  By embryonic days (e) 9-22.5 the dorsal and ventral pancreatic epithelium evaginate into the 
adjoining mesenchyme. The pancreatic epithelium is made up of a multi-layered core containing 
unpolarised cells that are submerged by the basement membrane. Blood vessels surround the 
epithelial buds but have not yet penetrated. (B) By e12.5, the outer tip (green) layer of the 
epithelium forms branch protrusions and the primitive plexus forms in the trunk where newly 
polarised cells are organised into rosettes surrounding the lumen (purple). At this point, blood 
vessels intercalate into the epithelium and come into contact with the cells at the trunk. (C) At e15.5, 
the luminal plexus becomes a single-layered epithelium which consists of branched primitive ducts 
and acinar cells. Ngn3-expressing endocrine precursors (orange) migrate from the progenitor cords 
and form the endocrine clusters. Blood vessels become intercalated between the pancreatic ductal 
tree and the nascent branches. (D) Mature pancreas: acinar cells cap the endings of small terminal 
ducts and form functional exocrine secretory units. Islets of Langerhans are formed and endocrine 
cells become clustered and penetrated by the a dense network of blood vessels  [3]. 
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1.1.3 Islets of Langerhans  
  The endocrine pancreas is formed by five different cell types aggregated to resemble ‘islands’, 
known as the “Islets of Langerhans”, named after the German anatomist Paul Langerhans in 1869 
[7]. These cell types are; the β-cells (65-80% of total islet cells) which produce the hormone insulin, 
the α-cells (15-20%), which produce the hormone glucagon, the δ-cells (3-10%) which produce the 
hormone somatostatin (3-10%) , the PP cells (3-5%) producing pancreatic polypeptides and the ξ-
cells (<1%)  producing the hormone ghrelin [8]. The structure of the pancreas and the Islets of 
Langerhans is illustrated in figure 1.2. Islets have a dense network of sinusoidal capillaries: larger 
islets receive blood from one to three afferent arterioles and the capillaries of smaller islets are 
integrated with exocrine capillaries [9]. Islets tend to have an oval or clover-leaf shape indicating a 
complex pattern of subunits. It has been suggested  that in rodents blood flows from within the core 
of islets outwards going from β- to α- to δ- cells (“B-A-D” pathway) [9]. Whether this pathway exists 
in humans remains unclear, although it has been suggested that β-cells are perfused before non-β 
cells indicating an opposite path of microcirculation [10]. Other studies suggest that blood enters at 
the arterial pole of the islet and travels through the islet capillaries to the venous pole in humans 
[11].  As the different cell types in the islet are located in specific locations, the pattern of blood flow 
within the islet can impact on the ability of cells to communicate with each other within the islet 
[11].  
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Figure 1.2 - The localisation and anatomy of the pancreas and the islets of Langerhans  
In humans, the pancreas is situated behind the stomach (outlined with dashed line). Exocrine acinar 
cells secrete enzymes for the breakdown of carbohydrates, proteins and lipids and the endocrine 
pancreas contains clusters of cells known as the Islets of Langerhans (magnified section). These cells 
include, glucagon secreting α-cells and insulin secreting β-cells. Islets are surrounded by a thick 
network of capillaries where hormones are secreted into the blood stream [3]. 
 
1.2 The β-cell and glucose stimulated insulin secretion 
 
1.2.1 The pancreatic β-cell 
 
  The primary function of the pancreatic β-cell is in the secretion of insulin in response to nutritional, 
hormonal and nervous stimuli in order to maintain homeostatic plasma glucose levels. This ensures 
that glucose is efficiently taken in and stored (as glycogen) by peripheral tissues (e.g. muscle, 
adipose tissue). The full mechanism of glucose-stimulated insulin secretion is explained in full later in 
this chapter. In brief, increasing glucose concentrations in the blood initiates the transport of glucose 
into the β-cell, stimulating the generation of ATP and Ca2+ influx into the cell via the closure of 
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voltage-gated K+ channels and opening of Ca2+ channels. This Ca2+ influx stimulates insulin exocytosis 
from the β-cell [12].   
  Each individual β-cell contains 10,000-13,000 secretory granules [13] with an average diameter of 
350nm. These granules contain an electron-dense Zn2-insulin6 crystal, 105 mol of insulin [14] and 
roughly another 50 polypeptides. Some of these polypeptides will have biological functions, for 
example the islet amyloid polypeptide (IAPP), responsible for decelerating gastric emptying, and 
chromogranin A which promotes the generation of secretory granules. Several low-molecular weight 
compounds are stored in these granules such as adenosine triphosphate (ATP), γ-aminobutyric acid 
(GABA), serotonin and glutamate as well as metal ions including Ca2+ and Zn+ [15]. 
1.2.2 The insulin granule 
  Insulin plays a fundamental role in glucose homeostasis throughout the entire body. In humans, 
insulin is synthesised as a 110 amino acid precursor, known as preproinsulin, in the rough ER of the 
β-cell [12]. After the removal of a 24 residue signal sequence and packaging in the golgi body, insulin 
becomes stored as proinsulin in immature secretory granules. Pro-insulin is converted into its 
mature form of insulin and c-peptide via Ca2+-dependent endoproteases, proprotein convertases 
(PC)1-2 and the exoprotease, carboxypeptidase H (CPH), which is a carboxypeptidase B-type 
metalloprotease that removes the COOH-terminus from peptide precursors [16, 17]. This process of 
insulin granule maturity is illustrated in figure 1.3. Mature insulin can be stored for days before being 
secreted from the β-cell or degraded by crinophagia (destruction by lysosomes) [18]. The last of the 
granules to be generated are the ones most likely to be secreted when β-cells are stimulated, 
however the reason for this remains unclear [19, 20].  
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Figure 1.3 - Formation of preproinsulin and the insulin granule 
Preproinsulin is converted to proinsuiln after the removal of the N-terminal in the ER where it is 
folded and oxidised. Proinsulin is then transported via transport vesicle to the golgi apparatus where 
it is packaged into insulin storage granules. Protein convertase 1/2 and carboxypeptidase H cleaves 
proinsulin into mature insulin and C-peptide, ready for release upon stimulation. This figure was 
partially generated using “Servier Medical Art” (http://www.servier.com/servier-medical-art) [21]. 
 
1.2.3 Glucose sensing and phosphorylation in the β-cell 
  The study of glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells was introduced in 
the 1960s after the production of insulin radioimmunoassays (RIA) [22]. Two hypothesis exist as to 
how GSIS occur; (1) putative cell surface receptor analogues will bind both hormones and 
neurotransmitters and (2) the model known as the “fuel hypothesis” which proposes that insulin 
secretion is mediated via the metabolism of sugar [23]. It is now largely believed that the latter 
hypothesis is the primary mediator of insulin secretion [24]. This theory is supported by the fact that 
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insulin secretion after a rise in blood glucose concentration is accompanied by elevated glucose 
utilisation and oxidation [25], and that the inhibition of glucose consumption results in the inhibition 
of insulin secretion [22]. Furthermore, non-metabolic glucose analogues are ineffective in 
stimulating insulin secretion, whilst metabolic amino acids, e.g. glutamate, leucine and certain 
branched chain amino acids such as heto-isocaproate , are potential secretagogues [26]. 
  Pancreatic β-cells express, predominantly, the glucose transporter isoform 2 (GLUT2) [27]. It 
remains contested whether other GLUT isoforms, such as GLUT1 or 3, play an equal or more 
important role than GLUT2 in human β-cells [28]. GSIS is initiated by the rapid movement of glucose 
across the β-cell membrane; phosphorylation, in comparison, is thought to be a slow and rate-
limiting step [29]. Glucose is phosphorylated to form glucose-6-phosphate (G6-P) by glucokinase 
(GK), thereby promoting glycolysis [30]. GK is a type IV hexokinase [31] and presents strongly 
cooperative kinetics. Given its flux-generating role in β-cells glycolysis, GK has been dubbed “The β-
cell glucose sensor”. Inactivation of the GK gene in β-cells in mice leads to impaired glucose 
sensitivity and decreased insulin release in vivo [32, 33]. In man, inactivating mutations in the GK 
gene leads to maturity-onset diabetes of the young (MODY2)[34]. The full process of GSIS in the 
pancreatic β-cell is represented in the schematic shown in figure 1.4 and described in more detail in 
later sections. 
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Figure 1.4 - GSIS of the pancreatic β-cell 
Increasing concentrations of extracellular glucose initiate the transport of glucose into the cell through 
glucose transporter 1/2 and is phosphorylation to glucose-6-phosphate via glucokinase (1.2.3). After 
glycolysis, pyruvate enters the mitochondria where ATP is generated through the citrate cycle (1.2.5). 
This up-regulation of ATP in the cytosol results in closure of KATP channels and depolarisation of the 
cell (1.2.6). Voltage gated L-type Ca2+channels will open, resulting in an influx of Ca2+ into the cytosol 
and triggering insulin exocytosis (1.2.7). The figure was generated using images from “Servier Medical 
Art”. (http://www.servier.com/servier-medical-art). 
Citrate 
Cycle 
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1.2.4 Biphasic insulin secretion 
  Insulin secretion in response to high glucose concentrations takes place in a biphasic manner. The 
two stages consist of (1) transient secretion, (which is dependent on a rise in [Ca2+]cyt) causing a rapid 
and short insulin secretion and (2) a longer lasting second phase [35]. Additional signals are necessary 
for this second phase to occur, in particular an “amplifying pathway” (known as KATP-channel 
independent stimulation of insulin secretion) [36]. The second phase of insulin secretion involves the 
supply of new insulin granules for release by ATP- and time-dependent granule preparation and is a 
rate-limiting step of insulin exocytosis [37]. 
  The exact mechanisms (and coupling factors) involved in the stimulation of the second phase of 
insulin secretion remains uncertain in both human and rodent β-cells [38]. As mentioned above, this 
phase exhibits a dependency on Ca2+ [39, 40] as well as a strong tetrodotoxin-sensitive sodium 
conductance, in humans from voltage-gated Na+(Nav1.6/Nav1.7)- channels which contribute to the 
firing of action potentials in β-cells [41]. 
1.2.5 Metabolic activation of mitochondria 
  ATP is the primary metabolic factor during GSIS, causing closure of KATP channels leading to Ca2+ 
elevation and insulin exocytosis [42]. Mitochondria generates metabolic signals and allows the 
generation of ATP which is necessary for the elevation of [Ca2+]cyt and insulin secretion during 
processes known as the citrate/ krebs cycle and the electron transport chain (ETC). The role of 
mitochondria in β-cell stimulus-secretion coupling is discussed in more detail below.  
1.2.5.1 The Krebs/ Citrate cycle 
  After glycolysis takes place in the cytoplasm (1.2.3) of pancreatic β-cells, pyruvate enters the 
mitochondria resulting in depolarisation of the mitochondrial membrane [43] (Figure 1.4). After its 
entry into the mitochondria, pyruvate loses either a carbon to generate acetyl-CoA or gain a carbon 
to form oxaloacetate (catalysed via pyruvate dehydrogenase (PDH) [44] and pyruvate carboxylase 
(PC), respectively [45]). 4-carbon oxaloacetate then enters the krebs/ citrate cycle where citrate is 
generated via condensation of the 2-carbon acetyl group of acetyl CoA catalysed by citrate synthase 
[45].  
1.2.5.2 The Electron transport chain 
  The citrate cycle extracts reducing equivalents from the metabolic intermediates of this cycle, using 
these to generate NADH and FADH2 for oxidation by the ETC. The ETC consists of five complexes such 
as; Complex I (the electron acceptor/ NADH dehydrogenase), Complex II (succinate dehydrogenase) 
which transfers electrons to coenzyme-Q from FADH2, and Complex V which catalyses ATP formation. 
ATP and glycerol 3-phosphate dihydrogenase is then translocated to the cytosol via the adenine 
  Chapter 1 - Introduction 
27 
 
nucleotide translocator (ANT) in exchange for adenosine diphosphate (ADP). NADH electrons are 
transferred to the ETC to supply the energy needed for the proton electrochemical gradient that drives 
ATP synthesis. Enhanced NADH generation during GSIS thus follows increased glucose metabolism and 
results in mitochondrial hyperpolarisation [46] 
 Complex 1 causes continued reoxidation of mitochondrial NADH to NAD+ to maintain a reduced redox 
state in order to maintain pyruvate input to the citrate cycle during glucose stimulation. However, 
complex I activity is restricted by the inherent thermodynamic constraints of proton gradient 
formation [47] and so additional NADH are reoxidised via other dehydrogenases such as through 
cataplerotic functions (confirmed by use of NMR spectroscopy) [48]. 
  The reducing equivalents cause hyperpolarisation of the mitochondrial membrane as well as 
generation of ATP. Electrons are transferred by NAD+ and FAD, in the mitochondrial membrane of 
note, several citrate cycle dehydrogenases are activated via Ca2+ [49]. This stimulation may contribute 
to the sustained stimulation of ATP synthesis and insulin release [50]. 
1.2.6 ATP-sensitive K+ channels  
  The ATP-sensitive K+ channel (KATP) is a hetero-octameric protein comprising a channel-forming 
subunit (Kir6.2) and a larger transmembrane protein which is part of the “ABC cassette family”. 
These subunits are encoded in β-cells by the K+ channel, Inwardly Rectifying Subfamily J, Member 
11 (KCNJ11) and the sulphonylurea receptor 1 (SUR) genes [51-53]. When glucose levels in plasma 
are low, KATP channels are open, thereby allowing K+ to exit the cell and maintaining resting 
membrane potential at a hyperpolarised level (~-70mV) [54]. 
  Generation of ATP from the mitochondria results in closing KATP channels and suppresses K+ ion 
efflux. This leads to depolarisation of the plasma membrane [55] and the firing of action potentials 
resulting in a decrease in voltage and the opening of voltage-sensitive, L-type Ca2+ channels. This, in 
turn, will increases cytosol free Ca2+ ([Ca2+]cyt) concentrations [56]. The latter surge in [Ca2+]cyt 
concentrations is the main trigger for insulin exocytosis (1.2.7) [57]. 
  As well as pancreatic β-cells, KATP channels have been found in a variety of cell types  including 
pancreatic α-cells, intestinal L-cells, cardiac muscles, brain, kidneys, skeletal and smooth muscles 
[55]. Therefore, any mutations in KATP channels may affect multiple systems leading to diseases such 
as Diabetes, Epilepsy and Neurodevelopment [58]. 
  In β-cells with mutations in SUR1 (and therefore lacking KATP channels), glucose readily promotes 
insulin release and there was no apparent defects in K+ or Ca2+ voltage-gated channels [59]. Which 
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indicates that the sustained release of insulin depends particularly on the activation of KATP channels, 
but is dependent on metabolic factors. Nonetheless an elevation of [Ca2+]cyt is required to observe 
significant rates of insulin release [36].  
1.2.7 Insulin exocytosis 
  Exocytosis of insulin from the β-cell is dependent on increases in [Ca2+]cyt. L-type Ca2+ channels form 
tight complexes with the secretory granule to ensure high exposure of [Ca2+]cyt  [60]. However, low-
affinity Ca2+ sensor allows exocytosis when [Ca2+]cyt levels are relatively low [61, 62].   
  The process of insulin release from their secretory vesicles relies on intracellular ATP and the 
translocation of vesicles to the cells surface before they fuse with the plasma membrane. The 
pancreatic β-cell is of neuroendocrine origin, therefore exocytosis of insulin bears a strong 
resemblance to the release of neurotransmitters in synapses and many SNAP 
(Soluble NSF Attachment Protein) receptor (SNARE) proteins which are vital for synaptic vesicle 
release are also expressed in the β-cell [63].  This includes the t-SNAREs syntaxin 1 and synaptosomal-
associated protein (SNAP)-25 [64] which concentrate in cholesterol-rich membrane regions, causing 
removal of cholesterol from the plasma membrane using methyl-β-cyclodextrin (MBCD) inhibits 
insulin secretion and exocytosis [65]. Phosphorylation of SNAP-25 via protein kinase C (PKC) has been 
found to induce exocytosis in insulin-secreting cell lines [66]. High concentrations of cyclic adenosine 
monophosphate (cAMP) (<10 µM) has been found to enhance insulin exocytosis through a PKA-
independent mechanism [67, 68], therefore SNAP-25 plays a key role in the adjustment of β-cell 
exocytosis over a range of cAMP concentrations [57].  
  As mentioned above, GSIS occurs in two phases, during the first phase of insulin secretion, granules 
are pre-docked on the plasma membrane in what are referred to as the ‘readily releasable pool’ (RRP) 
and are fused rapidly (Figure 1.5). Granules deeper within the cell, known as the ‘storage granule 
pool’s move to the periphery of the cell in order to replenish RRP at the cells surface [69, 70]. The RRP 
make up a small pool, approximately 50-200 β-cells and <10,000 mature insulin granules [71]. 
Replenishment of RRP takes place during the first phase with the mobilisation, docking and priming of 
previous non-RRP to support the second phase of insulin secretion [69]. Note, however, that this 
relatively simple model based in part on electrophysiological approaches including capacitance 
measurements [72] has been questioned by measurements using total internal reflection of 
fluorescence (TIRF) measurements which suggest that “deeper” granules also contribute to first phase 
insulin secretion [73].  
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Figure 1.5 – Insulin exocytosis from the β-cell 
During the first phase of insulin secretion, insulin granules are pre-docked on the plasma membrane, 
these granules are known as the readily releasable pool (RRP) and fuse rapidly with the plasma 
membrane before insulin secretion via exocytosis [72]. 
 
1.2.8 Disallowed genes 
  Several β-cell specific genes are essential for β-cell function and GSIS, when mutated lead to 
abnormalities in insulin secretion and some forms of diabetes. Examples of these genes include; GK 
[74], pancreatic duodenum homeobox-1 (PDX1) [75] and ATP-binding cassette transporter sub-family 
C member 8 (ABCC8) [76]. These genes are known as “allowed/ β-cell specific genes”. In recent years, 
it has become apparent that alongside the expression of these “allowed/ β-cell specific genes” the 
repression or silencing of certain genes known as “disallowed genes” [77] which are normally 
expressed in all other cell types are important for normal β-cell action .  
  Examples of “disallowed genes” include; monocarboxylate/ lactate transporter (MCT-1) [78] and 
lactate dehydrogenase (LDHA) [79]. Expression of these genes is reduced in β-cells in comparison to 
α-cells and the liver. Both these enzymes play key “housekeeping” roles in the majority of cell types, 
therefore it seems likely that their suppression in β-cells is a requirement for normal GSIS and/or β-
cell survival [80]. In other tissues MCT1 and LDHA are vital for anaerobic production of lactate and is 
therefore critical for cell survival when at low oxygen concentrations [81]. Due to the absence of these 
enzymes from the β-cell, compensatory mechanisms must be present to ensure that glucose is 
sufficiently oxidised and circulation of metabolites, such as lactate, cannot stimulate insulin release 
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[80]. Expression of glycerol phosphate dehydrogenase which creates an alternative metabolic fate (via 
mitochondrial oxidation at complex II of the respiratory chain reaction) for NADH production during 
glycolysis [82, 83] was found in β-cells. As well as in β-cells, low expression of LDHA was also found in 
other oxidative cell types such as insect flight muscle cells, empathising the likely role of oxidative 
metabolism and ATP production in coupling glucose metabolism to insulin secretion [84]. Studies have 
confirmed that β-cells produce very little pyruvate [45, 83] and that the CO2 needed for lipid and amino 
acid synthesis is obtained via pyruvate carboxylase, acting to “top-up” the citrate cycle [80]. 
  Overexpression of Mct-1 and Ldha selectively in β-cells has been found to greatly impair GSIS in both 
MIN6 cells and isolated islets [85-87], supporting the importance of these genes. In Type 2 Diabetes, 
up-regulation of disallowed genes were identified in β-cells [88] for example, Acyl-coA thioesterase 
(Acot) 7 and Nuclear factor I/B (Nfib) [80]. Furthermore, up-regulation of several disallowed genes has 
been observed in β-cell enriched tissue for Type 2 Diabetic patients [89]. Modulation of some of these 
genes may provide a new therapeutic target for some forms of Type 2 Diabetes as well as contribute 
to the development of new sources of transplantable β-cells for Type 1 Diabetes.  
1.2.9 Type 2 Diabetes 
  Both Type 1 and 2 Diabetes are diseases associated with malfunctions of the endocrine pancreas 
resulting in uncontrolled hyperglycaemia. Whilst the development of Type 1 Diabetes is due to 
autoimmune destruction of pancreatic β-cells, Type 2 Diabetes occurs during early insulin resistance 
and the failure of β-cells to compensate for the resulting hyperinsulinemia. The most successful 
therapy for uncontrolled hyperglycaemia is the use of insulin injection in Type 1 diabetes and in the 
later stages of Type 2 diabetes. Insulin was first introduced as a treatment in 1922 by Frederick Banting 
and Charles Best. However, a permanent “cure” for diabetes is yet to be discovered. In the early stages 
of Type 2 Diabetes disease progress can be delayed with exercise and improved diet.  
  It is believed that several factors including genetic components, the fetal environment and the 
nutritional environment in early life are all critical factors affecting the functional β-cell mass and 
susceptibility to diabetes in adult life. Obesity-induced insulin resistance occurs when insulin demand 
increases, resulting in an increase in insulin secretion and β-cell mass.  Chronic exposure of 
hyperglycaemia to β-cells leads to the loss of β-cell function and dedifferentiation due to 
glucolipotoxicity and β-cell death [90]. Mechanisms for measuring β-cell mass in vivo remain to be 
established [91, 92]. Therefore, measurements rely chiefly on histological analysis of pancreas 
obtained post mortem. As insulin resistance and hyperinsulinemia are enhanced in patients with Type 
2 Diabetes it is assumed that β-cell mass will also increase. However, histological analysis has shown 
that β-cell mass decreases by approximately 65% in obese patients with Type 2 Diabetes in comparison 
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to non-diabetics with matching body mass index (BMI) [93, 94]. Apoptosis of β-cell is enhanced in Type 
2 Diabetes [95], whereas β-cell replication and neogenesis is unchanged, indicating that the main 
cause of declining β-cell mass is β-cell loss.  
  Various mechanisms that initiate β-cell loss have been suggested for this reduction in β-cell mass 
such as hyperglycaemia (glucotoxicity), fatty acids (lipotoxicity), oxidative stress, mitochondrial 
dysfunction, ER stress and dedifferentiation of β-cells.  
1.2.9.1 Mechanisms of β-cell loss 
  Chronic hyperglycaemia (glucotoxicity) leads to enhanced glucose metabolism via oxidative 
phosphorylation, causing mitochondrial dysfunction and the production of reactive oxygen species 
(ROS) which may damage cell structure [96]. 
  Due to the abundance of ROS in the islet in response to high concentrations of glucose, and the low 
expression of anti-oxidant enzyme defence mechanisms, β-cells are highly susceptible to oxidative 
stress. Thus antioxidant enzymes such as, superoxide dismutase 1 and 2 (SOD1-2), glutathione 
peroxide 1 (GPX1) and catatase (CAT) are more weakly expressed in islets in comparison to other 
tissues [97]. In addition, islets have a poor DNA repair capacity against oxidative stress [98]. In patients 
with Type 2 Diabetes, markers of oxidative stress were found to be significantly up-regulated in 
comparison to healthy controls, levels of expression of these markers positively correlate with the 
degree of impairment in insulin secretion [99, 100]. 
  Oxidative stress is a critical factor in the induction of β-cell dysfunction. Isolated islets exposed to 
high glucose concentrations resulted in an increase in intracellular levels and reduction of insulin 
content and secretion [101]. In contrast, β-cell function in the leptin deficient db/db mouse model and 
islets isolated from diabetic mice when treated with antioxidant agents was found to improve function 
[99, 100]. 
  The mechanism by which ROS reduce β-cell mass and function remains unclear. Oxidative stress 
results in a decrease in the transcription of the insulin gene by decreasing MaFA and PDX1 binding 
activity to the insulin gene [102]. ROS will also activate stress inducing pathways such as, NF-κB, JNK 
and mexosamine pathways which affect insulin gene expression [103]. Oxidative stress can also lead 
to the induction of ER stress [104] and trigger the formation of the inflammasome complex. 
  These studies indicate that ROS play and important role in the impairment of β-cell function during 
hyperglycaemia. However, it is important to note that ROS may also be required for normal β-cell 
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function. Low concentrations of H2O2 in INS1 cells and mouse islets increase GSIS at low concentrations 
of glucose [105].  
1.2.9.2 Treatment and prevention of Type 2 Diabetes   
  The best proposed treatment for Type 2 Diabetes emphasises on improving the lifestyle of the patient 
by reducing body weight which in turn cuts down on the β-cell workload. Prior to the introduction of 
metformin treatment in 1995 (which prevents hepatic gluconeogenesis), the only oral anti-
hyperglycaemia drugs available which target the β-cell were sulfonylureas. Sulfonylureas work by 
binding to the SUR1 on the β-cell resulting in closure of K+ATP channels and subsequent insulin secretion 
[106]. There are indications that sulfonylurea treatment may be associated with heart failure since 
patients on high doses of sulfonylurea were admitted to hospital for heart failure more than patients 
receiving metformin treatment [107].  
  Glucose like peptide (GLP)-1 analogues have been found to up-regulate GSIS and β-cell mass in 
rodents by activating the mitogen activated protein kinase (MAPK) and PKC pathways inducing β-cell 
proliferation [108]. In human islets GLP-1 inhibits β-cell apoptosis [109], however has no effect on β-
cell mass. GLP-1 is discussed in more detail in section 1.7 later in this chapter. 
  A greater understanding of the mechanisms and function of GSIS and β-cell mass are needed to 
develop more efficient targets for treating Type 2 Diabetes.             
                                                                                                                                                                                                                                                   
1.3  Glucagon and the α-cell 
 
  Glucagon is a 29-amino acid peptide hormone is secreted by the pancreatic α-cell [110]. Glucagon 
has a strong stimulatory effect on hepatic glucose production, resulting in a surge in blood glucose 
levels [111] and acts as a counter-regulatory hormone to insulin. The balance between insulin and 
glucagon is important for normal glucose homeostasis [112]. Dysfunction in this balance may lead to 
some forms of diabetes. 
1.3.1 Discovery and production 
  The term hyperglycaemia was defined in 1922 after secretion extracts were taken from the pancreas 
and an unknown substrate separated, this substrate was injected into dogs resulting in a surge of 
blood glucose. These finding lead to the discovery of a second pancreatic hormone which was later 
termed glucagon  [111]. Glucagon, GLP-1, GLP-2 and glicentin are all encoded by the preproglucagon 
gene. The structure of this preproglucagon gene was established in 1983 [113], with 160 amino acids 
and it is expressed predominantly in the central nervous system (CNS), L-cells and pancreatic α-cells. 
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In α-cells, maturation of the preproglucagon hormone occurs by a post-translational cleavage by 
prohormone convertase (PHC) 2 [114]. The main products of this cleavage are  glucagon and glucagon 
related polypeptides [115].  
1.3.2 Glucagon in development 
  α-cell granules containing glucagon, are formed in the pancreas during evagination from the foregut 
[116] and are similar to that of the adult pancreas [117], suggesting that glucagon plays a role in 
growth and differentiation of early embryonic development [116]. Evidence for this has been obtained 
in in vitro studies of cultured pancreas suggesting that glucagon is needed in the early formation of 
insulin cells (E11-13) but not in the later E15 pancreas. 
1.3.3 Glucagon secretion from the α-cell 
  Glucose transporter 1 (GLUT1) mRNA and protein has been detected in rodent α-cells , rather than 
GLUT2 which is chiefly expressed in β-cells [118]. Overall, rates of glucose transport are 10-fold lower 
in α- than β-cells [118]. Activity of GK in α-cells is similar to that of β-cells with its main role being as a 
metabolic glucose sensor [119]. Hexokinase IV is also expressed in α-cells and is involved in the sensing 
of low glucose concentrations [119]. Glycolytic flux in the β-cell is aerobic but is anaerobic in the α-
cell [45]. Therefore, glucose induces smaller changes in cytoplasmic ATP [120-122], NADPH [123] and 
FAD [124] in α- than β-cells. However, glucose metabolism is necessary for glucose recognition as 
glucose-inhibited glucagon release is mimicked via a GK activator, and secretion is not affected by a 
non-metabolisable glucose analogue [125].                    
  In the absence of glucose, α-cells become electrically active and display Ca2+ oscillations which initiate 
glucagon exocytosis. Action potentials start at more negative potentials in α- than in β-cells due to the 
presence of T-type Ca2+ channels, which activate at -60mV and tetrodotoxin (TTX)-sensitive Na+ 
channels that activate at potentials more positive than -30mV [126, 127]. As with β-cells, the action 
potential in α-cells leads to the opening of L- and N-type Ca2+ channels [128]. These channels 
contribute to the majority of Ca2+ entry into α-cells. However, the relationship between cytosolic 
[Ca2+]cyt and glucagon secretion in α-cells is less clear than for insulin secretion in β-cells. These 
channels in the α-cell are illustrated in Figure 1.6.  
  In rodents, L-type Ca2+ channels act as the dominant channel (80%). However when these channels 
are inhibited in α-cells, there is little effect on glucagon secretion [128]. By contrast, inhibitors of non-
L-type channels despite having little effect on [Ca2+]cyt inhibit glucagon secretion as efficiently as if 
glucose was elevated to 6mM [128-130]. This may be due to the close association between non-L-type 
Ca2+ channels and the secretory granules [131]. In human α-cells, non-L-type channels open very 
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briefly and mediate only a small fraction of Ca2+ entry [132]. In the presence of adrenaline, Ca2+ entry 
into the α-cell occurs through L-type channels and strongly triggers glucagon secretion [130, 133]. 
Importantly, glucose inhibition of glucagon secretion is associated with small changes of [Ca2+]cyt 
signalling [123] suggesting that other signals or microdomains of [Ca2+] are important in triggering 
exocytosis in these cells.   
1.3.3.1 KATP channel-dependent glucose sensing 
  It has been suggested that an increase in glucose concentration in the α-cell increases [ATP/ADP]cyt 
resulting in KATP channel closure. However, unlike the situation in β-cells, depolarisation causes 
inhibition of secretion from α-cells. KATP channel conduction is low when α-cells are exposed to high 
glucose concentrations. High threshold voltage-dependent channels will only trigger exocytosis if low-
threshold voltage-dependent channels are opened. These low-threshold voltage-dependent channels 
undergo inactivation upon sustained depolarisation [123, 126]. Therefore, closure of KATP channels in 
response to glucose-induced ATP formation leads only to a small degree of depolarisation, which is 
unable to open voltage-dependent Ca2+ channels. Instead this sustained depolarisation inactivates low 
threshold T-type Ca2+ and Na+ channels.  
  In the above model, change in glucagon secretion depends on the frequency and amplitude of action 
potentials and implies that these cause glucagon secretion under a narrow window of membrane 
potentials. Action potentials are prevented by sustained depolarisation which inactivates the T-type 
Ca2+ channels. KATP channel closure, and slight depolarisation, at high glucose mimic the inhibitory 
effect of glucose [129, 134], and weaker hyperpolarisation with low concentrations of the KATP channel 
opener diazoxide causes glucose inhibition of glucagon secretion. Additionally, more prominent 
hyperpolarisation inhibits glucagon secretion [129, 135]. Notably, the inhibitory effect of glucose is 
lost following functional knock-out (KO) of the KATP channel [134, 135]. 
  Although quite widely accepted, there is evidence that question this model of KATP channel 
dependent glucagon secretion. For example, though glucose decreases [Ca2+]cyt in α-cells, several 
studies show that KATP channel closure by sulfonylureas leads to β-cell like [Ca2+]cyt elevations instead 
of the expected decrease [123, 125, 136, 137]. Also, glucose maintains its inhibitory effect on glucagon 
secretion when KATP channels are closed in the presence of high sulfonylurea concentrations [138] and 
this is associated with a lowering of [Ca2)]cyt [123, 138]. Glucose was found to maintain its inhibitory 
effect on glucagon secretion in islets blocked for the KATP channel using tolbutamide [125, 139]. 
Tolbutamide prevents glucagon secretion via two mechanisms 1) direct stimulation of α-cells and 2) 
indirect inhibition of somatostatin secretion from δ-cells [140]. Thus, tolbutamide effect is reinforced 
  Chapter 1 - Introduction 
35 
 
by the disruption of somatostatin signalling which eradicates its inhibitory effect on glucagon secretion 
[125]. 
  The fact that glucose depolarises the α-cell has also been met with disagreement. 
Electrophysiological measurements have suggested that both depolarising [134] and hyperpolarising 
[126, 141, 142] effects occur. This may be related to the increased input resistance of small α-cells 
[126], therefore the potential is sensitive to small currents which may be due to the invasive 
approaches carried out on these cells. When using dye-based techniques that are not invasive, α-cells 
were found to hyperpolarise after glucose stimulation [143]  
1.3.3.2 Ca2+ dependent glucose sensing 
  As discussed above, lack of glucose results in the opening of voltage-dependent Ca2+ channels and 
the entry of Ca2+ that will trigger glucagon secretion from α-cells [126, 137]. In guinea-pig α-cells, 
adrenaline causes mobilisation of glucose-incorporated Ca2+ due to ATP-energised Ca2+ sequesteration 
into the ER which lowers [Ca2+]cyt [144]. However, the ER has a limited capacity for Ca2+ sequesteration 
suggesting that use of uptake and release is only temporary. 
  Due to this temporary nature of the above mechanism, a store-operated mechanism made of Ca2+ 
influx is involved. Thus, Ca2+ store depletion has been suggested to trigger depolarisation and lead to 
Ca2+ influx. This depolarising current is minor causing only moderate [Ca2+]cyt elevation [137, 145, 146] 
and nonetheless activation of this current after sarco(endo)plasmic Ca2+ ATPase (SERCA-pump) 
inhibition exerts a pronounced effect on [Ca2+]cyt  in α-cells [137], resulting in glucagon release but 
minor changes in β-cells [138, 147]. The higher sensitivity to SERCA subunit of α-cells is probably due 
to their higher input resistance [137], causing the membrane potential to be more sensitive to small 
currents which can trigger voltage-dependent Ca2+ influx. In hypoglycaemic conditions, the α-cell ER 
contains little Ca2+ and the store-operated pathway depolarises the cell stimulating glucagon release. 
In normol-glycaemic conditions, the SERCA pump becomes energised to fill the ER and prevent this 
stimulatory cascade [148]. 
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1.3.4 Glucagon secretion during hyperglycaemia 
1.3.4.1 Reduced inhibition of glucagon secretion 
    Glucagon secretion is inhibited when glucose rises to 7-8mM [149, 150]. It has been suggested that 
this inhibition significantly decreases at higher concentrations of glucose in both mouse [150] and 
human [150] islets. Indeed, previous reports have indicated that glucagon secretion may in fact 
become accelerated at glucose concentrations above 20mM in mouse [125] and rat [151] islets. This 
diminished inhibition may be due to the presence of a strong stimulatory component which may 
overcome the inhibition at 7-8mM glucose as well as any additional inhibition from paracrine factors 
when β- and δ- cells become stimulated at high glucose concentrations. It is possible that the latter 
stimulation of glucagon secretion occurs via mechanisms that mirror β-cells [152, 153]. It has also been 
suggested that because 20-30mM glucose elevates cAMP levels in α-cells [154], cAMP acts as a 
stimulatory messenger for glucagon secretion [128, 136].  
Figure 1.6 - Glucose stimulated glucagon secretion from the pancreatic α-cell 
When extracellular concentrations of glucose increase, the α-cell becomes electrically inactivated after 
closure of KATP channels results in the opening of T-type Ca2+ and tetrodotoxin (TTX)-sensitive Na+ 
channels, suppressing action potentials, this activates L- and N- type Ca2+ channels (1.3.3). Closure of, 
the latter, channels restrict Ca2+ influx into the cell which in turn inhibits glucagon secretion (1.3.2.2).  
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  During hyperglycaemia, β- and δ- cell secretion becomes stimulated and inhibitory paracrine factors 
are activated which affect glucagon secretion. Experiments looking at islet hormone secretion kinetics 
from both mouse [155] and human [156] islets have supported this. Insulin, glucagon and 
somatostatin secretion occur at stable rates at 3mM glucose. However, at 20mM glucose, hormone 
secretion becomes pulsatile with insulin and somatostatin in phase and glucagon in antiphase [155].  
  Though individual α- and δ-cells have been shown to display oscillations in [Ca2+]cyt at 3mM glucose 
[157, 158], hormone secretion in whole islets occurs without pulsality [155, 156]. This is due to the 
fact neither cell type are electrically coupled and show asynchronas behaviour within islets [159]. 
Pulsatile insulin, glucose and somatostatin secretion at high concentrations of glucose indicates that 
paracrine factors which originate from β-cells determine the pulsatility of somatostatin and glucagon 
secretion. A similar relationship between the pulsatile release of insulin and glucose was found in 
humans [160] where pulsatile delivery of insulin and glucagon have greater effects in controlling 
endogenous glucose production than continuous infusion [161]. Though an increase in glucose from 
3 to 20mM inhibits time-average glucagon release from islets, the secretion peak exceeds secretion 
at lower concentrations of glucose. This highlights the stimulatory component and the effect of 
glucose. Because insulin and glucagon pulses in the opposite phase, the insulin/glucagon ratio (to 
determine the storage and release of glycogen from the liver) varies 20-fold [155, 156]. This results in 
the liver switching between the storage and release of glycogen during hyperglycaemia, the overall 
effect being storage. The reason why energy is spent on this cyclic mechanism remains unclear. This 
inverse pulsatile secretion of insulin and glucagon is not seen in patients with Type 2 Diabetes and 
hyperglucagonemia leading to the conclusion that loss of pulsatile secretion contributes to the 
impaired glucagon release found in diabetic patients [160]. 
1.3.5 Influence of glucagon in Type 2 Diabetes 
  In the 1970s it was suggested that glucagon is a pathophysiological factor in Type 2 Diabetes leading 
to the suggestion that Diabetes is a “bi-hormonal disease” [162]. Evidence for this was provided by 
the observation that patients with Type 2 Diabetes show higher baseline levels of glucagon both 
before and after a high in carbohydrate meal in comparison to non-diabetic participants [163]. 
Hyperglycaemia in patients with Type 2 Diabetes thus may be due to insulin resistance in α-cells, 
resulting in them being less responsive to the inhibitory action of insulin and/or due to defective 
suppression of glucagon secretion at high concentrations of glucose. However, the exact mechanisms 
underlying this remain uncertain [164]. More recently it has been demonstrated that impaired 
suppression of glucagon secretion is more evident after oral rather than intravenous glucose 
administration, suggesting that the mechanism is related to incretin hormones such as gastric 
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inhibitory polypeptide (GIP) and GLP-1 (discussed more in section 1.7) released after oral 
administration of glucose [165]. 
  Glucagon action and α-cell number in Type 2 Diabetes appears to be unaffected [166, 167]. Of note, 
it has been suggested that glucagon plays an initial role in the development of Type 1 Diabetes, since 
glucagon receptor KO mice did not develop Diabetes after streptozopotin injection [168]. Questioning 
this view, diabetes ensues in man after surgical removal of the pancreas, whereas both insulin and 
glucagon are lost [169].  
1.3.6 Glucagon as a therapeutic target  
  The roles of glucagon in controlling circulating glucose levels during both fasting and postprandial 
conditions and during hyperglycaemia have made glucagon a potential target for glucose-lowering 
therapies in healthy subjects and diabetic patients. The potential utility of this strategy is also 
supported by the improvement of hyperglycaemia resulting from GLP-1 receptor agonism and 
dipeptidyl peptidase (DPP)-4 inhibition (that prolong the incretin effect) [170, 171]. Treatment by 
suppressing the action of glucagon using immunoneutralization of glucagon, glucagon receptor 
antisense and glucagon receptor antagonists  appears to be successful in the experimental settings 
however is yet to be used clinically [172].  Indeed important contraindications include hepatic lipid 
accumulation and steatosis [173]. The use of GLP-1 and its receptor as a therapeutic target is discussed 
in detail later in this chapter.  
 
1.4 Glutamate signalling  
 
  Glutamate (L-glutamic acid) is a multifunctional amino acid present in food either in a free form or 
within peptides and de-protonated proteins. Despite being abundant in food, concentration of 
glutamate in the blood is low as glutamate becomes oxidised in the small intestines [174]. As well as 
being a building block for proteins [175], glutamate acts as a major neurotransmitter [176], a precursor 
of the citrate cycle [175], an intracellular messenger [177], and an inducer of taste [178]. 
  In pancreatic β-cells and the inhibitory neuro-transmitting GABAergic neurones, intracellular 
glutamate can be transferred into γ-amino butyric acid (GABA) by the enzyme glutamic acid 
decarboxylase (GAD), also an autoantigen in T1D [179]. Gain-of-function mutations in glutamate 
dehydrogenase (GDH) leads to hyperinsulinemic syndrome [180] suggesting that in β-cells intracellular 
glutamate acts as a secondary messenger for GSIS [177]. 
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  There are three types of glutamate receptors: (i) ionotropic N-methyl-D-aspartate (NMDA); this 
receptor is doubly-gated and requires ligand binding and membrane depolarisation for activation 
[181], (ii) ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor for 
rapid synaptic transmission; responses to the agonist kainite act through this receptor [182], [183], 
and (iii) the metabotropic glutamate synthetic receptors (mGluRs) which are G-protein coupled 
involved in slow synaptic transmissions [184]. Ionotropic and metabotropic glutamate receptors are 
found primarily in the brain but are also expressed in peripheral tissues such as pancreatic β-cells [185] 
and the liver. Glutamate signalling in these tissues play a key role in the control of metabolic 
homeostasis [186]. Glutamate influences both glucagon and insulin secretion from pancreatic α- and 
β-cells, respectively [187, 188]. 
1.4.1 Glutamate-stimulated insulin secretion 
  Early experiments performed of glutamate signalling in the β-cell failed to find an effect on insulin 
release from mouse pancreatic islets [183]. However, these studies involved long lasting static 
experiments may have other effects on secretion [183]. In studies performed on the isolated perfused 
rat pancreas, glutamate-dependent stimulation of insulin secretion via the AMPA receptor was 
observed at high concentrations of glucose, but not at low concentrations. This shows that glutamate 
acts as a potentiator of GSIS [183]. 
  Ionotropic glutamate receptors in neuronal cells were found to be functionally expressed in MIN6 β-
cells, suggesting that these receptors have a physiological role in islets [189]. RT-PCR revealed  several 
functional subtypes of AMPA/kainite and NMDA expressed in β-cells [185].  
  mRNA encoding metabotropic receptor subtypes mGluR3 and mGluR5 was detected in rat and 
human islets as well as mGluR2 in MIN6 β-cells [190]. In addition, mGluR2 and mGluR3 
immunoreactivity was also displayed in islet cells [191] as well as genes encoding mGlu8 [192].  
  Glutamate transport activity was detected in isolated rat islets [193] and glutamate transport has 
been found in human islets [194, 195], indicating that glutamate signalling plays a role in pancreatic 
islets.  
  Electrophysiology experiments demonstrated that glutamate receptors on β-cells initiate membrane 
depolarisation and an increase in [Ca2+]cyt via AMPA/kainite and NMDA receptors [185]. As mentioned 
above, previous studies had found that kainite and AMPA receptors stimulate insulin secretion, 
however NMDA does not have this effect in the perfused pancreas [183]. This failure from NMDA 
receptors is possibly due to its low expression and response of [Ca2+]cyt [185].  
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1.4.2 Glutamate-induced activation of glucagon secretion 
  L-glutamate has been found to stimulate glucagon secretion in the isolated rat pancreas mediated 
via AMPA receptors [188]. The competitive non-NMDA antagonist, CNQX, was found to completely 
prevent the glucagon response to glutamate [196] and NMDA stimulation of α-cells at very high 
concentrations (10-3M) was found to be ineffective [188]. The three non-NMDA agonists AMPA, 
quisqualace and kainite also leads to a glucagon response [188]. Though glutamate stimulated insulin 
has a high efficacy (similar to kainite), efficacy of glucagon secretion is low [188] 
  α-cells express a high affinity Na+-dependent glutamate/aspartate transporter [195] and secrete 
glutamate via Ca2+ dependent exocytosis [197]. [188]IHC staining of α-cells have shown that glutamate 
is released from α-cells [185]. Due to the presence of the vesicular glutamate transporter, Na+-
dependent inorganic phosphate (DNPI) co-transporter, it is thought that α-cells play a role in the 
storage and secretion of glutamate [198, 199].  
  mGlu8 immunoreactivity has been displayed in α-cells containing both glutamate and vesicular 
glutamate transporter 2 (VGLUT2), suggesting that mGlu8 may act as an autoreceptor and inhibit 
glucagon secretion [192]. 
  The physiological role of glutamate in pancreatic islets remains unclear. However, it is clear that 
glutamate plays a role in the secretion of islet hormones by binding to both ionotropic and 
metabotropic receptors [192]. 
 
1.5 AMP-activated protein kinase (AMPK)  
 
  The AMP-activated protein kinase (AMPK) signalling cascade was first discovered in 1973 [200] and 
was only the second protein kinase-cascade discovered alongside the cAMP-dependent protein 
kinase/phosphorylase system [201]. AMPK is activated via elevation of intracellular 5-AMP from heat 
shock, fuel derivate and other stresses [202] and is regarded as a central energy sensor/switch in the 
regulation of metabolism [203]. It is one of the better known sensors involved in cellular energy 
metabolism [204] and plays roles in the regulation of cell growth, proliferation and polarity [205]. 
When activated, AMPK will activate ATP-generating pathways and inactivate ATP-consuming 
pathways restoring cellular energy balance [206].  
   AMPK is part of the serine/threonine family of protein kinases and forms a heterotrimeric complex 
as described in more detail below. AMPK phosphorylates enzymes involved in the control of lipid 
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metabolism, such as HMG-CoA reductase, acetyl-CoA carboxylase and hormone sensitive lipases 
[207]. Activation of AMPK has been shown to improve insulin sensitivity and glucose homeostasis 
making it a therapeutic target in the treatment of Type 2 Diabetes [208].   
1.5.1 The heterotrimeric structure of AMPK   
  Mammalian AMPK is a heterotrimeric enzyme (containing several isoforms of each enzyme) 
comprising of a catalytic α-subunit (α1 and α2) the non-catalytic β (β1 and β2) and γ (γ1-γ3) subunits 
[209, 210]. The α-subunit has a mass of 63kDa [211]. In skeletal and cardiac muscle, the α2 isoform is 
the predominant form [212] whereas equal levels of α1 and α2 are present in the liver [213]. In β-
cells, α1 is the dominant isoform [214, 215]. The β- isoform is less well characterised is highly 
expressed in the liver whereas β2 is the dominant isoform in skeletal muscles. Both γ1 and γ2 isoforms 
are widely distributed throughout tissues though γ3 is specifically expressed in skeletal muscle [216, 
217]. Co-expression of the catalytic and non-catalytic subunits is needed for optimal expression of the 
α-subunit. The structure of the AMPK heterotrimeric complex is illustrated in Figure 1.7.  
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Figure 1.7 - Structure of the heterotrimeric AMPK complex 
The top panel illustrates the linear layout of the three domains and the bottom a 3-D model of a 
human AMPK complex. The complex is divided into two separate regions, the catalytic and nucleotide 
binding modules. The extended linker connects the autoinhibitory domain (AID) and C-terminal 
domain (CTD), which wraps around one side of the C subunit [218].  
 
1.5.2 Regulation of AMPK in the β-cell 
  AMPK activity is regulated via direct phosphorylation of upstream kinases such as liver kinase B (LKB) 
1, calcium/calmodulin dependent protein kinase kinase (CAMKK) 2 and transforming growth factor β 
(TGFB) activated kinase (TAK) 1 [219, 220]. ATP, ADP and AMP modulate the activity of AMPK as well 
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as the phosphorylation via upstream kinase LKB1, which will be discussed in further detail later in this 
chapter. AMP and ADP bind to the γ-subunit resulting in AMPK phosphorylation and a conformational 
change of the kinase that prevents dephosphorylation and maintains AMPK activity. On the other 
hand, ATP binding will stimulate dephosphorylation [219, 220]. AMPK activation via CAMKK2 and TAK1 
have been observed in HeLa and yeast cells, inhibition of the R6 regulatory subunit for protein 
phosphatase 1 (PP1) leads to a reduction in PP1-R6 activity causing preservation of P-AMPK levels in 
high glucose concentrations [221, 222] and inhibition of insulin secretion in MIN6 β-cells [223]. In β-
cells, glucose phosphorylation by GK and its further metabolism is needed for dephosphorylation of 
AMPK. This indicates that AMPK activity is controlled via glucose during a regulated dephosphorylation 
step [223]. These studies target PP1-R6 as a possible therapeutic target to regulate activity of AMPK 
signalling [224].   
1.5.3 Expression of AMPK in the β-cell 
  In MIN6 [214], INS1 cells and rat islets [225], AMPKα1 was found to be the predominant subunit of 
AMPK. However, in insulin-sensitive tissues such as skeletal muscle [226] and the liver [227] the α2 
subunit (AMPKα2) appears to be the predominant subunit in mouse. AMPKα1 expression in MIN6 β-
cells appears to be restricted to the cytosol whereas AMPKα2 was found in both the cytosol and 
nucleus. Blockage of AMPKα2 activity using antibody microinjection mimiced the effects of glucose by 
leading to transcription of pro-insulin [214]. These observations suggest a role for AMPKα2 in the 
control of electrical activity and Ca2+ homeostasis in β-cells [228]. 
  When islets are cultured with palmitate there is a decrease in AMPKα1 expression as well as a 
decrease in GSIS [225] whereas, in MIN6 β-cells exposed to palmitate, increases in AMPK 
phosphorylation and insulin secretion occur [229]. 
  Other members of the AMPK family present in the β-cell and phosphorylated by the up-stream kinase 
LKB1 include, Qin-induced kinase (QIK), QSK , salt-induced kinase (SIK), microtubule-affinity regulating 
kinase (MARK)-1, MARK2, MARK3, MARK4, AMPK-related kinase 5 (ARK5), SNF/AMPK related kinase 
(SNARK), brain specific kinase 1 (BRSK/SAD-1), BRSK2/SADB and sucrose non-fementing related kinase 
(SNRK) [204].  The roles of some of these kinases in the AMPK signalling pathway is illustrated in figure 
1.8.  
  Another Ser/Thr kinase more distantly related to AMPK is PAS kinase (PASK) which has been shown 
to play a role in β-cell and proinsulin gene expression [230]. PASK becomes activated in β-cells in 
response to glucose by reversible phosphorylation at Thr-152 in the “T-loop” [230] and via up-
regulated expression of the PASK gene. Inhibition of PASK using antibody injection blocked pre-
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proinsulin and Pdx-1 induction by glucose [230]. PASK-/- mice showed impaired GSIS although pre-
proinsulin expression appeared normal [231]. These mice also showed improvement in insulin 
sensitivity after being exposed to a high-fat diet, indicating that lowered levels of PASK may protect 
against insulin resistance [231]. Other reports however, have suggested that PASK expression is 
insensitive to glucose regulation in islets [232].  
 
                                                     
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 
 
Figure 1.8 - The AMPK signalling pathway- controlled by LKB1 and AMPK intracellular signalling and 
metabolism  
LKB1, in complex with the scaffold protein MO25 and pseudokinase STRAD, phosphorylates the AMPK 
family of proteins (13 members) [233], regulating diverse intracellular and extracellular biological 
processes. For example, AMPK regulates the central regulator of cellular energy metabolism mTORC 
as well as MARK/Par1 which plays a central role in cell polarity and glucose sensing 
 
1.5.4 The role of AMPK in insulin secretion 
  There is contradictory evidence supporting both the positive and negative regulatory effects for 
AMPK in the control of insulin secretion. The relationship between AMPK and glucose homeostasis 
was first examined using the cell permanent analogue of AMP, 5-Aminoimidazole-4-carboxamide 
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ribonucleotide (AICAR) [215], AICAR is taken up by the cells and rapidly phosphorylated to form the 
AMP mimetic, AICAR monophosphate (ZMP), without changing the intracellular levels of ATP or AMP 
[234]. AICAR stimulates insulin release at basal glucose levels in mouse [235] and human islets [236]  
whist secretion at high glucose was inhibited. 
  In addition, after INS1 and isolated rat β-cells are treated with AICAR, KATP channel trafficking to the 
cell surface under high glucose concentrations increases [237]. This suggests a link between AICAR, 
AMPK and the inhibition of insulin secretion through the KATP channel [237]. AMPK both inhibits and 
promotes insulin secretion, as discussed in detail below. 
1.5.4.1 AMPK inhibits GSIS 
  Pharmacological activity of AMPK provides evidence which supports the view that AMPK activation 
inhibits insulin secretion. Thus, in a study monitoring the phosphorylation of the AMPK substrate 
acetyl CoA carboxylase (ACC)1 in INS1 cells [238], AICAR was found to both block GSIS and inactivate 
ACC1 through phosphorylation of Ser-79. Using INS1, MIN6 and HIT (clonal hamster β-cell line [239]) 
cell lines AMPK activity was found to be inversely related to insulin secretion when exposed to a 
variety of glucose concentrations [235, 240]. Acute treatment with AICAR was found to decrease 
insulin secretion triggered by glucose in both MIN6 cells and rat islets [241]. Additional evidence for 
the inhibitory effect of AMPK on GSIS was provided using the anti-diabetic drug thiazolidinedione 
(TZD), which reduced insulin secretion and activated AMPK [242, 243]. Long-term activation of AMPK 
using pharmacological agents has been shown to inhibit insulin secretion, whereas acute AMPK 
activation has a more varied effect [244, 245]. Inhibition of insulin secretion using AICAR was found to 
be restored when treating with the AMPK inhibitor compound C, suggesting GSIS inhibited by AICAR 
occurs via AMPK activation [246].   
  To further support the active view that AMPK inhibits GSIS, dominant negative (DN)-AMPK and 
constitutively active (CA)-AMPK constructs have been used. DN-AMPK overexpression at low 
concentrations of glucose reduced AMPK activity by 50% (similar to high glucose). By contrast, 
expression of CA-AMPK maintained AMPK activity at elevated levels even in the presence of high 
concentrations of glucose. In MIN6 cells and human islets, DN-AMPK was found to increase insulin 
secretion at low glucose concentrations whereas, CA-AMPK completely blocked GSIS [228, 235]. On 
the other hand, overexpression of DN-AMPK in INS1 cells slightly reduced AMPK activity but had no 
effect on GSIS [247]. At high glucose concentrations, DN-AMPK will decrease AMPK activity and 
increased GSIS in human islets, though this finding was not mirrored in cell lines or rat islets [235]. 
When CA-AMPK islets were transplanted into STZ-induced diabetic mice, restoration of glucose 
tolerance was blocked, whereas glucose tolerance was improved after transduction of DN-AMPK 
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expressing islets [236]. The impaired glucose clearance in mice that received CA-AMPK cells may have 
been due to an increase in apoptosis, suggesting that CA-AMPK plays a role in β-cell survival. This view 
has been supported in experiments using cell lines [248]. Moreover, CA-AMPK expression in MIN6 
cells reduce the number of insulin granules, vesicle movement and actin reorganisation for exocytosis 
[249]. In addition to ATP and Ca2+ activity, expression of CA-AMPK leads to increases in response to 
glucose and inhibits sulfonylurea induced insulin secretion [228, 250].   
1.5.4.2 AMPK promotes GSIS 
  Early studies showing AICAR mediated inhibition of gluconeogenesis in hepatocytes prompted to 
study of the impact of AICAR treatment on β-cells [251]. Perfusion of the pancreas at 6mM glucose 
whilst increasing the dosage of AICAR results in enhanced insulin secretion which indicates that 
activation of AMPK promotes GSIS [252]. However, the removal of AICAR results in further increases 
in insulin secretion, suggesting the possibility that AMPK inactivity may in fact promote insulin 
secretion [252]. Further studies showed that AICAR treatment increases insulin secretion in rat islets 
and cell lines when exposed to varied glucose concentrations [240, 247, 252, 253]. From the effect of 
AICAR on enzymatic activity on AMPK in these studies it was concluded that there is a correlation 
between AICAR treatment and an increase in AMPK activity. However, it is still unclear whether the 
effect of GSIS after AICAR treatment works independent from AMPK.  
  Experiments using Pre-diabetic Zucker rats showed that when AMPK activity became stimulated in 
both β-cells and in the periphery by AICAR administration, hyperglycaemia is prevented and β-cell 
mass preserved. However, in treated animals insulin sensitivity was greatly improved and β-cell 
“stress” decreased compared to wild type littermates [254]. 
1.5.5 The role of AMPK in apoptosis 
   The effect of long-term AMPK activation on β-cell survival has been studied using MIN6 cells cultured 
in high glucose concentrations and exposed to AICAR for 24 hours. Here AMPK was found to block 
glucose oxidation and insulin secretion as well as to increases in reactive oxygen species (ROS) 
production and cell death [255]. It possible this was due to changes in NADH/NAD+  ratio and effects 
on the oxidative state of mitochondrial flavin (FMN) in complex 1 [256]. There was an accumulation 
of BIM, BIP and BAX, which are pro-apoptotic, and Bcl-2 homology (BH) 3-domain containing members 
of the BCL2 family [245]. After overexpression of the anti-apoptotic BCL2 protein, β-cell survival was 
rescued. AICAR induced apoptosis treatment in wild-type (WT) islets (rather than AMPKα2 KO islets) 
indicate that activation of AMPK may contribute to apoptosis [257]. Low glucose treatment in MIN6 
cells results in apoptosis mediated via C-jun N-terminal kinase (JNK) and c-myc. This was mimicked by 
AICAR induced AMPK activation, indicating that prolonged AMPK activation may cause starvation 
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induced apoptosis in β-cells [258, 259]. On the other hand, INS1 cell treatment with AICAR in high 
glucose restored GSIS and reduced apoptosis indicating prolonged inhibition of AMPK which may 
underlie  β-cell dysfunction in a glucotoxic environment [260]. 
  There are other means by which active AMPK may prevent cell survival for example, via the inhibition 
of proliferative pathways.  AMPK directly phosphorylates TSC2 [261], this complex acts as a GTP-
activating protein on the mTOR activating Rheb, allowing transmission of growth factor receptor 
tyrosine-kinase derived signals to the P70 S6 kinase tumour suppressor [261]. Inhibition of Rheb leads 
to suppression of these proliferative signals and instead favours opposing cell death pathways. TSC2 
KO mice have improved glucose tolerance, insulin secretion and β-cell mass which is also consistent 
with the suggestion that AMPK and its targets weaken insulin secretion and proliferation [262, 263]. 
Persistent activation of AMPK leads to phosphorylation of the tumour suppressor p53 at ser15 causing 
cellular senescence and eventual cell death [264]. It has been suggested that the inhibition of cyclin 
dependent kinases (CDK) p21Waf1/Cip1 is involved in this cell death pathway [265]. Suppression of AMPK 
activity appears to reduce cell death caused by proinflammatory cytokines and immunoreactive CD8 
and T-cells [266], suggesting that AMPK activation may play a part in the immediate post-
transplantation stage leading to cell death [267].                      
1.5.6 Deletion of AMPKα1 and α2 
  Knock-out models of the catalytic subunits AMPKα1 and α2 has demonstrated a role for AMPKα2 in 
multiple tissues in regulating glucose homeostasis [268, 269]. These global AMPKα2 KO mice became 
insulin resistant, have low levels of plasma insulin and raised blood glucose. However, normal islet 
insulin secretion is observed in vitro [269]. AMPKα1KO mice displayed no phenotype, suggesting some 
compensation of insulin production and secretion from the α2 subunit [270]. In comparison, the α1 
subunit is unable to compensate for the loss of α2, suggesting tissue-specific roles for α1, the α1 
subunit can compensate for α loss in β-cells.  
  Independently, two groups have generated β-cell and brain specific AMPKα2 deficient mice using the 
RIP2 Cre promoter [271, 272]. Breeding of these animals to mice null globally for AMPKα1 resulted in 
animals inactivated for both alleles in these tissues [271, 272]. In both studies, mice showed impaired 
glucose tolerance, lowered plasma insulin levels and no change in β-cell mass. The AMPKα1 and -α2 
deleted strain using the rat insulin promoter (RIP2) Cre promoter studied in our group also noted in 
increase in β-cell proliferation and in vitro insulin secretion [271]. Whereas in the second study of 
AMPK α-subunit deletion, mice appeared to have some defect in GSIS [272]. 
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  Regarding these studies it has been argued that the loss of the α-subunits in the brain via the RIP2 
Cre promoter may mask potential β-cell dependent defects in glucoregulation [273]. Deletion of the 
α2-subunit in proopiomelanocortin (POMC) neurones of the brainstem (where RIP2 Cre expression 
occurs) results in an increase in body mass and fat, as well as loss of glucose responsiveness. In 
addition, these mice become more insulin sensitive, have lower plasma insulin levels and enhanced 
blood glucose levels. Therefore, the phenotype observed in the RIP2Cre AMPKα1α2 KO may be 
partially due to the effect of AMPK in peripheral tissues [274]. Further studies are required to assess 
the β-cell specific function of the AMPK α-subunits.     
1.5.7 Downstream mechanism of AMPK action in β-cells 
  The most likely mechanism for AMPK action in the pancreatic β-cell is the phosphorylation and 
inhibition of acetyl CoA carboxylase-1 (ACC1) and subsequent down-regulation of malonyl-CoA 
synthesis. ACC1 catalyses the rate limiting step in fatty acid (FA) biosynthesis and becomes inactivated 
when phosphorylated by AMPK at the Ser residues 79, 1200 and 1215 [275]. Chronic inactivation and 
KO of ACC1 has been found to inhibit GSIS, glucose metabolism, ATP production and the synthesis of 
mitochondrial metabolites [276]. AMPK also plays a role in programming β-cell gene expression via 
SREBP, FOXO1a and HNF4α [277]. Phosphorylation of cytoskeletal machinery components involved in 
secretory granule transport may also be involved in the mechanistic action of AMPK. For example, 
AMPK activation has been found to subdue granule movement whilst having no effect on vesicle 
fusion at the plasma membrane [249]. The exact mechanism by which AMPK suppresses glucose 
metabolism as well as Ca2+ signals [278] remain unclear.  
1.5.8 The role of AMPK in the control of food intake by the hypothalamus 
  As mentioned above, AMPK acts through peripheral tissues to control food intake. Stereotactic 
injection of an adenovirus expressing activated AMPK into the hypothalamus of rats has been 
performed to study the role of AMPK in feeding centres of the ventromedial hypothalamus [279, 280]. 
These studies demonstrated that hypothalamic AMPK is activated by the orexigenic agent ghrelin and 
inhibition by intracerebrovascular (ICU) leptin. Recent studies show that changes in ACC activity and 
endogenous cannabinoid levels may be involved, implicating that AMPK plays a role in the control of 
body mass [281, 282]. Mice deficient for the AMPK α-subunits specifically in the hypothalamic nuclei 
became hypoglycaemic, demonstrating that AMPK activation plays a role in the sympathetic response 
to hypoglycaemia [283]. This suggests that AMPK is important in the control of glucose sensing 
neurones in the arcuate nucleus and paraventricular hypothalamus.  
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1.5.9 AMPK and glucagon secretion 
  Little is known of the roles of AMPK in glucagon secretion. In a study performed in our lab several 
years ago, the α-cell line αTC1-9 was used to find that activation of AMPK stimulates glucagon 
secretion, whereas inactivation prevents [Ca2+]cyt elevation and glucagon release even at low glucose 
concentrations [284]. 
 
1.6 Liver Kinase B 1(LKB1)  
 
  LKB1 (also known as STK11), is known of as a tumour suppressor due to the polyp formation following 
heterozygous germline mutation. Thus, mutations in the STK11 gene increase the risk of developing 
Peutz-Jeghers Syndrome (PJS) which causes polyps in the GI tract, mucocutaneous pigmentations as 
well as leads to a predisposition for tumour development in the breast and gynaecological organs 
[285, 286]. The roles that LKB1 plays in the development PJS are discussed in more detail in section 
1.6.6.  
  As mentioned previously, LKB1 acts as a major upstream kinase which phosphorylates and activates 
AMPK [287] leading to stimulation of its down-stream kinases and inhibition of protein synthesis, FA’s 
and glucose metabolism as well as up-regulation of glucose transport [288]. AMPK inactivates mTOR 
(mammalian target of rapamycin) via the tuberous sclerosis (TSC) 1/2 tumour suppressor complex and 
by direct phosphorylation of the mTOR-binding partner raptor [289-291]. TSC2/TSC1 will inactivate 
Rheb which activates mTOR. 
1.6.1 Protein structure and localisation of LKB1 
  LKB1 encodes a 433 amino acid ubiquitously-expressed protein (436 amino acids in mice) with N- and 
C- terminal domains and a central catalytic domain (residues 49-309). In the human genome LKB1 is 
part of single homolog and single ortholog in mouse. The N-terminal domain consists of a 
phosphorylation site (S31) and a nuclear localisation signal [292] whereas the C- terminal domain 
contains three phosphorylation sites (S325, T366 and S428). The latter two sites are targeted by PKA 
[293, 294]. LKB1 contains autophosphorylation sites (T185, T189, T336 and S404), a carboxylterminal 
prenylation motif and is farnesylated in cells [295], (indicated in Figure 1.9).  
  LKB1 forms a complex with Ste20-related adaptor (STRAD) and mouse protein 25 (MO25) which are 
needed for enzymatic activity [296, 297]. The overall LKB1-STRAD-MO25 complex is illustrated in 
Figure 1.9. When overexpressed, LKB1 is localised in the nucleus, though when co-expressed with 
STRAD and MO25, it is localised in the cytosol [298, 299]. Interaction with STRAD in the cytoplasm is 
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required for LKB1 to induce G1 arrest in a LKB1 KO melanoma cell line [299], indicating that interaction 
within this complex is required for the role LKB1 plays in cell proliferation and growth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 - Overall structure and interactions of the LKB1-STRADa-MO25a complex 
(A) Representation of the hetero-trimeric complex and two bound AMP-PNP molecules; LKB1 shown 
as yellow carbons and STRADa as pink carbons. (B) LKB1-STRADa interaction; STRADa and aEF-aF loops 
are shown in green and orange, respectively. (C) Interaction of the LKB1 CTFL with STRADa and LKB1 
N and C lobes, the proline rich CFTL is shown in red. In this panel we also see the phosphorylation 
sites, mentioned above, that act as autophosphorylatio sites. (D) LKB1-MO25a interaction. The LKB1 
activation look is shown in pink. (E) The LKB1 A-loop interaction. Backbone interactions are shown as 
dashed lines. The residues Asp208, Thr230 and Ser232 which are normally mutated in PJS are labelled 
and side chains shown. Between Glu199 and Lys175, the dashed line represents a salt bridge and the 
interaction between the LKB1 activation segment and its catalytic loop (C-loop). The corresponding 
interaction in PKA between the phosphorylated Thr197 and Arg165 is shown and PKA residues are 
represented as transparent sticks [300]. 
 
1.6.2 The role of LKB1 in cell polarity 
  Using mammalian intestinal epithelial cells and Drosophila kinase-dead mutants of LKB1, LKB1 was 
discovered to play a role in cell polarity. These epithelial cells were unable to polarise,  suggesting that 
the catalytic functions of LKB1 are needed for this process [301]. Furthermore, STRAD-mediated 
translocation of LKB1 is needed from the nucleus to cytoplasm [302]. It is likely that LKB1 plays a role 
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in polarity in a cell specific manner with different contributions from different members of the AMPK 
family [295]. For example, the phosphorylation of LKB1 on a C-terminal S431, via agonist activated 
cAMP dependent PKA is important for polarisation of follicular epithelial cells and drosophila oocytes 
[303]. Also, the brain-derived neurotrophic factor was found to promote axon differentiation in a 
manner that depends on PKA-mediated LKB1 phosphorylation, providing a link between extracellular 
signals and LKB1 mediated axon specification [303]. Finally, the farnesylation motif of LKB1 is needed 
for A-P polarity in Drosophila [304]. 
  The regulatory subunit of myosin II, myosin regulatory light chain (MRLC), is important in AMPK-
mediated changes in structure in certain cell types [305]. MRLC mutants in drosophila have similar 
defects as AMPK KO mice. MRLC acts as a direct target of AMPK phosphorylation at a site which 
initiates the MRLC polarity function [305]. Importantly, a phosphomimetic mutant MRLC transgene 
appears to rescue the AMPK KO phenotype in Drosophila which indicates the importance of the LKB1-
AMPK-MRLC pathway in polarity control [295]. 
  MARK 1, 2, 3 and 4, which are regulated by LKB1, are also linked to the control of cell polarity. 
Through the regulation of tubulin dynamics the MARK family promotes epithelial polarisation [306]. 
In mice, germ line deletion of MARK2 suggested a role for this enzyme is energy metabolism as these 
mice become hyperphagic and show a decrease in adiposity [307, 308]. To elucidate the relationship 
between the role of LKB1 in controlling cell polarity, and in its tumour suppressor function, mammary 
epithelial cells were grown in a 3D Matrigel culture system. Activation of c-Myc and inactivation of 
LKB1 caused abnormal cell-cycle progression of quiescent acinar cells resulting in structural defects 
indicating that polarity is needed to restrain cell proliferation after mitogenic stimuli [309]. Another 
suggestion is that defects in polarity via LKB1 inactivation causes tumorigenesis via defects in genomic 
stability, as shown in Drosophila [305, 310]. 
1.6.3 The role LKB1 in cell growth and proliferation 
  It has been suggested that LKB1 plays a role in phosphatase and tensin homolog (PTEN) signalling 
through upregulation of PTEN transcription or via direct protein binding and phosphorylation [311-
313]. In human endothelial cells, LKB1 down-regulates protein kinase B (AKT) phosphorylation under 
oxidative stress, consistent with the existence of a LKB1-PTEN-AKT pathway [313]. By contrast, in other 
cell types AKT signalling does not appear to be regulated by LKB1 [290]. LKB1 also regulates Wnt/β-
catenin signalling [314, 315]. It has been suggested that LKB1 acts upstream of glycogen synthase 
kinase 3 (GSK3), up-regulating β-catenin activity [316]. KO models of the Xenopus LKB1 ortholog 
XEEK1, resulted in phenotypes similar to those following Wnt loss of function, indicating that they 
regulate a common pathway [314].  
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1.6.4 LKB1 in diabetes 
  A link between LKB1 and diabetes was uncovered by examining the effects of LKB1 inactivation in the 
liver. These studies revealed that LKB1 is essential for the beneficial effects of metformin [317]. 
Activation of LKB1 plays a role in gluconeogenesis via the regulation of AMPK and phosphorylation of 
the transcriptional co-activator target of rapamycin (TORC2). This results in inactivation of 
gluconeogenesis via sequestration in the cytoplasm which negatively regulates transcriptional events 
that promote synthesis of gluconeogenic enzymes. In the absence of LKB1, TORC2 is unable to become 
phosphorylated and gluconeogenesis may resume [317].  
1.6.5 Roles of LKB1 in the β-cell 
  LKB1 has been deleted in adult mouse β-cells using a Pdx1-CreER transgene (PLB1) where LKB1 is 
deleted after tamoxifen injection [318, 319] as well as using the RIP2Cre transgene [320]. Both of these 
deletor strains show improved insulin content and secretion as well as β-cell size and polarity. This 
reveals the detrimental roles that LKB1 plays in the β-cell and in insulin secretion as discussed below.  
1.6.5.1 LKB1 and β-cell polarity 
  β-cells, which are epithelial in nature, express the transmembrane protein E-cadhenin [321] and also 
concentrate GLUT2 in microvilli in lateral surfaces [322]. In isolated islets, insulin is secreted to the 
lateral surfaces away from blood vessels [323]. However, as β-cells do not have a visible lumen and 
appear as symmetric spheres they are not regarded as polarised epithelium [323]. 
  Ordinarily β-cells are organised as rosettes around islet capillaries [321] and monocillia localise at the 
lateral surfaces whereas, in the PLKB1 and RIP2Cre mice, β-cell cellular organisation undergoes 
dramatic changes. The nucleus becomes relocated towards the intrarosette capillary and the cilium 
moves to the opposite pole of the cell. This phenotype is similar to that occurring in the absence of 
Par1b [318-320, 324]. Both PLKB1 and par1b mutant mice show a shift toward columnar polarity. 
Par1b KO mice have similar redistributions of nuclei as these RIP2Cre LKB1 mice [318]. 
  A loss of interaction between Par1b and E-cadherin may result in relocalisation of the latter to the 
apical pole, as found in RIP2Cre LKB1 β-cells. Par1b has been found to regulate glucose metabolism in 
adipose tissues [307], via syntaxin-4 interactions [325] but control GLUT4 trafficking to the plasma 
membrane. Syntaxin-4 is needed in the second phase of GSIS [326], therefore impaired 
phosphorylation of par1b when LKB1 is deleted may have an effect on β-cell trafficking of secretory 
granules to the cell surface [320].  
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1.6.5.2 LKB1 and β-cell size. 
  LKB1, independent of its effects on polarity, is known to restrict β-cell size through the mTOR 
pathway [289, 290]. In both the PLKB1 and RIP2Cre LKB1 mouse model, β-cell size became markedly 
enhanced, as assessed by optical projection tomography (OPT). This improvement seems to be due 
both to an increase in the volume of individual β-cells and a surge in proliferation. A similar phenotype 
was found in TSC1/2 deleted β-cells. Increased phosphorylation of ribosomal protein S6 and decreased 
phosphorylation of 4E-BP1 suggest that this increase is due to elevated mTOR signalling [320]. 
  The rosette arrangements found in β-cells occurred twice as ofetn in the RIP2Cre mice. This may be 
due to the increase in individual cell size. Arguing against this view, there was a 60% up-regulation in 
β-cell volume after mTORC overexpression, similar to that seen in the LKB1KO, whilst there was no 
increase in rosette number in mTORC overexpressing β-cells. Here there was an increase in β-cell mass 
but no change in the number of rosette structures [327-329]. With deletion of both AMPKα1 and α2 
insulin release became impaired and there was no change in mass indicating the deletion of LKB1 does 
not reflect its requirement to activate AMPK [320]. The increase of islet acini may be due to kinases 
such as MARKs1-3 [320].  
1.6.6 Peutz Jeghers Syndrome  
  Mutations in LKB1 are linked to PJS in humans [330-332], as discussed previously. Homozygous 
mutations of LKB1 are embryonically lethal in mice which die mid-gestation with vascular 
abnormalities and neural tube defects [333]. On the other hand, mice with heterozygous mutations 
develop hamartomatous GI polyps similar to those detected by human PJS patients[334].  These 
polyps appear at 4-6 months of age [335] and cause premature mortality at 11 months due to 
obstructions in the GI tract. 
  Studies of the coding regions and splice site mutations revealed that the LKB1 gene germline 
inactivating mutation occur in 35-70% of PJS patients. When scanning patients with PJS using multiplex 
ligation dependent probe amplification (MLPA), it was found that 94% of the patients that were 
screened had mutations in the LKB1 gene [336, 337]. Whereas no mutations were identified on the 
related genes STRADα and MOD25α [338]. 
  Patients with PJS are predisposed to other cancers [339, 340]. Heterozygous LKB1 mice are also 
predisposed to cancer of the liver [341], bone [342] and endometrium [343]. Also mutations in p53 
are detected in human PJS patients [344], whereas in heterozygous mice polyposis is enhanced when 
p53 becomes impaired [345, 346]. Examples of polyps from a patient with PJS  are illustrated in Figure 
1.10. 
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  PJS polyps are thought to contain all cell types of surrounding tissue [335]. However, it has been 
noted that in LKB1+/- mice, epithelial differentiation is disrupted in gastric and intestinal polyps [335]. 
Polyps in both human PJS patients and LKB1+/- mice contain a large section of smooth muscle tissue. 
Additionally, in mice where LKB1 was deleted specifically in smooth muscle, polyps appeared in the 
stomach of mice with homo- and heterozygous mutations [347].  
There are currently no drugs available for the treatment of PJS. Management of PJS depends mainly 
on endoscopies in the attempt to remove larger polyps [348]. The best short-term treatment for PJS 
patients is the enzyme cyclooxygenase-2 (COX-2) which is used for catalysing the rate-limiting step in 
prostaglandin synthesis as well as a role in tumour promotion [349] 
 
 
 
 
 
 
Figure 1.10 – Polyps extracted from a patient with PJS 
A) Macroscopically lateral surface of a polyp from a 46 year old female with PJS, B) Capsule endoscopy 
image of polyp, C) Microscopically tree-like branching core derived from the muscularis mucosa 
covered by normal epithelium [350] 
 
1.7 Glucagon-Like Peptide 1  
 
Glucagon-like peptide 1 (GLP-1) is an insulinotropic incretin hormone expressed from the proglucagon 
gene. Preproglucagon is cleaved into mature peptides depending on the enzyme involved. In α-cell 
cleavage by PC2 and PC1/3 in intestinal L-cells, GLP-1 is generated [351].  
1.7.1 The GLP-1 receptor (GLP-1R) and its presence on the β-cell  
  GLP-1 binds to and activates the membrane-bound GLP-1R in pancreatic β-cells, which is a ligand 
specific 7-transmembrane domain member of the G-protein coupled receptor family B [352, 353]. 
Members of this family contain a glucagon receptor subclass which includes receptors for glucagon, 
GLP-2, GIP and secretin. The human GLP-1R gene is located on the long arm of chromosome 6p21[354] 
encoding 463 amino acid containing a long extracellular N-terminal and 7 membrane spanning 
  Chapter 1 - Introduction 
55 
 
hydrophobic motifs. Murine GLP-1R KO models display reduced glucose tolerance and impaired GSIS 
[355]. GLP-1 responsiveness has been found to decrease in β-cells of Type 2 diabetic patients due to  
hyperlipidemia [356] and/or hyperglycaemia [357] associated with reduced expression of GLP-1R.  
  On ligand binding, the GLP-1R becomes activated and couples to the trimeric G-protein complex 
releasing the Gαs subunit. This results in an increase in the enzymatic activity of membrane bound 
adenylate cyclase (AC) and cAMP [352] production. Upon GLP-1R activation there is a rise in cAMP 
activity and the downstream signalling pathways protein kinase A (PKA) and exchange protein 
activated by cAMP (EPAC2) [358]. However, the roles of cAMP in the downstream pathways are 
unclear. 
1.7.2 GLP-1 mediated regulation of insulin secretion 
  GSIS is activated when glucose enters the β-cell and undergoes glycolysis resulting in KATP channel 
closure, membrane depolarisation and Ca2+ influx which stimulates insulin exocytosis. Usually after 
feeding, GLP-1 released from the gut binds to GLP-1R, resulting in a rise in cAMP, and activation of 
PKA and EPAC2, as described above. This activation results in closure of KATP channels, depolarising 
the cell further.  
  Closure of the KATP channel is regulated through the pore forming Kir6.2 and SUR regulatory subunits 
via the GLP-1R effector PKA inhibiting ADP binding [359, 360]. On the other hand, activation of EPAC2 
results in the opening of ryanodine receptor (RYR) Ca2+ channels. Activated PKA and EPAC will also 
induce mobilisation of granules from the RP to the RRP. EPAC2 interact directly with SUR1, resulting 
in the acidification and priming of insulin granules [67]. EPAC2 may also activate proteins such as 
SNAP25 and Rim2, involved in the priming and fusion of insulin secretory granules with the plasma 
membrane [361, 362]. GLP-1R signalling inhibits compensatory repolarisation by opening  KATP 
channels, this inhibition leads to an increase of glucose-initiated membrane depolarisation leading to 
the opening of VDCC [359]. EPAC2 also increases channel inhibition, increasing the effectiveness of 
KATP channel closure [359]. As illustrated in Figure 1.11.  
  GLP-1 also plays a role in insulin gene transcription and biosynthesis by activating key transcription 
factors such as cAMP response element-binding protein (CREB) and pancreatic and duodenal 
homeobox (PDX-1). When activated, CREB binds to cAMP response element (CRE) sites in promoter 
regions of genes such as insulin, insulin receptor substrate (IRS)-2, pro-hormone convertase-1 and 
CREB itself [363]. PDX1 plays a role in pancreatic development and β-cell function and its binding to 
the insulin promoter is increased upon GLP-1 treatment [364]. Studies examining glucose and GLP-1-
stimulated RIN insulinoma cells demonstrated that the PKA inhibitor H89 led to a decrease in PDX1 
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mRNA, protein and nuclear translocation. This correlates with complete inhibition of GLP-1-induced 
insulin secretion under these conditions, indicating that PDX1 activation via GLP-1 is partially 
dependent on PKA [365]. Other studies have revealed a role for phosphoinositide 3-kinase (PI3K) in 
the effect of GLP-1 on the insulin gene promoter [364]. Thus, at low glucose concentrations, insulin 
mRNA levels decrease in β-cells, a consequence of reduced mRNA stability. However, mRNA stability 
was enhanced in the presence of elevated intracellular cAMP [365].  Finally, GLP-1 increases the 
expression of β-cell  glucose transporters, GK, Kir6.2 and SUR1, improving the capability of β-cells to 
sense and respond to glucose [366].  
 
1.7.3 Effect of GLP-1 in β-cell proliferation, differentiation and apoptosis 
 
  Chronic activation of GLP-1R signalling in both normal and diabetic animals causes an increase in β-
cell mass due to an augmentation in β-cell proliferation and differentiation as well as a decrease in β-
cell apoptosis. However, due to difficulties in measuring human islet mass the effect of human β-cell 
proliferation, differentiation and apoptosis is unclear [367]. 
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1.7.3.1 GLP-1 stimulates β-cell proliferation 
  Studies of GLP-1 signalling in β-cell proliferation in rodents have shown the involvement of epidermal 
growth factor receptor (EGFR), PI3K [364] as well as components of the cAMP, PKA, Akt/PKB and MAPK 
signalling pathways [368]. PDX-1 has a central role in the stimulatory effect of GLP-1 on cell 
proliferation, resulting in improved effects on blood glucose in both diabetic and db/db mice [369]. 
However, this effect in humans remains unclear [370].  
1.7.3.2 GLP-1 affects β-cell differentiation 
  Agonists of GLP-1R are able to induce differentiation of islet cell precursors and other exocrine cells 
into hormone-producing β-cells. Thus, long-term stimulation of GLP-1R on the acinar cell line AR42J 
and pancreatic ductal cells increases intracellular cAMP and Ca2+ levels as well as the PKA-dependent 
Figure 1.11- GLP-1 binding to and activating GLP-1R plays a role in GSIS 
Whilst glucose enters the β-cell closing KATP channels during normal GSIS, GLP-1 binds to the GLP-1R 
resulting in cAMP up-regulation in the cell and subsequent PKA and EPAC2 activation. This leads to the 
further closure of KATP channels and the opening of ryanodine receptor Ca2+ channels, as well as 
mobilisation of the RP to RRP. The Figure is generated using images from “Servier Medical Art”. 
(http://www.servier.com/servier-medical-art). 
 
GS 
  Chapter 1 - Introduction 
58 
 
expression of insulin, glucagon and somatostatin [371, 372]. Similarly, long-term treatment of 
immature islet precursors become differentiated into insulin-immunopositive cells and enhances GSIS 
[367]. 
1.7.3.3 GLP-1 on β-cell apoptosis 
  GLP-1 can also act as an anti-apoptotic agent. Thus, human islets incubated with GLP-1 were 
protected from glucolipotoxicity [109]. In Zucker diabetic mice, db/db mice and streptozotocin (STZ) 
induced diabetic mice, GLP-1 treatment was found to restore insulin secretion, lower blood glucose 
concentrations and decrease apoptosis [357]. Islets from GLP-1R KO mice treated with STZ were found 
to be more susceptible to apoptosis in comparison with islets from their WT littermates [373]. The 
anti-apoptotic properties of GLP-1R signalling indicate multiple signal transduction pathways including 
activating EGFR, PDX-1, PI3K/PKB signals and cAMP/PKA-dependent activation of CREB. Inhibition of 
β-cell apoptosis via GLP-1R is associated with anti-apoptotic proteins such as bc1-2, and reduced levels 
of pro-apoptotic proteins such as caspase-3 [374]. Reduction of ER stress-mediated expression of 
CHOP, Gadd34 (involved in growth arrest) and activating transcript factor 4, which inhibits 
dephosphorylation of elf2α, has also been observed. These transcription factors enhance recovery 
and protect cells from ER stress [375].  
1.7.4 Actions of GLP-1 in pancreatic α-cells 
  GLP-1 and PC1/3 immunoreactivity has been found in α-cells [351, 376] indicating a role for GLP-1 in 
glucagon secretion [351]. GLP-1 inhibits glucose dependent-glucagon secretion in vivo [377] but in 
vitro has been found to stimulate glucagon release from α-cells [378]. GLP-1R expression in α-cells is 
unclear [379, 380]. Reports of expression of GLP-1R on α-cells have varied from zero [381], to little 
[379], to 20% of α-cells [380]. It has also been suggested that GLP-1R expression in α-cells is less than 
0.2% to that of β-cells therefore, GLP-1-induced reduction of glucagon secretion does not rely on GSIS 
but is dependent on PKA [382]. Other studies here demonstrated that the inhibition of glucagon 
secretion via GLP-1 is mediated by somatostatin receptor substrate-2 (SSTR-2) [383].  
  It is possible that GLP-1 inhibition of glucagon secretion is initiated via regulation of insulin, GABA or 
somatostatin secretion. Though it is apparent that GLP-1 plays a role in the regulation of glucagon 
secretion, GLP-1R deleted mice have shown glucagon secretion is not dependent on GLP-1 [384]. 
  In addition to L-cells, pancreatic α-cells are a source of GLP-1 [385]. When incubating the α-cell line 
αTC1-6, at high concentrations of glucose, PC2 transcription is unchanged. Secretion of GLP-1 is 
enhanced when exposed to high concentrations of glucose [386].  
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  G-protein coupled receptor (GPR) 120, GPR119 and TGR5 expression are involved in the secretion of 
GLP-1 from L-cells. This is also observed in α TCI-6 cells. TGR5 agonist treatment was found to enhance 
GLP-1 secretion and PC1 expression [387], indicating that proglucagon can be processed to release 
GLP-1 from α-cells [388]. Therefore, intra islet GLP-1 may contribute to β-cell growth, survival and 
insulin secretion.    
1.7.5 The role of GLP-1 in Type 2 Diabetes 
  In the 1980s it was recorded that patients with Type 2 Diabetes exhibited a reduction in incretin 
effects [389]. Insulinotropic incretin hormones GLP-1 and GIP account for over 50% of postprandial 
insulin response in non-diabetics [390] and only 20% in diabetic patients [389].  
  Several studies suggest that the reduction in GIP and GLP-1 secretion in Type 2 Diabetes doesn’t 
significantly contribute to the loss of the incretin effect and that there is a decrease in insuilnotropic 
action in GIP (whereas GLP-1 action remains preserved) secondarily to impairment in β-cell function. 
In addition, hyperglycemia further reduces the β-cell response to GIP and leads to the down-regulation 
of its receptor [391]. The reduction of the incretin effect in Type 2 Diabetic patients is a bi-product of 
chronic hyperglycemia, [391], as consistent with the fact that loss of insulinotropic efficacy in diabetic 
patients with other conditions such as secondary to chronic pancreatitis or autoimmune diabetes 
[392].  
1.7.6 GLP-1 treatment for Type 2 Diabetes 
  A ‘glucagonocentric’ vision for the treatment of Type 2 Diabetes has been proposed relying on the 
fact that glucagon enhances the catabolic process which occurs without insulin present [393]. In poorly 
controlled diabetes hyperglucagonemia occurs however, glucagon receptor null mice following β-cell 
destruction do not develop diabetes [168]. The absence of hyperglycemia in this model may, as well 
as the lack of glucagon, be due to high concentrations of fibroblast growth factor 21(FGF-21) and GLP-
1 displayed by these mice [394]. 
  The three drugs clinically used for the abnormalities of glucagon secretion in Type 2 Diabetes include; 
the GLP-1 receptor agonists (GLP-1RA), the inhibition of DPP-4i and the amylin agonist pramlintide. 
The first two exert insulinotropic effects, these drugs do not markedly increase insulin concentrations 
which is thought to be due to the GLP-1 signalling effect to lower glycemia, thereby decreasing β-cell 
stimulation [395]. It has also been suggested that GLP-1 treatment improves GSIS, causing secretion 
rates to remain unchanged, whilst glucagon secretion reduces [395]. These suggestions indicate that 
the glucagonostatic and insulinotropic effects of GLP-1 both equally contribute to its hypoglycaemia 
efficacy [396]. Patients with Type 2 Diabetes when treated with the DPP-4i, Vildagliptin showed a 
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reduction in post-meal glucagon levels after 4 weeks of treatment [397] whilst the GLP-1RA liraglutide 
reduces 24 hour glucagon levels [398]. Type 1 Diabetes patients also showed a reduction in glucagon 
levels with liraglutide treatment [399], these findings suggest that liraglutide inhibits glucagon 
irrespective of intra-islet insulin, via the GLP-1 receptor in α-cells [396].  
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Aims of thesis 
 
This thesis is split into two main objectives. 
1. To understand the role of LKB1 in the pancreatic β-cell by deleting this kinase selectively in 
this cell type and to examine the effects this deletion has on β-cell mass and insulin 
secretion.  
2. To explore the roles, if any, of LKB1 and AMPK in proglucagon-expressing cells, including 
enteroendocrine L- and pancreatic α-cells and to determine if deletion of either of these 
kinases (in these cell types) improves GLP-1 production and secretion, thereby improving 
overall glucose homeostasis in the mouse.  
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Chapter 2  
Materials and Methods 
 
2.1 In vivo mouse experiments 
2.1.1 Generation of mice selectively lacking LKB1 in pancreatic β-cells 
  Mice homozygous for the floxed allele of the LKB1/Stk11 gene were bred against mice expressing 
Cre under the mouse Ins1 promoter (Ins1Cre) [400]. The heterozygous offspring were inter-crossed 
to generate Ins1LKB1KO mice (LKB1f/f Cre positive) and WT mice (LKB1f/f Cre negative). All mice were 
kept on a mixed FVB/129S6 and C57BL/6 background, offspring genotypes were obtained in the 
expected Mendelian ratios.   
2.1.2 Generation of mice selectively lacking LKB1 in proglucagon-expressing cells 
  Mice homozygous for the floxed alleles at exons 3-6 of the LKB1/Stk11 gene (Mouse Models of 
Human Cancer Consortium. http://mouse.ncifcrf.gov/) were first bred against mice expressing 
Rosa26tdRFP reporter mice [401]. The resulting double heterozygous LKB1f/+, RFP mice were inter-
crossed to generate LKB1f/fRFP mice which were subsequently crossed with mice expressing iGlu Cre. 
The heterozygous LKB1f/+iGlu CreRFP littermates were once again inter-crossed with LKB1f/+ mice to 
generate GluLKB1KO (LKB1f/f, Cre and RFP positive), GluLKB1het (LKB1f/+, Cre and RFP positive) and 
LKB1WT (LKB1+/+, Cre and RFP negative). All mice were kept on a mixed FVB/129S6 and C57BL/6 
background, offspring genotypes were obtained in the expected Mendelian ratios.  
2.1.3 Generation of mice selectively lacking AMPKα1 and α2 in proglucagon-
expressing cells 
  Mice homozygous for the floxed allele of the AMPKα1 gene were first bred against mice with 
homozygous floxed allele for the AMPKα2 gene (both provided by Dr Benoit Viollet, CNRS, Paris, 
France [402]), resulting in double heterozygous AMPKα1f/+α2f/+ mice. These heterozygous mice were 
inter-crossed to generate homozygous AMPKα1f/fα2f/f mice which were subsequently crossed with 
mice expressing Cre-recombinase under the control of the proglucagon promoter (iGlu Cre) [403]. 
The heterozygous AMPKα1f/+α2f/+iGlu Cre littermates were then inter-crossed with AMPKα1f/fα2f/f 
mice to generate GluAMPKKO (AMPKα1f/f, AMPKα2f/f, iCre positive) and WT mice (AMPKα1f/f, 
AMPKα2f/f, iCre negative). All mice were kept on a mixed FVB/129S6 and C57BL/6 background, 
offspring genotypes were obtained in the expected Mendelian ratios.   
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2.1.4 Mice maintenance and diet 
  Mice were housed at up to five animals per cage in a pathogen free facility with a 12 hour 
light/dark cycle and unrestricted access to standard mouse chow diet (Research Diet, New 
Brunswick, NJ, USA). All in vivo procedures were conducted at the Imperial College Central 
Biomedical Service and approved by the UK Home Office Animals Scientific Procedures Act, 1986. 
2.1.5 Body weight  
  Body weight of mice was monitored weekly after weaning as well as being assessed using the 
mouse body condition score [404].  
2.1.6 Oral and Intraperitoneal glucose tolerance test 
  Mice were fasted for 15 hours, with free access to water, before being given 2g glucose/kg of 
glucose administered either through oral gavage (OGTT) or via intraperitoneal injection (IPGTT). 
Blood (2-4µl) from the tail vein was collected at 0, 15, 30, 60 and 120 mins. after injection. Blood 
glucose levels were measured using an automatic glucometer (Accuchek; Roche, Burgess Hill, UK).  
2.1.7 Insulin tolerance test (ITT) and plasma glucagon measurement  
  Mice were fasted for 5 hours, with free access to water, before being given intraperitoneal injection 
with 0.75 U/kg bovine insulin (Sigma, Dorset,UK) between 14:00 and 15:00 hours. Blood glucose 
levels were measured at 0, 15, 30, 45 and 60 mins. after injection.  
2.1.8 Plasma glucagon and insulin measurement 
  For measurement of plasma glucagon, 100ul of blood was collected from the mice tail veins into 
heparin coated tubes (Sarstedt, Beaumont Leys, UK) at 0, 15 and 30 mins. after insulin injection. 
Plasma was separated by centrifuging the blood at 4°C 13,200 r.p.m. for 20 mins. Blood serum (50µl) 
was used to measure plasma glucagon levels by radioimmunoassay (RIA) with a competitive 125I 
labeled glucagon (Millipore, Watford, UK).   
  For measurement of plasma insulin levels after glucose injection, mice were faster for 15 hours and 
given intraperitoneal injected of 2g glucose/kg mouse weight. 100µl blood from mice tail was 
collected and plasma was separated by centrifugation at 13, 2000 r.p.m. for 20 mins. As before, 
plasma insulin levels was measured using RIA with a competitive 125labelled insulin (Millipore, 
Watford, UK) and described in more detail in 2.2.3.   
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2.2 In vitro cell experiments 
 
2.2.1 Islet isolation and dissociation 
Mice were sacrificed via dislocation of the neck followed by decapitation. Collagenase NB8 from 
Cloctridium histolyticum (SERVA Electrophoresis): (1mg/ml in RPMI-1640) was injected into the 
pancreatic duct (5ml/mouse).  The inflated pancreas was then incubated at 37°C for 10 mins. The 
digested pancreas was washed 2-3 times with RPMI-1640 and separated from exocrine tissues by 
centrifuging through a Histopaque gradient (Sigma Aldrich, Dorset, UK) at the densities of 1.110, 
1.083 and 1.077g/ml at 2,500 r.p.m for 20 mins. After washing in RPMI-1640, individual islets were 
picked and incubated further in RPMI-1640 medium treated with 100U/ml penicillin and 
streptomycin and 10% [vol./vol.] heat-inactivated fetal bovine serum (FBS) for 24 hours before 
further analysis.  
  Islets were dissociated after isolation to obtain single cells for imaging by washing the islets 2-3 
times in PBS and incubating at 37°C for 10 mins. in Hanks Balanced Salt Solution. After a brief 
centrifugation, this solution was replaced by RPMI-1640, and the islets were disrupted by vigorous 
pipetting. Cells were incubated for over 4 hours on circular glass coverslips pre-treated with 0.01% 
[wt./vol.] polyLysine (Sigma, Dorset, UK). 
2.2.2 Treatment of islets for glucagon and insulin measurements 
  To measure glucagon secretion from mouse islets, 12 size-matched islets were pre-incubated for 30 
mins. at 37°C in Krebs-Ringer bicarbonate buffer (KRB) solution(in mmol/l: 130 NaCl, 3.6 KCl, 1.5 
CaCl2, 0.5 MgSO4, 0.5 KH2PO4, 2NaHCO3, 10 HEPES and 0.1% [wt/vol.] BSA, pH 7.4) containing 
10mmol/l glucose, with gentle shaking (120 rev/min). Islets were further incubated in 500µl KRB 
solution containing 0.1, 1, 3 or 17 mmol/l glucose for 1 hour at 37°C. Total glucagon extracts were 
lysed in 500µl acid-ethanol-Triton solution (1.5% [vol./vol.] HCl, 75% [vol./vol.] ethanol, 0.1% 
[vol./vol.] Triton X-100).  
  To measure insulin secretion from pancreatic mouse islets, 6 size-matched mouse islets were pre-
incubated in KRB solution containing 3mmol/l glucose, for 1 hour at 37°C with gently shaking (120 
rev/min). Islets were further incubated in 500µl KRB solution containing 3 or 17 mmol/l glucose for 
30 mins. at 37°C. 
2.2.3 Insulin and glucagon radioimmuno-assay 
  To measure glucagon or insulin levels a RIA kit (Millipore, Watford, UK) with competitive 125I-
labelled glucagon or insulin was used according to the manufacturer’s instructions.  
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  To measure secreted and total glucagon levels, 50µl of supernatants from islets treated with KRB 
solution or 50µl of total islets (1:500 diluted in assay buffer (provided by the kit)) were incubated 
with glucagon antibody at 4°C overnight. After a further overnight incubation with 125I labelled 
glucagon at 4°C, precipitation buffer was added. After 20 mins. incubation, the 125I labelled glucagon 
bound to the antibody was precipitated by centrifuging at 2,000 r.p.m. for 20 mins. and measured 
using a gamma counter. The glucagon levels were calculated against the glucagon standards 
(20pg/ml-400 pg/ml) provided in the kit.  
  To measure secreted and total insulin levels, 100 µl of supernatants from islets treated with KRB 
solution or 100 µl of total islet lysates (1:1000 diluted in assay buffer) were incubated with insulin 
antibody and 125I labelled insulin at 4°C overnight. After a further 20 mins. of incubation with 
precipitation buffer, 125I labelled insulin bound to the antibody was precipitated by centrifuging at 
2,000 r.p.m. for 20 mins. and measured using a gamma counter. The absolute insulin levels were 
calculated against the insulin standards (0.1 ng/ml- 10 ng/ml) provided. 
2.2.4 Ca2+, TMRE and ATP imaging using confocal microscopy 
  Isolated islets were incubated (37°C, 90% O2/ 5% CO2) for 40 mins. in fluo2-AM (Cambridge 
Bioscience, UK) (10 µmol/L) diluted with a mixture of DMSO (0.01% [wt./vol.]) and pluronic acid 
(0.001% [wt./vol.]) (Invitrogen, Paisley, UK) in a bicarbonate buffer solution (120mmol/L NaCl, 
4.8mmol/L KCl, 1.25mmol/L NaH2PO4, 24mmol/L NaHCO3, 2.5mmol/L CaCl2, 1.2 mmol/L MgCl2 and 
3mmol/L D-glucose, all Sigma Aldrich, Dorset, UK) adjusted to pH 7.4. Islets were placed in a custom-
manufactured 36 C chamber (Digital Pixel) mounted on a Zeiss Axiovert coupled to a Nipkow 
spinning disk head and the resulting traces were normalised to minimum fluorescence (Fmin). 
Whole-islet multicellular Ca2+ imaging was performed as described [405]. Briefly, Ca2+ dynamics were 
captured with cellular resolution from the 50-200 fluo-2-loaded cells residing within the first and 
second layers of the intact islets. A solid-state laser (CrystaLaser) controlled by a laser-merge module 
(Spectral Applied Physics) provided wavelengths of 491nm to excire fluo-2 (rate=0.5Hz; exposure 
time 260ms). Emitted light was filtered at 525/50nm, and images were captured by a highly sensitive 
16-bit, 512 x 512 pixel back-illuminated EM-CCD camera (ImageEM 9100-13; Hamamatsu). 
Throughout the recordings islets were kept at 36°C and continuously perfused with the bicarbonate 
buffer at 95% O2/CO2.  
  Islets were imaged similarly using tetramethylrhodamine, ethyl ester (TMRE) to measure 
mitochondrial membrane potential. For cytosolic ATP/ADP imaging with Perceval [50], islets were 
infected for 48 hours with adenovirus at multiplicity of infection 10. Cells were imaged using the 
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bicarbonate solution (as mentioned above). Absobance/ emission was 491/525nm and islets were 
captured as above. 
2.2.5 Detection of ATP  
  Size-matched islets were separated into batches of 30 and treated in either 3 or 17mM of glucose 
for 30 mins. at 37°C before removal of supernatant and extraction of lysate using percholoric acid 
followed by sonication and storage on ice [406]. ATP concentration in the supernatant was 
measured using a luciferase-based detection kit according to the manufacturer’s instructions (ATP 
Determination Kit, Life Technologies). 
2.2.6 Seahorse Bioscience XF24 assay 
  Real-time measurements of mitochondrial oxygen consumption rates (OCR) was achieved using 
Seahorse XF analyser and the XF24 islet capture FluxPak and XF cell mito stress test kits available 
(Seahorse Bioscience, USA). Briefly, the XG sensor cartridge provided in the pack was calibrated by 
incubating overnight at 37°C without CO2 in XF calibration buffer. 70 size-matched isolated islets 
were selected per well and washed once in Seahorse Bioscience MA media (8g/L Dulbecco’s 
modified eagle’s medium without additives (Sigma, Dorset, UK) and 1% FBS pH 7.4) and 500ul of MA 
media was added to each well. Islets were carefully positioned to the depression at the bottom of 
the well and the islet capture screen plates provided were added to the bottom of each well to 
ensure islets remained in the depression. Whist the sensor cartridge was being prepared the 
microplate was incubated at 37°C without CO2. The compounds added to each port of the XF sensor 
cartridge are listed in table 2.1 below. 
Injection Port Volume Concentration in Port Final Concentration in Well 
A: Glucose 50ul 200mM 20mM 
B: Oligomycin 55ul 50uM 5uM 
C: FCCP 60ul 10uM 1uM 
D: Rotenone 65ul 50uM 5uM 
D: Antimycin 65ul 50uM 5uM 
Table 2.1: Compounds added to each port of XF sensor cartridge 
  After the XF sensor cartridge is filled with compounds for injection the cartridge was calibrated in 
the XF analyser. After calibration was completed the XF24 islet capture plate was added to the XF24 
analyser to start recordings, each port releasing its provided drug approximately every 30 minutes 
(going from A-B).  
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2.2.7 Metabolomic measurements 
  Islets were isolated and 200 islets per mouse were incubated for 30 mins. with gentle shaking in 
17mM glucose. Islets were then centrifuged, the supernatant removed and was quenched with 70µl 
ice-cold Milli-Q water. Metabolites were extracted and derivatised as described in [407] and 
analysed on an Agilent 6890N gas chromatograph (Agilent Technologies, Atlanta, GA) prepared with 
an Agilent 7683B auto—sampler (Agilent Technologies) and joined to a LECO Pegasus III TOFMS 
electron impact time-of-flight mass spectrometer (LECO Corp., St Joseph, MI) as described in [408]. 
These experiments were performed by Peter Spegel, Unit of Molecular Metabolism, Lund University 
Diabetes Centre. 
2.2.8 Electron microscopy of islets 
  Approxaimatly 100 islets were isolated per mouse, spun at 500r.p.m. for 30 seconds and 1ml of 
fixative added to islets (2% formaldehyde, 2.5% glutaraldehyde, 3mM CaCl and 0.1M sodium 
cacodylate buffer (pH 7.4)). Islets were incubated for 30 mins. At 37°C and washed with fresh fixative 
for a further 2 hours at room temperature. Islets were once again washed in fresh fixative and left at 
4°C overnight. Electron microscopy was performed as described in [409] and images were taken by 
Dr. Alejandra Tomas, Department of Cell Biology and Functional Genomic, Imperial College London. 
 
2.3 Protein Experiments 
 
2.3.1 Immunohistochemistry of whole pancreas and ileum sections  
  Isolated pancreata and ileum sections were fixed in 10% [vol./vol.] formalin, transferred into a 
tissue processing cassette and embedded in paraffin wax within 24 hours of being harvested from 
the mouse. Pancreas sections were cut at 5µm and gut sections were cut at 7µm and incubated 
overnight at 37°C on superfrost slides. Slides were submerged in histoclear (Sigma Aldrich, Dorset, 
UK) for 20 mins., followed by further sequential washes in decreasing concentrations of ethanol 
(100, 95, 75% and H2O) for removal of paraffin wax. Slides were treated with vector antigen solution 
and subsequently blocked in 0.25% [vol./vol.] goat/donkey serum (Dako, ely, UK) in 2% BSA with 
0.1% [vol./vol.] tween for 20 mins. at room temperature. The slides were then incubated in a 
mixture of the primary antibodies (see appendix 1 for a list of antibodies used) at 4°C in a moist box 
to ensure slides do not dry out. After washing in PBS, 0.25% bovine serum albumin (BSA) and 0.25% 
Triton X-100 three times for 10 mins. (each wash), slides were visualised with either Alexa Fluor 568 
or 488 conjugated IgG (Invitrogen, Paisley, UK) (see appendix 1 for the full list of antibodies used) 
and DAPI (Vectalaboratory) under fluorescent microscopy using a Zeiss Axio Observer inverted 
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widefield microscope with LED illumination and VivaTome spinning disc unit and running Zen 
acquisition software. 
2.3.2 Optical Projection Tomography and determination of relative β-cell and L-
cell mass 
  Whole pancreatic and gut optical projection tomography (OPT), to 19µm resolution, was performed 
as described [410]. In short, whole pancreata fixed in 4% [wt./vol.] paraformaldehyde for 3 hours at 
4°C were dehydrated and went through five freeze and thawing cycles (-80°C to room temperature). 
The pancreata were blocked overnight in TBS (pH 7.5), containing 10% goat/donkey serum (Dako, 
Ely, UK), 0.01% [wt./vol.] sodium azide and 0.05% [vol./vol.] Tween, before incubation with primary 
antibody (see appendix 1 for list antibodies) dissolved in the above buffer and further supplemented 
with 5% [vol./vol.] dimethylsulfoxide (DMSO) overnight for 48 hours at room temperature. Samples 
were visualised using either Alexa Fluor 594 or 568 conjugated IgG (Invitrogen, Paisley, UK), see 
appendix 1 for full list of antibodies used. The samples were mounted in 1% [wt./vol.] low melting 
temperature agarose, dehydrated in methanol and cleared in BABB solution (benzyl alcohol: benzyl 
benzoate [1:2] for optical tomographical scanning.  
  All specimens were scanned using two fluorescent channels (excitation: 580 ± 15nm and emission: 
650 ± 25 nm for insulin and glucagon positive staining; excitation: 480 ± 9 nm and emission: 650 ± 25 
nm for autofluorescence); performed in collaboration with Dr. James McGinty and Dr Chen Lingling, 
(Department of Photonics, Imperial College London, UK). The raw data for these two channels were 
reconstructed in a pair of 3D voxel data sets (voxel to µm = 1:19) using Matlab software and cell 
volumes (µm3) from each channel were measured using VolocityTM 5.0. Data from VolocityTM 5.0 
were further analysed in Microsoft Excel to provide total volume graphs and size frequency 
histograms. Relative β and L-cell mass was calculated by dividing the volume of the insulin/ glucagon 
positive area (“total beta/L cell mass”) by that of the autofluorescence area (“total pancreatic/ gut 
mass). 
 
2.4 Molecular Biology experiments  
 
2.4.1 DNA extraction and polymerase chain reaction (PCR) for genotyping studies 
  Genomic DNA from ear extracts of mice was obtained by lysing samples in 1.25µl proteinaseK 
(Sigma) (20mg/ml in ddH2O) with 5µl 10X PCR-buffer (New England Biolab, Hitchin, UK) and 43.75µl 
ddH2O at 55°C for 40 mins. and 95°C for 10 mins.   
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  For genotyping using LKB1 and Ins1 Cre primers, the PCR reaction was performed in 20µl reaction 
mixture containing: 5x PhireTM reaction buffer, 0.2 mmol/l dNTP (Qiagen, Hilden, Germany), 0.5 
µmol/l forward and reverse primers (see appendix 2 for list of primers used for genotyping), 0.4 µl 
PhireTM hot start DNA polymerase (Thermo Scientific) and 1µl DNA. The reaction consists of a 30s 
98°C pre-heating step, followed by an amplification step of 30 cycles: 98°C for 5 seconds, Tm 55-60°C 
for 5 seconds and 72°C for 10 seconds. After the last cycle, a prolonged extension step was carried 
out for 1 min. at 72°C. 
  For genotyping iGlu Cre, the PCR reaction was performed in a 25µl reaction mixture containing:  
12.5µl 5x GoTaq Green master mix (Promega, UK), 2.5µl primer (see appendix 2), 1.25µl DMSO and 
5.75µl H2O. The reaction consists of a 3 min. 95°C pre-heating step, followed by an amplification step 
of 40 cycles:  95°C for 1 min., Tm 58°C for 1 min. and 72°C for 1 min.. After the last cycle, a prolonged 
extension step was carried out for 5 min. at 72°C.  
2.4.2 RNA extraction and real-time (RT) PCR 
Total cellular RNA from mouse islets was obtained using Trizol reagent (Invitrogen, Paisley, UK), after 
10 mins. incubation 0.2 volume of Chloroform (Sigma) was added which was centrifuged at 
12000r.c.f. for 15 mins. at 4°C and the supernatant removed and mixed with 2µl glycogen. 0.8 
volume of isopropanol was added and incubated at 4°C for 15 mins. The RNA was then centrifuged 
for 15 mins. and the supernatant removed, the RNA was washed in 70% ethanol and centrifuged at 
12000r.c.f. for 5 mins., this step was repeated twice. Total RNA (2µg) was then reversed transcribed 
into cDNA with a high-capacity reverse transcription kit (Applied Biosystems). The PCR reaction was 
performed in 20µl of reaction mixture containing:  2µl 10x RT buffer, 0.8µl 25x dNTP mix (100mM), 
2µl 10x RT random primers, 1µl MultiScribeTM reverse transcriptase, 4.2µl H2O and 10µl 500ng/µl 
DNA. The PCR was heated at 25°C for 10 mins., 37°C for 2 hours and 85°C for 5 mins. 
2.4.3 Quantitative Real-Time PCR (qRT-PCR) 
  The expression levels of genes were quantified by real-time PCR using SYBR green. In 12µl final 
volume, the reaction contained: 6µl fast SYBR green master mix (Invitrogen, Paisley, UK), 0.35µmol/l 
forward and reverse primers, and 20ng cDNA (see Appendix 3 for the list of genes and primers). The 
PCR reaction was preheated at 60°C for 2 mins. and 95°C for 10 mins. PCR amplification was 
performed for 40 cycles of 95°C for 15 seconds and 60°C for 1 min. At the end of the last cycle, a 
deissociation step consisting of 95°C for 15 seconds, 60°C for 1 min. and 95°C for 15 seconds was 
performed.  
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  The PCR cycle numbers required to generate fluorescent signals for each gene were plotted in the 
equipment software (Fast 7500 v2.0.4, Applied biosystems) showing a shape of a sigmoidal curve 
(the amplification curve). A horizontal line intersecting the exponential part of the amplification 
curve above the background was drawn and the corresponding cycle number (Ct) was selected.  The 
relative gene expression against the house keeping gene cyclophillin was calculated by using the 
equation below [411]: 
Relative gene expression = 2 Ct(cyclophillin)-Ct(gene) 
 
2.4.4 Amplification and purification of high titre adenovirus 
  Approximately 80% confluent HEK 293 cells in a 25cm2 tissue culture flask were infected with 40-
50% of primary transfection viral supernatant. After 3-5 days, when 90% cells were expressing green 
fluorescent protein (GFP) and 30-50% of the cells had detached from the flask, the remaining cells 
were scraped from the flask and collected into a 15ml conical tube. Cells were centrifuged at 500g at 
4°C for 10 mins., resuspended in 15ml sterile PBS and after freezing in a dry ice/methanol bath and 
thawing in 37°C water bath five times, cells were used to re-infect 90% confluent HEK 293 cells in a 
75cm2 tissue culture flask. After 3-5 days this process was repeated re-infecting into 3-5 75cm2 tissue 
culture flasks and finally in a final round of large-scale amplification, re-infecting into 20 75cm2 tissue 
culture flasks.  One pellet was generated from cells collected from the 20 flasks by centrifuging cell 
suspension at 500g for 10 mins. After the pellet had been re-suspended in 8ml PBS, another 4 
rounds of freeze-thaw cycles were applied. The pellet suspension was mixed thoroughly with 
caesium chloride -0.1M Tris-HCl (Sigma) (pH 8.0) solution at a ratio of 5:3 and centrifuged at 65,000 
r.p.m, 4°C overnight. The virus was collected from the middle layer of the ultra-centrifuge tube and 
further washed in dialysis buffer (10% [vol./vol.] glycerol, 10 mmol/l Tris (pH 8.0), 10 mmol/l 
MgCl2.6H2O and 150mM NaCl) and resuspended in the same volume of storage buffer (70% 
[vol./vol.] glycerol, 0.1333% [wt./vol.] BSA, 0.013 mmol/l NaCL and 1.3 mol/l MgCl2). 
 
2.5 Statistical analysis 
 
  Data are expressed as means ± SEM. Significance was tested using two tailed paired or unpaired 
Student’s t test or by ANOVA, unless stated otherwise, using GraphPad Prism 6.0. A value of p<0.05 
was considered significant.  
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Chapter 3 
LKB1 deletion in β-cells enhances β-cell mass despite impaired Ca2+ 
and ATP flux 
Abstract 
Background and Aims: Regulation of glucose-stimulated insulin secretion (GSIS) by the pancreatic β-
cell is vital for the preservation of glucose homeostasis and when compromised can lead to some 
forms of diabetes. The tumour suppressor Liver Kinase B1 (LKB1) exerts its biological effects largely 
via direct phosphorylation of AMP-activated protein kinase (AMPK) and related kinases. Here, we 
delete LKB1 in β-cells and examine insulin secretory function in these mice.  
Methods: Mice deleted selectively in the β-cell for LKB1 were generated by breeding animals bearing 
floxed alleles at exons 3-6 with the β-cell-selective Ins1Cre deleter line. Optical projection tomography 
of whole pancreata was performed to assess β-cell mass and radioimmunoassay to assess insulin 
secretion of isolated islets. Changes in cytosolic ATP/ADP and Ca2+ were measured by confocal 
microscopy of whole islets expressing the recombinant GFP-based probe Perceval, or loaded with the 
fluorescent Ca2+ dye, fluo-2, respectively. Seahorse XF24 analysis was used to measure oxygen 
consumption rate and the fluorescent dye TMRE to measure mitochondrial membrane potential in 
islets. Metabolomics profiling studies were performed using gas chromatography mass spectroscopy.  
Results: β-cell mass increased in LKB1 deleted mice (P<0.05). Despite this, insulin secretion was 
not affected by LKB1 deletion in vitro. We observed significant impairment in [Ca2+]cyt and 
[ATP/ADP]cyt increases (P<0.01, 0.05, respectively) in response to high glucose. Moreover, 
enhanced signalling by the glutamate receptor agonist kainite lead to intracellular Ca2+ changes 
and insulin secretion being significantly enhanced in these mice (P<0.05).  
Conclusions: LKB1 is vital for normal glucose signalling and mitochondrial function in β-cells. 
However, when deleted other signalling pathways become amplified, such as glutamate 
signalling, to maintain normal GSIS. These findings thus reveal a new mechanism which may be 
targeted to increase insulin release in some forms of Type 2 Diabetes.   
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3.1 Introduction 
 
  Regulation of insulin secretion from the pancreatic β-cell is vital for the maintenance of glucose 
homeostasis, as discussed in chapter 1. GSIS is initiated by the breakdown of glucose to pyruvate 
through glycolysis and pyruvate is in turn oxidised in the mitochondria leading to increased ATP/ADP 
ratio. ATP-sensitive potassium (K+ATP) channels on the plasma membrane of pancreatic β-cells detect 
an increase in ATP/ADP ratio in the cytoplasm and the closure of this channel initiates the 
depolarisation of the cell [55, 412]. This results in the opening of voltage-sensitive L-type Ca2+ 
channels and consequently the release of insulin granules from a readily releasable pool (RRP) [60, 
69]. The insulin secretory response is biphasic and after secretion from the RRP a slower and more 
prolonged second phase occurs which requires the recruitment and trafficking of insulin granules to 
the plasma membrane of the  β-cell [35]. Thus, GSIS requires normal mitochondrial function as well 
as an increase in the ATP/ADP ratio and influx of Ca2+ into the cytoplasm of β-cells [413-415]. β-cell 
dysfunction will result in impairment of GSIS and contributes to some forms of diabetes [416].  
  As mentioned in chapter 1, LKB1 is an upstream kinase for AMPK and other members of the AMPK 
family [204] that has previously been implicated in β-cell glucose sensing [228, 417]. LKB1 plays a 
central role in the determination and maintenance of cell polarity [418-420], cellular metabolism 
[421] and genome integrity [93].  A link between LKB1 and diabetes was uncovered upon LKB1 
deletion in the liver, demonstrating that LKB1 is essential for the beneficial effects of metformin 
[317]. Additionally, activation of LKB1 via the regulation of AMPK and phosphorylation of TORC2 will 
prevent gluconeogenesis by preventing synthesis of gluconeogenic enzymes [319]. 
  LKB1 has been previously deleted in pancreatic β-cells of adult mice carrying the Pdx1 CreER 
promoter as well as in LKB1 floxed mice expressing the RIP2 Cre deletor [318-320].  In vivo insulin 
secretion, β-cell proliferation and mass were improved in these mice (~20-65% increase) and MARK 
became inactivated resulting in alterations in cell polarity [318-320]. These studies indicate that the 
deletion of LKB1 in β-cells may work as an effective therapy for the treatment of Type 1 and Type 2 
Diabetes. However, the precise mechanisms underlying the enhanced insulin secretion in these mice 
remained unclear.  
  Several phosphorylation targets for LKB1 have been suggested as positive regulators of GSIS such as 
SIK2, which improves insulin secretion via the degradation and phosphorylation of CDK5RI/p53 [422] 
and SAD-A, which regulates GSIS and β-cell size [423]. Nevertheless, deletion of these genes results 
in impairment of GSIS [422, 423]. Deletion of LKB1 prevents phosphorylation of these proteins, 
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despite this GSIS becomes enhanced overall. Therefore, it is thought that an alternative pathway 
may be present for normal GSIS to occur.  
  The neurotransmitter glutamate is thought to play a role in GSIS [185, 187, 189, 190, 194] and 
though primarily expressed in the brain, both ionotropic and metabotropic glutamate receptors are 
present in the pancreatic β-cell [185]. The precise mechanism by which glutamate affects insulin 
secretion remains unclear. RNASeq analysis in islets of mice deleted for LKB1 revealed an up-
regulation of the genes Nptx2, Gria3 and Dlgap2, involved in glutamate signalling. Thus, Gria3 
encodes for the ionotropic glutamate receptor GluR1 [424], Dlgap2 encodes large homologue-
associated protein 2 which Is  a membrane-associated protein which makes up part of the 
postsynaptic density scaffold [425] and Nptx2 is involved in synaptic formation and in the clustering 
of AMPA receptors. 
  In this chapter we use Ins1Cre recombinase to delete LKB1 floxed alleles and so generate β-cell 
selective null alleles. Ins1Cre induces deletion in approximately 94% of pancreatic β-cells from the 
immediate postnatal period to adulthood therefore differing from the previously used Pdx1CreER 
transgene which was induced in 8-10 week old mice [426] and the RIP2Cre promoter which deletes 
in the hypothalamus as well as the β-cell [320]. Thus, we aimed to determine the role of LKB1 in the 
β-cell, GSIS and whether alterations of glutamate signalling contributes to the LKB1 phenotype.   
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3.2 Results 
 
3.2.1 Ins1LKB1KO improves β-cell mass and has no effect on insulin secretion in 
vitro 
 
  As shown by Kone et al, 2014 [427], glucose tolerance and plasma insulin measurements are 
significantly improved in Ins1LKB1KO mice versus littermate controls (Appendix 4). To study β-cell 
mass in these mice we used OPT, allowing us to analyse (alongside conventional 
immunohistochemistry) mean, average, total volume, size and number of islets within the whole 
pancreas, see materials and methods 2.3.2 (Figure 3.1a-e).  Relative β-cell mass was increased in 
Ins1LKB1KO versus WT mice, P<0.05 (1.50 ± 0.30%, 0.80 ± 0.09%, respectively). Overall, islet number 
was greater in Ins1LKB1KO mice and in addition, the number of larger islets (3000- 40000µM3 X 103) 
was also higher (Figure 3.1e). Expression of the insulin gene Ins2 was up-regulated in islets of 
Ins1LKB1KO mice (WT: 1.297 ± 0.137, KO: 2.462 ± 0.045 normalised to cyclophillin, P<0.01) as was, 
to a lesser extent Ins1 expression, NS (WT: 1.13 ± 0.25, KO: 1.69 ± 0.10 normalised to cyclophillin, 
Figure 3.2a-b). This suggests that insulin production is up-regulated in Ins1LKB1KO mice.  
  As glucose tolerance and β-cell mass (Figure 3.1) were exaggerated in Ins1LKB1KO in comparison to 
WT mice, we anticipated an improvement in GSIS in vitro. Six size-matched islets per well were 
incubated in either 3mM or 17mM glucose and secreted and total insulin were measured using 
radioimmunoassay. As expected, in both Ins1LKB1 KO and WT islets insulin secretion was enhanced 
when islets were incubated in 17mM glucose in comparison to 3mM (WT: P<0.01, KO:P<0.05, Figure 
3.3). Surprisingly, when comparing the rate of insulin secretion between Ins1LKB1KO and WT islets, 
results were similar (3mM WT: 0.78 ± 0.27%, KO: 1.02 ± 0.22%; 17mM WT: 2.17 ± 0.60%, KO: 2.81 ± 
0.50%). 
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Figure 3.1 - β-cell mass is enhanced in Ins1LKB1KO mouse pancreata 
(A,B) Representative OPT images of fixed and permeabilised pancreatic tissue. Red, insulin-
positive structures within the pancreas. The overall shape of the pancreas was visualised as 
autofluorescence and is apparent as white/grey shading. Scale bar, 500µm. (C) Relative β-cell 
mass and (D) mean β-cell volume. (E) Distribution of pancreatic volume with dashed lines 
representing the magnified section. Data are from n=4 pancreatic tissue per genotype and 
expressed as means ±; *p< 0.05, by Student’s unpaired t-test. 
A. B. 
C. D. 
E. 
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Figure 3.3 - Insulin secretion is unaffected in Ins1LKB1KO islets 
Insulin secretion was measured in 6 size-matched islets isolated from WT and Ins1LKB1KO mice 
and incubated in either basal (3mM) or 17mM glucose. Data are expressed as means ± SEM, n=4 
mice/genotype, *P<0.05, **P<0.01, by 2-way ANOVA.  
Figure 3.2 - Gene expression of Ins1 and Ins2 are up-regulated in Ins1LKB1KO islets 
Levels of gene expression of (A) Ins1 and (B) Ins2 genes were measured in WT and Ins1LKB1KO 
mice normalising with β-actin. Data are expressed as means ± SEM, n=3 mice/genotype, 
***P<0.001, by Student’s unpaired t-test. 
A. B. 
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3.2.2 Defects in ATP and Ca2+in Ins1LKB1KO occur independently of insulin 
secretion 
 
  As mentioned earlier and shown in the previous LKB1 KO mouse models [318-320] in vivo insulin 
secretion and β-cell mass are increased in Ins1LKB1KO versus WT mice (Figures 3.1, 3.2). However, in 
vitro insulin secretion is unchanged in Ins1LKB1KO versus WT islets (Figure 3.3). To further 
investigate the functionality of these islets in vitro, islets from Ins1LKB1KO and WT mice were 
isolated and cytosolic ATP/ADP ([ATP/ADP]cyt) and Ca2+ ([Ca2+]cyt) levels measured after glucose 
stimulation (11mM) using confocal microscopy (Figures 3.4 and 3.6).  
  For normal insulin secretion, increasing the concentration of glucose in the β-cell results in elevated 
cytosolic ATP/ADP levels; this is vital for closure of KATP channels and subsequent depolarisation of 
the plasma membrane.  [ATP/ADP]cyt was measured in isolated islets after 48 hours expression of the 
ATP sensor Perceval (chapter 2.2.4) and response to glucose was found to be impaired in islets of 
Ins1LKB1KO versus WT mice (P<0.05, WT: 116.2 ± 3.46%, KO: 106.6 ± 1.12%, Figure 3.4b). In 
addition, the percentage of cells responsive to rising glucose concentrations was also greatly 
reduced in these Ins1LKB1KO islets (P<0.05 WT: 37.64 ± 4.51%, KO: 22.75 ± 2.90%, Figure 3.4c). We 
further demonstrate that ATP production is down-regulated in the islets of these mice by the use of 
a luciferase based ATP kit which, though not significant, demonstrated a decreasing trend of ATP 
detection in Ins1LKB1KO mice (NS, 3mM WT: 52.59 ± 11.84pmol/islet, KO: 38.47 ± 13.61pmol/islet; 
17mM WT: 238 ± 36.34pmol/islet, KO: 168.4 ± 60.51pmol/islet, Figure 3.5).  
  These results suggest that surprisingly normal cytosolic signalling is disrupted, despite normal 
insulin secretion. To further investigate the glucose-ATP-Ca2+ response, [Ca2+]cyt was measured using 
Fluo-2AM, a sensitive indicator for intracellular free ions. In stimulation of normal insulin secretion 
the surge in [Ca2+]cyt is the main trigger for insulin exocytosis [57]. By measuring [Ca2+]cyt we further 
confirmed that the fraction of responding β-cells is smaller in Ins1LKB1KO islets (P<0.001, WT: 66.88 
± 6.07%, KO: 28.67 ± 6.13%, Figure 3.6c), as is the amplitude of [Ca2+]cyt response (P<0.01, WT:180.1 
± 5.03, KO: 142.9 ± 5.93, Figure 3.6a-b). Thus Ins1LKB1KO islets have a defect in glucose-stimulated 
Ca2+ entry which remarkably does not interfere with normal GSIS. 
  To examine whether this defective cytoplasmic signalling function in Ins1LKB1KO islets acts in a cell 
autonomous manner, we re-introduced WT LKB1 by adenoviral infection (Ad-STK11, Vector Biolabs) 
into cultured Ins1LKB1KO islets. We found that within 48 hours of infection, levels of LKB1 in 
Ins1LKB1KO islets were restored (Figure 3.7a). In these islets, both cytosolic ATP and Ca2+ fluxes were 
restored to near normal levels ([ATP/ADP]cyt WT: 118.2 ± 15.09%, KO: 74.91 ± 7.28, LKB1 adeno: 
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113.8 ± 13.86, P<0.05 WT versus Ins1LKB1KO, Figure 3.7b; [Ca2+]cyt WT: 147.4 ± 6.10%, KO: 78.90 ± 
15.72%, LKB1 adeno: 135.4 ± 2.03%, P<0.001 WT versus Ins1LKB1KO, P<0.01 Ins1LKB1KO versus LKB1 
adeno). The percentage of cells responding to glucose stimulation was also restored to near normal 
levels ([ATP/ADP]cyt WT: 62.90 ± 2.22%, KO: 47.71 ± 6.39%, LKB1 adeno: 73.80 ± 4.50%, P<0.01 
Ins1LKB1KO versus LKB1 adeno, Figure 3.7d; [Ca2+]cyt WT: 75.20 ± 6.24%, Ins1LKB1KO: 53.50 ± 3.62%, 
LKB1 adeno: 64.33 ± 7.17%, P<0.05 WT versus Ins1LKB1KO, Figure 3.7g). These experiments indicate 
that defects in Ins1LKB1KO cell signalling are a direct effect of LKB1 loss in β-cells, rather than an 
indirect compensatory mechanism.  
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Figure 3.4 - Glucose-induced [ATP/ADP]
cyt
 changes are drastically impaired in Ins1LKB1KO versus WT  
mouse islets 
(A) [ATP/ADP]
cyt
 changes in WT versus Ins1LKB1KO islets (B) quantitation of amplitude and (C) % of  
islets or cells responsive to glucose. Data are expressed as means ± SEM, n=3 mice/genotype and 12 
islets/genotype, *P<0.05, by Student’s unpaired t-test. 
B. 
A. 
C. 
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Figure 3.5 - Luciferase-based measurements of ATP concentrations in glucose-treated islets 
Islets from WT and Ins1LKB1KO mice were incubated in 3 or 17mM glucose and ATP levels 
measured in the luciferase based ATP assay after 30 mins. Data are expressed as means ± SEM, 
n=3 mice/genotype, *P<0.05, by 2-way ANOVA. 
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Figure 3.6 - [Ca
2+
]
cyt 
changes are drastically impaired in Ins1LKB1KO islets 
(A) Glucose-induced [Ca
2+
]
cyt
 dynamics in islets from WT and Ins1LKB1KO mice, (B) quantitation 
of amplitude and (C) % of islets or cells responding to glucose. Data are expressed as means ± 
SEM, n=3 mice/genotype and 12 islets/genotype, **P<0.01, by Student’s unpaired t-test.  
A. 
B. C. 
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D. 
E. F. G. 
Figure 3.7 - In vitro rescue of LKB1 expression results in restoration of [ATP/ADP]
cyt
 and [Ca
2+
]
cyt 
 
signalling in Ins1LKB1KO mice 
(A) Expression of LKB1 was measured in WT and Ins1LKB1KO islets infected with the adenoviruses 
encoding WT LKB1 at the multiplicity of infection (MOI) indicated, n=3 mice/genotype (B) Rescue of 
glucose-stimulated calcium influx in Ins1LKB1KO islets. Both the amplitude (left) and the fraction of 
responding cells (right) returned to normal upon LKB1 re-expression, n=3 mice/genotype, 9-12 
mice/genotype (C) Rescue of glucose-stimulated [ATP/ADP]
cyt
 rise in Ins1LKB1KO islets, both amplitude 
(left) and the % of responding islets (right) are improved upon LKB1 overexpression n=5 mice/genotype, 
9-15 islets/genotype. Data are expressed as means ± SEM, *P<0,05, **<0.01, ***P<0.001, by one-way 
ANOVA.  
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3.2.3 LKB1 is required for normal mitochondrial function  
 
  Glucose entry into β-cells triggers Ca2+ influx and insulin exocytosis through oxidative 
phosphorylation in the mitochondria and generation of ATP, resulting in KATP channel closure. Given 
the defects found in [Ca2+]cyt and [ATP/ADP]cyt KO islets, we predicted that mitochondrial metabolism 
may also be impaired in islets of Ins1LKB1KO mice.  
 We first examined mitochondrial membrane potential in isolated islets using the mitochondrial 
membrane potential sensitive dye TMRE by confocal imaging (Figure 3.8). Ins1LKB1KO islets showed 
a reduction in TMRE staining in response to high glucose (P<0.01, WT: 119.3 ± 4.14%, KO: 96.09 ± 
6.38%, Figure 3.8a-b), though the % of cell responsive was not affected (NS, WT: 70.91 ± 7.30%, KO: 
60.14 ± 9.76%, Figure 3.8c). These results indicate some degree of mitochondrial dysfunction in 
Ins1LKB1KO islets.  
  To further assess metabolic regulation in the absence of LKB1 we performed metabolite profiling to 
determine which metabolites were affected in KO isolated islets after incubation in 17mM glucose 
(Figure 3.9). Data was analysed using orthogonal projections to latent structures- discriminant 
analysis (OPLS-DA) (data not shown). A shared-and-unique-structure (SUS)-like plot, revealed 
differences in metabolite levels in KO in comparison to WT islets (Figure 3.9a). This showed that 
fructose-6-phosphate was higher in Ins1LKB1KO islets whereas TCA-metabolites and FFAs were all 
down-regulated in these islets. Several FA derivatives levels were statistically higher in WT versus 
Ins1LKB1KO islets (P<0.05, Figure 3.9b). Other metabolites which tended to be up-regulated included 
citrate (NS, P<0.092), succinate (NS, P<0.096) and fumerate (NS, P<0.079) as well as glycerol (NS, 
P<0.066). On the other hand, fructose-6-phosphate was significantly increased in Ins1LKB1KO islets 
versus WT islets, P<0.001.  Metabolite measurements were performed by Peter Spegel, Unit of 
Molecular Metabolism, Lund University Diabetes Centre. 
  To further assess mitochondrial flux, we also measured oxygen consumption rate (OCR) in 
mitochondria of Ins1LKB1KO islets using a XF24 seahorse analyser (Figure 3.10 and 3.11). To 
determine the optimal concentrations of drugs to use for this experiment, islets were stimulated 
with varying concentrations of glucose, oligomycin and mesoxalonitrile 4-
trifluoromethoxyphenylhydrazone (FCCP) (Figure 3.10). 
  Oligomycin was added to islets to block ATP synthesis by inhibiting ATP synthase (complex V), thus 
allowing us to distinguish oxygen consumption dedicated to ATP synthesis and the proportion of 
oxygen consumption necessary to overcome the natural protein leak through the inner 
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mitochondrial membrane. ATP production can be calculated by comparing the decrease in OCR after 
oligomycin is added to islets with basal respiration. Proton leak can also be quantified by comparing 
the OCR in islets after oligomycin is added with non-mitochondrial respiration. We determined that 
islets responded best to oligomycin at 1µM Figure 3.10b. 
  The uncoupling agent FCCP disrupts ATP synthesis by carrying hydrogen ions across the 
mitochondrial membrane thereby collapsing mitochondrial membrane potential and resulting in the 
rapid consumption of oxygen without the generation of ATP. Exposing islets to FCCP allows us to 
calculate the “spare respiratory capacity” of islets, which is the quantitative changes between 
maximal uncontrolled OCR, and the original basal OCR. FCCP was found to work most efficiently at 
1µM. As concentrations of FCCP increased OCR dropped as islets appear to die (figure 3.10c).  
  Rotenone (a complex I inhibitor) and antimycin (a complex III inhibitor) prevents mitochondrial 
respiration allowing the calculation of both the mitochondrial and non-mitochondrial fractions that 
contribute to respiration. 
  Following optimisation, Seahorse experiments in islets from Ins1LKB1KO mice and their WT 
littermates were conducted by injecting islets with these above four drugs (including antimycin and 
rotenone) at different stages throughout the recordings as explained in 2.2.8, Figure 3.11a and table 
2.1. As expected OCR increased after glucose stimulation (port A) but was unaltered in Ins1LKB1KO 
versus WT islets. 
  OCR was unaltered between Ins1LKB1KO and WT islets after oligomycin was added, Figure 3.11a.  
There also appears to be no significant changes in proton leak between these islets (NS, WT: 35.25 ± 
1.53%, KO: 40.45 ± 2.85%, Figure 3.11d), or in the rate of ATP production (NS, WT: 24.40 ± 5.76%, 
KO: 27.15 ± 6.01%, Figure 3.11b).    
  Interestingly, we found that the % OCR was significantly higher in Ins1LKB1KO versus WT islets after 
FCCP injection, P<0.05 (Figure 3.11a). Thus, the maximal respiration of KO islets was elucidated 
versus WT, (NS, WT: 95.80 ± 7.20%, KO: 130.5 ± 14.89%, Figure 3.11c) as well as the spare 
respiratory capacity (P<0.05, WT: 47.20 ± 12.53%, KO: 102.9 ± 17.13%, Figure 3.11e).  When we look 
at OCR at 20mM glucose versus FCCP we see a significant difference between Ins1LKB1KO and WT 
islets (P<0.01, WT: 0.88 ±0.04%, KO: 0.64 ± 0.04%, Figure 3.11g). 
  Finally, to assess any effect LKB1 has on mitochondrial structure, EM was carried out on pancreatic 
sections of WT versus Ins1LKB1KO mice (Figure 3.12). These images show no changes in 
mitochondrial structure. 
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Figure 3.8 - Mitochondrial defects are present in Ins1LKB1KO mice 
Mitochondrial membrane potential was measured in WT and Ins1LKB1KO islets. (A) Quantification of 
fluorescence intensity of TMRE, (B) amplitude and (C) % of islets responsive to stimulation. Data are 
expressed as means ± SEM, n=3 mice/genotype, 9-12 islets/genotype, **
 
P<0.01, by Student’s unpaired t-
test.  
A. 
B. C. 
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Figure 3.9 - Metabolomic profiling data show that several citrate cycle intermediates and FA’s are 
down-regulated in Ins1LKB1KO islets whereas fructose-6-phosphate is up-regulated 
(A) Significant loadings, fold change of metabolites in KO islets in comparison to WT islets. (B) Student’s 
unpaired t-tests confirming this fold change. C14.0, C17.0 and C20.0 represent FA derivatives. Data are 
expressed as means ± SEM, n=4 mice/genotype (200 islets per mouse), *P<0.05, **P<0.01.  
Metabolomic experiments were performed by Peter Spegel, Unit of Molecular Metabolism, Lund. 
University Diabetes Centre. 
 
A. 
B. 
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Figure 3.10 - OCR measured by Seahorse XF24 analyser in the presence of glucose, oligomycin, FCCP, 
rotenone and antimycin 
Each plot represents the mean of 6 wells with 70 islets from WT and Ins1LKB1KO mice, (A) Port A injecting 
3mM of glucose and ports B, C and D injecting 17mM glucose, (B) Ports A, B and C injected increasing 
concentrations of oligomycin and port D injecting 5uM rotenone and antimycin, (C) Ports B and C injecting 1 
and 3uM (respectively) FCCP. Data are expressed as means ± SEM, n= 6 mice/genotype, *P<0.05, 
***P<0.01, ****P<0.001, by 2-way ANOVA.  
A. B. Glucose Oligomycin  
FCCP C. 
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Figure 3.11 - Respiratory capacity is up-regulated in Ins1LKB1KO islets 
OCR was measured in Ins1LKB1KO and WT islets using 70 islets/well/mouse. (A) % OCR measured over 
time , data is presented as % change from measurement 4, (B) ATP production, (C) proton leak, (D) 
maximal respiration and (E) spare capacity, (F) % Basal respiration, (G) OCR of glucose/ FCCP stimulated 
islets. Data are expressed as means ± SEM, n= 5 mice/genotype, *P<0.5, **P<0.01, by 2-way ANOVA 
and Student’s unpaired t-test. 
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WT 
Ins1LKB1KO 
Figure 3.12 - LKB1 is not essential for normal mitochondrial integrity in the β-cell 
Representative EM traces of pancreatic sections showing mitochondria (yellow arrows) in 
Ins1LKB1KO and WT mice, mitochondria are found intact in both mouse models.    
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3.2.4 Glutamate signalling is up-regulated in Ins1LKB1KO mice 
 
  As mentioned previously, RNAseq experiments performed on islets from Ins1LKB1KO versus WT 
mice revealed an up-regulation of certain genes involved in glutamate signalling [427]. These genes 
include Dlgap2, Nptx2 and Gria3 (3.60, 4.48 and 1.12-fold increase, respectively) [427]. We further 
confirmed the increase of Nptx2 expression in islets at the RNA level using qPCR (P<0.01, WT: 1.12 ± 
0.36, KO: 2.22 ± 10, normalised to cyclophillin, Figure 3.13a) and at the protein level using 
immunocytochemistry on whole pancreatic paraffin embedded slices (these experiments were 
performed by Dr Marie-Sophie Nguyen Tu, Appendix 5).  
  To investigate glutamate signalling, β-cells were dissociated from isolated islets and perforated 
patch clamping studies were performed where Ins1LKB1KO and WT β-cells were perfused with the 
glutamate receptor agonist kainite, binding to and activating ionotropic glutamate receptors [424] 
(Figure 3.13b-d). Perforated patch traces (Figure 3.12b) revealed that kainite stimulation leads to a 
more pronounced rise in cytosolic free Ca2+ ([Ca2+]cyt) in β-cells from Ins1LKB1KO mice versus WT 
(P<0.001, WT: 203.3 ± 14.53%, KO: 288.8 ± 21.99%, Figure 3.13c). Similarly, the peak response to 
kainite and area under the curve were higher in Ins1LK1BKO β-cells (P<0.01, WT: 5.17 ± 0.86AU, KO: 
10.75 ± 2.18AU, Figure 3.13c). These experiments were performed alongside Dr Chase Kantor. 
Consistent with increased glutaminergic signalling in these mice, kainite-stimulated insulin secretion 
was significantly increased in Ins1LKB1KO versus WT islets (P<0.05, WT: 0.57 ± 0.16%, KO: 1.25 ± 
0.24%, Figure 3.14). Insulin secretion also increases in Ins1LKB1KO versus WT islets when incubated 
in glutamate, though not significantly (NS, WT: 2.57 ± 0.80%, KO: 3.50 ± 0.56%, Figure 3.14). 
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Figure 3.13 - Up-regulation of Nptx2 expression and Ca
2+ 
signalling in Ins1LKB1KO mice using 
the glutamate receptor agonist kainite  
(A) Gene expression of Nptx2 was measured in Ins1LKB1KO and WT islets, normalising with β-
actin. (B) Glutamate receptor signalling increases intracellular [Ca
2+
]
cyt
 (C) mean amplitude of 
Ca
2+
 peak and (D) AUC in response to kainite. N= 4 mice/genotype. Data are expressed as 
means ± SEM, **P<0.01, by Student’s unpaired t-test. 
A. B. 
C. 
D. 
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Figure 3.14 - Glutamate signalling enhances insulin secretion in Ins1LKB1KO mice 
Insulin secretion was measured in 6 size-matched islets incubated in 3 and 17mM of glucose, 
kainite and glutamate. Data are expressed as means ± SEM, n=4 mice/genotype, *P<0.05, 
**P<0.01, by 2-way ANOVA.  
 Chapter 3 – LKB1 deletion in β-cells enhances β-cell mass despite impaired Ca2+ and ATP flux 
93 
 
3.3 Discussion  
 
  In this chapter, we show two contrasting effects of LKB1 deletion in the pancreatic β-cell. Differing 
to other studies [318-320] we used the highly β-cell selective Ins1Cre promoter that deletes at E11.5. 
The absence of LKB1 resulted in marked improvements in glucose tolerance, in vivo insulin secretion 
[427] and β-cell mass on one hand, whist on the other hand caused dramatic defects in Ca2+ and 
ATP/ADP signalling within the cytosol of β-cells whereas, in vitro GSIS remained unchanged. 
Moreover, islets of mice deleted for LKB1 showed an up-regulation in the expression of genes 
involved in glutamate signalling (Nptx2, Gria3 and Dlgap2) and glutamate signalling was enhanced, 
suggesting that LKB1 deletion stimulates the amplification of glutamate production and signalling 
resulting, overall, in normal GSIS.   
3.3.1 The Ins1Cre promoter deletes selectively in the β-cell at E11.5 
 
  It should be noted that LKB1 floxed mice crossed with Ins1Cre recombinase differ from mice 
deleted for LKB1 using RIP2Cre recombinase and the Pdx1 CreER transgene. As well as the Ins1Cre 
model being the more effective deletor [426], deletion occurs during the post-natal period and lasts 
until adulthood (also observed in the RIP2Cre model) whereas, Pdx1 CreER transgenic mice deletes 
from 8-10 weeks of age. Thus, experiments conducted on our Ins1LKB1KO mice occur at a much 
earlier stage in life than the Pdx1 CreER model. The RIP2Cre promoter deletes both in β-cells and a 
small population of cell within the hypothalamus. On the other hand, the Ins1Cre promoter deletes 
in a high population of β-cells (94%) specifically. RIP2Cre LKB1 deficient mice developed hind-limb 
paralysis and axon degeneration and died at approximately 20 weeks of age. Comparison of 
timelines between these three models is illustrated in Figure 3.15.  
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3.3.2 LKB1 deletion improves glucose tolerance and β-cell mass however, GSIS is 
unaffected 
 
  Our findings [427], together with those of previous studies [318-320] show that deletion of LKB1 in 
pancreatic β-cells improves both glucose tolerance, β-cell mass (Figure 3.1) and insulin expression 
(Figure 3.2). Whilst the mechanisms involved were not explored here they may reflect loss of the 
activity of LKB1 to restrict cell phosphorylation and consequent inactivation of the mTOR signalling 
pathway [428, 429].   
  However, when comparing our findings to that of these previous models, in vitro GSIS did not 
appear to improve in these Ins1LKB1KO mice versus  their WT littermates (Figure 3.3) [430, 431], 
despite the fact that glucose tolerance and β-cell mass were improved. The absence of GSIS 
improvement in Ins1LKB1KO mice may be due to other roles that LKB1 appear to play in insulin 
Figure 3.15 - Timeline of Ins1Cre, RIP2Cre and Pdx1 CreER mouse models floxed for LKB1 
The horizontal arrow represents the timeline of these mice, starting from development. The vertical 
arrow at E11.5 represents the point when Ins1 and RIP2 Cre recombinase deletes in the β-cell and 
hypothalamus.  In vivo experiments were performed in these mice from 8-10 weeks of age followed by 
sacrifice for islet extraction whereas deletion of LKB1 in Pdx1 CreER mice occurs at 8-10 weeks. In vivo 
experiments with these mice take place at 5-6 months, followed by sacrifice for islet isolation. Due to 
axon degeneration in the spinal cord of RIP2Cre LKB1 deleted mice, mice died prematurely at 
approximately 20 weeks of age. The Figure is generated using images from “Servier Medical Art”. 
(http://www.servier.com/servier-medical-art). 
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secretion. For example, previous studies show that two targets of LKB1 phosphorylation, SIK2 and 
SAD-A, up-regulate insulin secretion and thus their deletion impairs insulin secretion [422, 423]. In 
contrast, other targets of LKB1 are known to restrict insulin secretion. For example, MARK2 
phosphorylates and prevents translocation of TORC2 (a co-activator of CREB), which contributes to 
restoring β-cell metabolism after insulin secretion  [432, 433].  Thus, MARK2 could mediate LKB1 
action in β-cells as suggested in previous studies [318, 319]. 
3.3.3 Cytosolic signalling and mitochondrial defects are present in Ins1lkb1ko 
islets 
 
  Despite normal GSIS, enhanced β-cell mass and glucose tolerance in Ins1LKB1KO mice, Ca2+ and ATP 
responses to high glucose were drastically impaired (Figure 3.4 and 3.6). We confirmed that this 
defect is due to the deletion of LKB1 as re-introduction of LKB1 via adenovirus infection resulted in 
the recovery of normal [Ca2+]cyt and [ATP/ADP]cyt signalling (Figure 3.7)[430]. Similar results were 
found in the LKB1 floxed Pdx1-Cre mouse strain by Fu et al, 2015 [431], where despite enhanced 
GSIS, mitochondrial function was impaired.     
  We also assessed the rate of oxygen consumption in Ins1LKB1KO islets in response to high glucose, 
oligomycin to measure ATP production, the uncoupler FCCP to measure the maximal respiration and 
spare respiratory capacity of mitochondria and antimycin and rotenone to measure non-
mitochondrial respiration (Figure 3.11). Overall, we found that there was no difference in oxygen 
consumption between Ins1LKB1KO and WT islets when stimulated with glucose. However, after 
FCCP was added OCR was higher in Ins1LKB1KO versus WT islets, indicating higher spare respiratory 
capacity. It is thought that preservation of the spare respiratory capacity is a hint of the vitality and 
survival of cells and is influenced by the bioenergetic capacity of mitochondria that is determined by 
factors such as the functional capacity of enzymes in the electron transport chain and the cell’s 
ability to deliver substrates to the mitochondria. Our results differs to other studies performed on 
LKB1 deficient islets generated using Pdx1 CreER and studies in older animals where OCR was found 
to be impaired [430, 431].  Additionally, and as repeated in Swisa et al, 2015 [430], it was found by 
electron microscopy that LKB1 deletion using the Pdx1 CreER transgene in β-cells leads to 
mitochondrial defects as well as impairments in mitochondrial metabolism and its downstream 
signalling. These findings indicate that LKB1 is vital for normal mitochondrial function. However, 
mitochondrial integrity does not appear to be affected in islets of Ins1LKB1KO mice (Figure 3.12). 
  We show that LKB1 is vital for normal mitochondrial function in β-cells. Mitochondrial membrane 
potential was measured in these islets using the dye TMRE (Figure 3.8), and found to be significantly 
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impaired in KO islets. Previous studies in LKB1 KO mice find that mitochondrial defects were also 
present [430, 431]. Metabolic profiling experiments show that several citrate cycle derivates such as 
fumerate, citrate and succinate were all down-regulated in Ins1LKB1KO islets (NS), Figure 3.10.   
  The contrasting phenotypes of these Ins1LKB1KO mice, which are the improved glucose tolerance 
and cell mass whilst cytosolic and mitochondrial function are impaired and the resulting normal in 
vitro insulin secretion indicates that a compensatory mechanism must be present for overall 
improved GSIS in vivo.  
3.3.4 Glutamate release and action may compensate in LKB1 deficient β-cells 
 
  Consistent with the increased expression of the genes Nptx2, Gria3 and Dlgap2 (Figure 3.13), 
kainite which binds to and activates ionotropic glutamate receptors [424], caused a more 
pronounced increase in [Ca2+]cyt in Ins1LKB1KO than in WT islets (Figure 3.13). Furthermore, at low 
glucose concentrations, kainite stimulated insulin secretion in Ins1LKB1KO islets which was not 
noted in WT islets (Figure 3.14)[427].  In addition, our metabolomics measurements of citrate cycle 
intermediates found an up-regulation of pyroglutamate, a metabolite of glutamic acid synthesis (NS, 
data not shown). Here we suggest that LKB1 is required for normal signalling and mitochondrial 
function within the β-cell and that in mice deleted for LKB1, glutamate production and signalling acts 
as a compensatory mechanism to maintain normal insulin secretion, as illustrated in Figure 3.16. 
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Figure 3.16 - Model showing an alternative signalling system in the β-cell after LKB1 deletion  
As discussed in chapter 1, normal GSIS requires increases in glucose concentrations to initiate the 
transport of glucose into the cell via GLUT2 and is converted to G6P via GK, where glucose undergoes 
glycolysis. The by-product of glycolysis, pyruvate, enters the mitochondria and ATP is generated via 
the citrate cycle. Here, KATP channels close followed by depolarisation of the cell opening of voltage-
gated Ca2+ channels and the influx of Ca2+ into the cytosol, triggering insulin exocytosis. This process is 
shown in faded grey. However, in β-cells where LKB1 is deleted impairments are apparent in Ca2+ and 
ATP/ADP signalling despite normal insulin secretion. Due to the up-regulation in genes involved in 
glutamate signalling (Figure 5.13) [427] and insulin secretion in the presence of the glultamate 
receptor agonist kainite (Figures 5.13 and 14), we propose that glutamate signalling acts as an 
alternative pathway for GSIS in β-cells deleted for LKB1. The Figure is generated using images from 
“Servier Medical Art”. (http://www.servier.com/servier-medical-art). 
 
 
  Similar findings of alternative pathways to maintain normal GSIS in LKB1 deficient mice were found 
for example, in the Pdx1-Cre LKB1 floxed mouse where β-cells lacking LKB1 glucose usage favours 
citrate and glutamate production [431]. This increase in glutamate enhanced KATP channel opening 
and GSIS as well as maintaining higher NADPH and basal mitochondrial membrane potential levels 
[198]. The authors concluded that LKB1 deletion leads glucose usage away from the citrate cycle and 
towards other biosynthetic pathways such as amino acid synthesis and lipid generation and that the 
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enhanced ACC1 production seen in these mice results in the enhanced insulin secretion seen in 
these β-cells [431]. 
  In addition, metabolic profiling studies conducted in islets of Ins1LKB1KO mice show down-
regulation of FA’s (Figure 3.9b, c). Lipids are required for normal β-cell function and islets depleted 
for triglycerides have been found to be irresponsive to glucose both in rats [434, 435] and humans 
[436]. The link between glucose and lipid metabolism is thought to rely on the glucose-stimulated 
increase in malonyl-CoA [437] that inhibit carnitine palmitoyltransferase 1 (CPT1) by ACC which 
blocks FA-CoA transport into the mitochondria [438] resulting in reduced β-oxidation and an 
increase in cytosolic FA derivatives. Therefore, the up-regulation of ACC1 production found in Pdx1 
CreER LKB1 KO mice and down-regulation of FA which may result in ACC inhibition in Ins1LKB1KO 
suggests a possible link between lipid metabolism and GSIS in LKB1 depleted mice.  
 
3.4 Conclusions 
 
  In summary, we found that LKB1 is essential for the maintenance of normal ATP/ADP ratio and 
mitochondrial function in the pancreatic β-cell. On the other hand, glucose tolerance and β-cell mass 
is enhanced in mice lacking LKB1 selectively in the β-cell despite normal insulin secretion in vitro. 
Our data, consistent with other findings using different mouse models of β-cell selective LKB1 
deletion [430, 431], suggest that LKB1 regulates normal metabolic function and to compensate for 
these defects when LKB1 is deleted the glutamate signalling pathway becomes amplified in order to 
maintain normal GSIS upon LKB1 deletion.  
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Chapter 4 
Deletion of LKB1 in α- and L-cells and its effects on glucagon and 
GLP-1 levels 
 
Abstract 
 
Background and aims: The tumour suppressor LKB1 (STK11) is a serine/threonine kinase that is 
mutated in the premalignant disorder Peutz Jeghers Syndrome (PJS). PJS is characterised by polyps in 
the gastrointestinal tract. Proglucagon-expressing enteroendocrine L-cells are involved in the 
regulation of appetite and glucose homeostasis through the secretion of gut hormones, such as 
glucagon like peptide (GLP)-1, GLP-2 and peptide YY (PYY). Here, we deleted LKB1 in proglucagon-
expressing cells including enteroendocrine L-cells of the gut and pancreatic α-cells to explore the 
roles of LKB1 in these cells. 
Methods: Mice deleted selectively in proglucagon-expressing cells for LKB1 were generated by 
breeding animals bearing floxed alleles for LKB1 with those bearing iGluCre recombinase. Oral and 
intraperitoneal glucose tolerance tests were carried out in these mice, as were insulin tolerance 
tests, optical projection tomography (OPT) to measure L- cell mass and immunohistochemistry for α-
cell mass. Glucagon secretion was measured both in vivo and in vitro using radioimmunoassay. 
Results: GluLKB1KO mice displayed largely normal glucose homeostasis and circulating GLP-1 levels. 
However, these mice developed large gastro-duodenal polyps resulting in premature mortality 
(~120 days) due to blocked food transit. LKB1 deletion in pancreatic α-cells exerted no effect on 
glucagon secretion either in vivo or in vitro nor on pancreatic α-cell mass.  
Conclusion: The loss of LKB1 within enteroendocrine L-cell progenitor’s results in EMT to smooth 
muscle cells and is sufficient to initiate tumorigenesis. However, the deletion of LKB1 in these cells 
has no effect on glucose homeostasis, GLP-1 or glucagon synthesis and secretion. 
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4.1 Introduction 
  Liver kinase B1 (LKB1), otherwise known as serine/threonine kinase 11 (STK11) (see chapter 1), is a 
tumour suppressor and an up-stream kinase responsible for the phosphorylation and activation of 
the 13 members of the AMPK family [204].These include, Par-1 and MARK2 which are responsible 
for the regulation of cell polarity [439]. Together with cell growth, metabolism and survival, the 
control of cell polarity is likely to be an important factor in the actions of LKB1 as a tumour 
suppressor. On the other hand, activation of AMPK by LKB1 restricts growth factor signalling by 
stimulating TSC1/2 [440], thus inhibiting mTOR and consequently protein and lipid synthesis [441]. 
  Heterozygous mutations of LKB1 in humans result in the development of the premalignant disorder 
Peutz Jeghers Syndrome (PJS), characterised by hamatomatous lesions, polyps in the gastrointestinal 
tract, pigmentation of the lips and an increased risk of developing all cancers [442]. The main cause 
of mortality in these patients is from obstructions in the abdomen caused by large gastrointestinal 
polyps which may also result in infarction, intussusception and bleeding. There are currently no 
approved pharmaceutical treatments for PJS and a more thorough understanding of how LKB1 
controls tumour growth is needed for the development of an effective therapy. 
  Studies in mice lend further support to the control of LKB1 mutations in PJS. Thus, although mice 
homozygous null for LKB1 (LKB1-/-) are not viable beyond the 10th day of embryogenesis [333, 443], 
heterozygous null LKB1+/- mice develop polyps similar to those observed in PJS after five months 
[334, 444].  
  Enteroendocrine L-cells represent less than 1% of the epithelial cell lining of the intestinal wall of 
the gut. Despite their small number these cells are essential for normal physiology and energy 
metabolism [445, 446]. Through the action of prohormone convertase (PC) 1/3 on proglucagon, L-
cells generate and secrete the gut hormones glucagon-like peptide-1 (GLP-1), GLP-2 and peptide YY 
(PYY) [351]. GLP-1 is an incretin hormone that stimulate the release of insulin from the pancreas, 
and thus is of considerable therapeutic interest in the treatment of Type 2 Diabetes [447].  
  LKB1 has been found to play a role in insulin secretion, polarity and the control of β-cell mass [318-
320] as well as in glucagon secretion [284]. However, the role of LKB1 in enteroendocrine cells has 
not yet been explored. To determine whether LKB1 may be involved in the growth and function of 
proglucagon expressing cells and might contribute to the formation of polyps in PJS, we have 
crossed mice expressing floxed alleles for LKB1 to animals carrying Cre recombinase cDNA under the 
preproglucagon promoter (iGlu Cre) [403]. This has allowed us to determine the consequences of 
 Chapter 4 - Deletion of LKB1 in α- and L-cells and its effect on glucagon and GLP-1 levels 
 
101 
 
deleting LKB1 from enteroendocrine L-cells, pancreatic α-cells as well as GLP-1 expressing neurones 
in the brainstem.  
4.2 Results 
 
4.2.1 Deletion of LKB1 from preproglucagon-expressing cells causes dramatic 
tumour growth in the duodenum  
 
  WT, GluLKB1het and GluLKB1KO mice were generated by crossing mice in which exons 3-6 of the 
LKB1 gene were flanked with LoxP sites [334] to iGluCre mice. These mice were crossed with mice 
bearing a tandem dimer red fluorescent protein (RFP) transgene at the Rosa26 locus distal to a 
STOP-LoxP-STOP control cassette [403]. Genotyping of these mice show RFP, iGluCre, WT and floxed 
alleles for LKB1 KO and pPCR demonstrates the successful expression of iGluCre in GluLKB1KO islets 
(Figure 4.1a-b). This led to Glu-Cre expression in glucagon-positive pancreatic α-cells of which ~70% 
were positive for tdRFP (Figure 4.1d-e).  
  The body weight of each group was measured weekly (Figure 4.2a) and showed a dramatic 
reduction in weight of the GluLKB1KO mice versus GluLKB1het and WT after approximately 100 days 
(12-15 weeks). Weight loss was closely followed by the premature death of GluLKB1KO mice (within 
a week), as illustrated in the Kaplan Meir curve shown in Figure 4.2c. Although premature death 
occurred  occasionally in WT or GluLKB1het mice, 100% of the GluLKB1KO mice had died by day 120 
(Log-rank Mantel-Cox test, P<0.001). By day 197, 93.7% of WT, 64.3% of GluLKB1het mice and 0% of 
GluLKB1KO mice survived. Vertical deflections in the curve represent censored data where the exact 
date of death is unknown or when mice were euthanised due to ill-health. Both GluLKB1KO and WT 
mice were dissected at 15 weeks (Figures 4.3a-f) and it was discovered that whilst WT mice 
appeared normal, the stomach of GluLKB1KO became bloated in appearance (Figure 4.3c and 4.3d). 
Upon post-mortem examination large polyps were apparent in the duodenum of GluLKB1KO mice 
(Figure 4.3f). Therefore, it is likely that the weight loss in these mice was caused by bowl 
obstructions as a result of the polyp growth (Figure 4.3e). No polys were found during the post-
mortem examination in WT or GluLKB1het mice (Figure 4.3b) nor were polyps observed lower in the 
gastrointestinal tract (jejunum, ileum, and colon) of GluLKB1KO mice.  
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 WT LKB1 
RFP 
iGluCre 
β-actin 
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GluLKB1 
KO A. B. 
C. 
D. 
Figure 4.1 - Generation of GluLKB1KO mice use of a Rosa26tdRFP reporter to assess recombination  
(A) PCR analysis of LKB1, RFP, iGluCre and β-actin expression in mice, (B) GluCre expression, (C) 
representative immunostaining of panceatic islets using antibodies against RFP and either glucagon or 
insulin, nuclei are shown by DAPI (blue) staining. (D) Images of stained islets (6-8) were used to calculate 
the percentage of cells positive for insulin or glucagon and co-expressing RFP. N= 6 mice/genotype, 
**P<0.01 by unpaired Student’s t-test. Data are expressed as means ± SEM. 
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Figure 4.2 - Decreased body weight and life-span of GluLKB1KO mice  
Changes in body mass over time in (A) Male and (B) Female WT, GluLKB1het or GluLKB1KO mice were 
measured weekly between 4 to 15 weeks of age, n=10-15. (C) Kaplan-Meir survival curve for WT, n=16, 
GluLKB1het, n=16, and GluLKB1KO, n=21, mice. GluLKB1KO mice showed premature death from 50-120 
days. 
A. 
B. 
C. 
Male 
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WT 
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Duodenum Stomach  
WT 
Figure 4.3 - Polyp formation in GluLKB1KO mice 
(A) WT mouse with normal phenotype, (B) Abdomen of WT mouse showing normal gastric contents, (C) 
GluLKB1KO mouse showing bloated appearance, (D) Abdomen of GluLKB1KO mouse showing distended 
duodenum and stomach due to large duodenum polyp. (E) Stomach of GluLKB1KO mouse which 
becomes blocked due to polyp formation in the duodenum, (F) Polyp formation within the duodenum of 
GluLKB1KO mouse. Scale bar: 5mm. 
D. 
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4.2.2 GluLKB1KO mice have normal glucose tolerance and in vivo GLP-1 secretion 
 
  To investigate the effect of LKB1 deletion from proglucagon-expressing cells on glucose tolerance 
both oral and intraperitoneal glucose tolerance tests (GTTs) were performed. IPGTTs performed at 
10 and 15 weeks (Figure 4.4) failed to reveal any significant change in glucose tolerance between 
WT, GluLKB1het and GluLKB1KO mice, for both males and females. However, when comparing the 
area under the curve in 10 week old male GluLKB1KO mice versus GluLKB1het mice, glucose 
tolerance was enhanced (P<0.01, WT: 1235 ± 88.3mmol/L, het: 1388 ± 51.97mmol/L, KO: 1276 ± 
109.7mmol/L, Figure 4.4a). On the other hand, though no difference was apparent in glucose 
tolerance of WT versus GluLKB1KO 10 week old female mice, analysis of the area of the curve 
showed impaired glucose tolerance in GluLKB1KO mice versus WT (P<0.05, WT: 972.5 ± 
35.36mmol/L, het: 1009 ± 48.47mmol/L, KO: 1183 ± 65.45mmol/L, Figure 4.4b). AUC was unaffected 
by genotype for either male or female mice at 15 weeks (Figure 4.4c-d).  
  To determine whether LKB1 deletion affected incretin secretion from L-cells and might thus 
contribute to improved glucose tolerance, OGTTs were performed (Figure 4.5). As with IPGTT’s 
(Figure 4.4), OGTT’s failed to reveal a significant change in glucose tolerance in either male or female 
WT, GluLKB1het and GluLKB1KO mice at 12-14 weeks of age. AUC were similarly unaffected.  
  To further examine whether GLP-1 synthesis might be up-regulated in GluLKB1KO mice, OPT was 
performed using an anti-proglucagon antibody (red) on the duodenum of WT and GluLKB1KO mice 
[410]. This allowed us to analyse average, total volume, size and total number of proglucagon 
expressing enteroendocrine L-cells within the duodenum of these mice (Figure 4.6a-e). Relative L-
cell mass (WT: 0.51 ± 0.08%, KO: 0.53 ± 0.17%) and L-cell volume (WT: 44.38 ± 3.34%, KO: 46.18 ± 
12.16%) was unaffected in GluLKB1KO versus WT mice.  
  To measure GLP-1 secretion in vivo plasma was collected from WT, GluLKB1het and GluLKB1KO 
mice which were either fasted overnight or fed. GLP-1 levels were then measured using 2-site 
microtitre plate based immunoassay with electrochemical luminescence detection (performed by 
the Core Biochemical Assay laboratory, Cambridge). Measurement after normal feeding showed 
GLP-1 levels tended to be higher in GluLKB1KO versus WT mice (NS, WT: 22.88 ± 5.87pg/ml, KO: 
33.53 ± 16.79pg/ml). However, several of the samples had become haemolysed (Figure 4.7a).  As 
expected, GLP-1 levels decrease in mice fasted overnight compared to fed mice as GLP-1 acts as a 
marker for satiety. In fasted mice GLP-1 levels were found to be similar in GluLKB1KO and WT mice 
(NS, WT: 10.83 ± 1.21pg/ml, het: 14.57 ± 0.58pg/ml and KO: 9.85 ± 1.26pg/ml, Figure 4.7b).  
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Figure 4.4 - Glucose tolerance is unaffected in GluLKB1KO mice 
Intraperitoneal glucose tolerance tests were performed in (A, B) 10 week old male and female mice and (C, 
D) in 15 week old male and female mice, NS by 2-way ANOVA. AUC is also displayed in bottom right panels, 
*P<0.05, **P<0.01, by Student’s unpaired t-test. Data are expressed as means ± SEM; n=5-15 per genotype. 
A. B. 
C. D. 
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Figure 4.5 - Oral glucose tolerance tests performed in GluLKB1KO mice show no difference in glucose 
tolerance versus WT littermates 
(A) Glucose tolerance of male and, (B) female mice aged 12-14 weeks, NS, by 2-way ANOVA and AUC 
displayed in right panels, NS by Student’s unpaired t-tests. N=3-9 per genotype. Data are expressed as 
means ± SEM.  
A. 
B. 
 Chapter 4 - Deletion of LKB1 in α- and L-cells and its effect on glucagon and GLP-1 levels 
 
108 
 
WT GluLKB1KO 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
C. D. 
E. 
Figure 4.6 - L-cell mass is unaffected in GluLKB1KO mice 
(A, B) Representative OPT images of fixed and permeabilised gut tissue. Red staining indicates glucagon-
positive structures (likely to be L-cells). The overall shape of the gut was visualised as autofluorescence and 
is apparent as white/grey shading. Scale bar, 500µm. (C) The Relative L-cell mass , (D) mean L-cell volume  
and (E) Distribution of L-cell volume with arrows representing the magnified section was measured, NS, by 
Student’s unpaired t-test and 2-way ANOVA, respectively. Data are from n=3 gut tissues per genotype and 
expressed as means ± SEM. 
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Figure 4.7 - Plasma GLP-1 levels in fed and fasted mice had little effect in GluLKB1KO mice 
Plasma GLP-1 levels were measured in WT, GluLKB1het and GluLKB1KO mice with (A) unrestricted 
access to food and (B) mice fasted for 15 hours and GLP-1 measured by two-site microtitre plate based 
immunoassay with electrochemical luminescence detection. Data are expressed as means ± SEM, n=5-8 
mice/genotype, *P<0.05, by Student’s unpaired t-test.  
A. 
B. 
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4.2.3 Glucagon secretion and α-cell mass is unaffected in GluLKB1KO mice  
 
  As LKB1 plays a role in cell growth through inhibition of the mTOR signalling pathway [428], we 
investigated changes in α-cell mass in GluLKB1KO mice. Wax-embedded pancreatic slices from WT 
and GluLKB1KO mice were stained with an anti-insulin guinea-pig antibody (green), to identify β-
cells, and rabbit anti-glucagon antibody (red), to identify α-cells (Figure 4.8). Through this analysis, 
the overall α:β cell ratio in islets was found to be increased in GluLKB1KO versus WT mice 
(P<0.05,WT: 0.25 ± 0.026AU, KO: 0.38 ± 0.04AU, Figure 4.8d). Neither α- or β- cell mass was altered 
in GluLKB1KO versus WT mice (NS, α-cell WT: 1.01 ± 0.05%, KO: 0.93 ± 0.07%; NS, β-cell WT: 1.82 ± 
0.11%, KO: 1.78 ± 0.14%, Figure 4.8b-c). 
  To determine whether the above increase in the α:β cell ratio (Figure 4.8e) affected overall 
glucagon secretion from α-cells, insulin tolerance tests (ITT) were performed and plasma collected to 
assess glucagon levels after insulin injection (Figure 4.9). At 8 and 12 weeks old, insulin sensitivity 
was unaffected in both male and female GluLKB1KO versus WT mice (Figure 4.9a-d). Similarly, in vivo 
glucagon secretion, measured at the 0, 15 and 30 min. in vivo glucagon secretion after insulin 
injection was unaltered between WT and GluLKB1KO mice (Figure 4.9e-f).  
  Additionally, in vivo glucagon secretion was measured in GluLKB1KO and WT mice when fed freely 
and after overnight fast. Confirming the results obtained by ITT, LKB1 deletion had no effect on in 
vivo glucagon secretion in α-cells (NS, Fed WT: 64.00 ± 3.67pg/ml, KO: 71.67 ± 3.80pg/ml; NS, Fasted 
WT: 28.33 ± 3.33pg/ml, KO: 23.75 ± 5.54, Figure 4.10)  
  To investigate the effects of deleting LKB1 from α-cells on glucagon secretion in vitro, islets were 
isolated from GluLKB1KO and WT mice and incubated in varying concentrations of glucose (0.5,1 ,3 
10mM) and glucagon secretion measured after 1 hour of incubation (Figure 4.11). Islets isolated 
from either WT or GluLKB1KO mice and incubated in the lower concentrations of glucose (0.5 and 
1mM) were found to have significantly higher levels of glucagon secretion in comparison to islets 
incubated in higher glucose concentrations (3 and 10mM), as expected (P<0.01, 0.5mM WT: 0.73 ± 
0.20%, KO: 0.78 ± 0.22%; 1mM WT: 0.70 ± 0.11%, KO: 0.75 ± 0.10%; 3mM WT: 0.40 ± 0.17, KO: 0.37 
± 0.16; 10mM WT: 0.10 ± 0.02, KO: 0.13 ± 0.03%). However, as observed in vivo, in vitro glucagon 
secretion was identical in islets of GluLKB1KO versus WT mice. 
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Figure 4.8 - α:β cell ratio increases in GluLKB1KO mice, whilst there is no effect in cell mass 
(A) Representative images of wax embedded pancreatic slices of islets stained for insulin, glucagon and DAPI, 
(B) % β-cell mass and (C) % α-cell mass. (D) α:β cell ratio. Dare expressed as means ± SEM, n=4 pancreata per 
condition, *P<0.05, by Student’s unpaired t-test. 
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Figure 4.9 - Insulin tolerance and glucagon secretion in vivo are unaffected in GluLKB1KO mice 
Insulin tolerance tests performed in (A,B) 8 week old male and female mice and (C,D) 12 week old male and 
female mice (n=6-9 mice/genotype) . Glucagon secretion was measured after insulin injection after 15 and 
30 mins. in (E) 8 week and (F) 12 week old male and female GluLKB1KO and WT mice. NS, by 2-way ANOVA, 
data are expressed as means ± SEM, n=8-11 mice/genotype.  
A. 
F. E. 
D. C. 
B. 
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Figure 4.10 - Glucagon levels in plasma of GluLKB1KO mice both fed and fasted overnight 
are unaffected 
Glucagon levels in the plasma of WT and GluLKB1KO mice (A) fed ad libitum and (B) fasted 
overnight (15 hours) measured by RIA. Data are expressed as means ± SEM, n=6 
mice/genotype, NS, by Student’s unpaired t-test. 
Figure 4.11 - Glucagon secretion is unaffected in GluLKB1KO mice 
Glucagon secretion was measured in 10 size-matched islets incubated in 0.5, 1, 3 and 10mM 
glucose of WT and GluLKB1KO mice. Data are expressed as means ± SEM, n=4 mice/genotype, 
**P<0.01, by 2-way ANOVA. 
FED 
A. B. 
FASTED 
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4.3 Discussion  
 
  The aims of this chapter were to determine whether the deletion of LKB1 from proglucagon-
expressing cells may contribute to (1) the development of PJS and/or (2) impact GLP-1 and glucagon 
secretion, thereby enhancing GSIS. If this was the case then LKB1 in the gut may become a new 
therapeutic target in the treatment of Type 2 Diabetes.  
  To address this question we used the proglucagon-specific Cre recombinase, iGluCre, to delete 
floxed alleles of LKB1 so generating GluLKB1KO mice lacking this kinase in L-cells, pancreatic α-cells, 
as well as other proglucagon-expressing cells in the hind-brain and olfactory bulb (not shown).  
4.3.1 GluCre expression is localised in α- and L-cells 
 
  GluLKB1KO mice and their WT littermates were crossed with mice bearing tdRFP at the Rosa locus 
(Rosa26tdRFP), thereby, allowing us to determine the degree of deletion of LKB1 in proglucagon-
expressing cells. We found approximately 70% recombination of RFP occurred in the α-cells these 
mice (Figure 4.1b).  We note that there may be a potential loss of RFP fluorescence when staining 
and a difference in recombination efficiency between the Rosa26 and LKB1 loci resulting in an over- 
or under- estimation of the degree of recombination. RFP fluorescence was also seen in a smaller 
percentage of β-cells, though no phenotypic effect in insulin secretion or β-cell mass was found in 
these mice. Recombination in enteroendocrine L-cells was also demonstrated when staining for RFP 
using the same method as Figure 4.1b and shown in [448] and Appendix 6.  
4.3.2 Deletion of LKB1 causes dramatic tumour growth in the duodenum  
 
  Homozygous deletion of LKB1 led to the growth of large polyps at the gastro-duodenal junction 
(Figure 4.3). These polyps displayed resemblances to the polyps found in human PJS patients as well 
as to those of mice with heterozygous mutations in LKB1 [444]. However, some differences were 
noted between these GluLKB1KO polpys and earlier studies of LKB1 KO in the gut. Thus, in 
GluLKB1KO mice, L-cells account for approximately 1% of cells in the gastrointestinal tract and 
deletion of LKB1 on these cells resulted in polyps selectively in the duodenum of roughly 3cm in size 
in mice of 120 days. The size of these polyps was similar to that of polyps found in 6 month old 
LKB1+/- mice [449] and larger than those found in both LKB1+/- and LKB1-/- mice selectively deleted for 
LKB1 in smooth muscle cells (~0.6mm)[347]. Additionally, LKB1 deletion in intestinal epithelial cells 
in previous models did not result in polyp growth [450], but inhibited differentiation of secretory 
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goblet cells resulting in an immature and less differentiated phenotype, indicating that LKB1 
influences epithelial-mesenchymal transition (EMT) in epithelial cells. Polyps derived from 
GluLKB1KO mice appeared to be larger and were present at an earlier age than apparent in previous 
models [334, 444]. Out of sixteen GluLKB1het mice, only one developed polyps and mortality 
appeared to be enhanced in these mice in comparison to their WT littermates.  It is possible that 
such large polyps grow in such an area of low cell population because the deletion of LKB1 affects 
polarity of these cells resulting in hyperproliferation in this area of the gastrointestinal tract.  
However, RFP tracing in the gastrointestinal tract of these mice provides no such evidence [448].  
  As described by Zac-Varghese et al, essentially no proglucagon staining or immunoreactive 
glucagon was found in the GluLKB1KO polyps [448]. We therefore suspect that immature LKB1-/- L-
cells undergo EMT and then go on to develop tumours. As explored in parallel studies [448], mice 
expressing GFP under the glucagon promoter allowed us to show that a small percentage of pro-
glucagon-expressing cells express the EMT marker vimentin and so presumably undergo EMT by the 
10th day of age. Lineage-tracing studies in GluLKB1KO mice also revealed that there was a greater 
number of cells in the duodenum with mesenchymal characteristics. Therefore, it is possible that 
LKB1 plays a role in the prevention of proliferation of cells in this cellular compartment. It seems 
most likely that polyps develop from this mutated population of smooth muscle cells than L-cells.  
4.3.3 GluLKB1KO display normal glucose tolerance and GLP-1 levels 
 
  We were unable to detect GLP-1 in polyps of the KO mice [448], and levels of GLP-1 in the blood 
when given normal access to food and after overnight fasting was similar between GluLKB1KO and 
WT animals. GLP-1 was also measured by staining for proglucagon in the gut and we estimated L-cell 
mass by OPT. However, no difference was observed between KO and WT mice. Had GLP-1 secretion 
differed in GluLKB1KO mice versus WT we may have expected alterations in glucose tolerance [451]. 
However, when glucose tolerance tests were performed via both intraperitoneal and oral glucose 
administration, we found no differences between GluLKB1KO mice and their WT littermates (Figure 
4.5 and 4.6). Although this may suggest that LKB1 expression in proglucagon-expressing cells plays 
little role in the control of incretin secretion and glucose homeostasis, this conclusion must be 
tentative given the tendency of LKB1 null L-cell progenitors to undergo EMT. In contrast, when LKB1 
was deleted specifically in pancreatic β-cells, as discussed in chapter 3, glucose tolerance and insulin 
secretion were enhanced [318, 452]. In models of LKB1 deletion in α-cells (but not L-cells) using mice 
crossed with PPGCre recombinase, glucose tolerance was found to improve [453, 454]. 
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  Supporting our data that GLP-1 secretion is unchanged in GluLKB1KO mice,  GLP-1 mRNA and 
protein levels were also found to be unaffected in the intestines of these mice [448]. Similarly, in 
polyps of GluLKB1KO mice GLP-1 protein expression was similar to that of WT duodenum [448]. 
4.3.4 GluLKB1KO mice display normal glucagon secretion 
 
  By deleting LKB1 in α-cells, we aimed to explore the effect that LKB1 has on glucagon 
production/secretion in mice. Modifying glucagon levels may be used as a potential therapeutic 
approach for diabetes, a concept already introduced and explored in studies in which mice deleted 
for the glucagon receptors resisted β-cell damage during Streptozocin induced diabetes [168, 455]. 
In contrast, in studies using the diphtheria toxin to reduced α-cell mass (by <90%), glucose 
homeostasis was only slightly altered, indicating that α-cells can be flexible in different conditions 
[456]. However, in our case, glucagon secretion measurements both in vivo and in vitro revealed 
that LKB1 deletion in proglucagon secreting cells has little effect on glucagon or glucose homeostasis 
[430].  
  As discussed previously, LKB1 plays a role in cell growth via inhibition of mTOR. Models of LKB1 
deletion in the β-cell reveal enhancement of β-cell mass due to the up-regulation of this signalling 
pathway [318-320]. On the other hand, we find that LKB1 deletion in α-cells, alongside LKB1 floxed 
mice crossed with the preproglucagon (PPG) promoter [453], has little effect on the overall α-cell  
number or size (Figure 4.8). Thus, re-stimulation of mTOR activity by LKB1 does not appear to 
influence α-cell proliferation.  
 
4.4 Conclusions 
 
  The role of LKB1 in enteroendocrine cells has not been explored until now. We deleted LKB1 in 
proglucagon-expressing cells (including enteroendocrine L-cells and pancreatic α-cells) by crossing 
LKB1 floxed mice with the iGlu Cre recombinase and explored the effects on glucose tolerance and 
GLP-1 and glucagon secretion. We found that LKB1 deletion has little effect on GLP-1 or glucagon 
secretion but results in large gastro-duodenal polyp growth similar to polyps found in Peutz Jeghers 
Syndrome. 
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Chapter 5 
Deletion of AMPKα1 and α2 in proglucagon-expressing cells up-
regulates GLP-1 levels and improves glucose homeostasis 
 
Abstract 
Background and aims: Enteroendocrine L-cells synthesise and release the gut hormone glucagon-like 
peptide-1 (GLP-1) in response to food transit. Deletion of the tumour suppressor kinase LKB1 from 
proglucagon-expressing cells leads to the generation of intestinal polyps but no change in circulating 
GLP-1 levels. Here, we explore the role of the downstream kinase AMP-activated protein kinase 
(AMPK) in these cells.  
Methods:  Loss of AMPK from proglucagon-expressing cells was achieved using a preproglucagon 
promoter-driven Cre (iGluCre) to catalyse recombination of floxed alleles of AMPKα1 and α2. Oral 
and intraperitoneal glucose tolerance tests were performed and L- and α-cell mass measured by 
immunocytochemistry. GLP-1 and glucagon secretion were measured by electrochemical-based 
luminescence detection or radioimmunoassay. 
Results: Recombination with iGluCre led to efficient deletion of AMPK from enteroendocrine L- and 
pancreatic α-cells. In contrast to GluLKB1KO mice, mice deleted for AMPK displayed an increase (WT: 
0.050 ± 0.006%, KO: 0.090±0.016%, p<0.01) in L-cell mass and elevated plasma fasting (WT: 5.62 ± 
0.80pg/ml, KO: 14.5 ± 1.87pg/ml, p<0.01) and fed (WT: 15.7 ± 1.48pg/ml, KO: 22.0 ± 6.62pg/ml, 
p<0.01) GLP-1 levels. Oral, but not intraperitoneal, glucose tolerance was significantly improved by 
AMPK deletion, whilst insulin and glucagon levels were unchanged despite an increase in α- to β-cell 
ratio (WT: 0.23 ± 0.02AU, KO: 0.33 ± 0.03AU, p<0.01). 
Conclusions: AMPK restricts L-cell growth and GLP-1 secretion to suppress glucose tolerance.  
Targeted inhibition of AMPK in L-cells may thus provide a new therapeutic strategy in some forms of 
Type 2 Diabetes.     
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5.1 Introduction 
  As discussed in previous chapters, enteroendocrine L-cells make up less than 1% of the epithelial 
cells lining of the intestinal wall, but are vital for normal physiology and energy metabolism [445, 
446]. L-cells are thus responsible for the synthesis and secretion of the gut hormones glucagon-like 
peptide-1 (GLP-1), GLP-2, peptide YY (PYY) and oxyntomodulin via the action of prohormone 
convertases (PC) 1/3 on proglucagon [351]. GLP-1 receptors (GLP-1R) are present on pancreatic β-
cell and agonism at these receptors by L-cell-derived hormones or by stabilised analogues such as 
liraglutide [457] is of considerable therapeutic interest in the treatment of Type 2 Diabetes. Thus, in 
response to food transit, secreted GLP-1 binding to GLP-1R activates pancreatic β-cell cAMP 
synthesis and downstream signalling by Protein kinase A (PKA) and Exchange Protein Activated by 
cAMP-2 (EPAC2), activating insulin secretion (Figure 1.11) [359, 458]. Although the mechanisms 
involved are debated [459],  enhanced  ATP synthesis [460], closure of ATP-sensitive K+ (KATP) 
channels and Ca2+ influx appear to play a role, particularly in human β-cells [461]. Thus, GLP-1R null 
mice mouse models display impaired glucose-stimulated insulin secretion (GSIS) in common with 
patients affected by Type 2 Diabetes [357, 462].  Importantly these actions of incretin hormones 
complement the effects of GLP-1 and its congeners to control appetite, energy expenditure and 
body weight. These pleiotropic effects combine to elicit marked improvements in glucose tolerance 
and in the levels of glycated haemoglobin 1c (HbA1c) [463], a predictor of subsequent disease 
complications [170, 395, 398]. Whether the effects of GLP-1 are chiefly achieved through the effects 
of the circulating hormone [464], or reflect the actions of released GLP-1 to act locally in the gut to 
trigger an autocrine reflex act which ultimately controls blood glucose [465, 466], is contested.  
  AMP-activated protein kinase (AMPK) is a highly conserved fuel-sensitive serine/threonine protein 
kinase implicated in the regulation of blood glucose levels [317] by acting as a cellular nutrient 
sensor [467]. AMPK exists as a heterotrimeric complex comprising a catalytic α (α1and α2) subunit, a 
scaffold β (β1 and β2) and a regulatory γ (γ1, γ2 or γ3) subunit [209, 210]. The AMPK complex is  
extremely sensitive to intracellular ATP/AMP [206] and ATP/ADP ratios [220]. It has been proposed 
that stimulation of AMPK in the liver and muscle respectively via the glucose-lowering agents 
metformin and thiazolidinedione may contribute to the improvements in overall insulin sensitivity 
[296] brought about by these agents. The activity of AMPK is chiefly controlled by the activity of 
upstream kinases, notably LKB1 (STK11) and Ca2+ calmodulin kinase II (CamKII) [468] which 
phosphorylate threonine 172 in the key catalytic  loop [296].  
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  Glucagon is the main anti-hypoglycaemic hormone available in all mammals [469]. Stimulation of 
glucagon secretion from pancreatic α-cells occur after blood glucose levels drop and impairment of 
glucagon release is observed in patients suffering from Type 1 diabetes as well as in long-standing 
Type 2 Diabetes [470]. However, earlier in disease progression, an increase in circulating glucagon 
levels is usually present in patients suffering from Type 2 Diabetes, contributing to increased blood 
glucose levels [163].  
  At the cellular level, the fall of blood glucose will stimulate depolarisation of the α-cell [69, 137] and 
the opening  L- (and to the lesser extent N-) type voltage-dependent Ca2+ channels [128]. This will 
result in Ca2+ entry into the cell and the stimulation of glucagon exocytosis. However, the exact 
mechanisms through which glucagon secretion is controlled are still debated [471] and likely to 
involve both cell-autonomous effects of glucose lowering on the α-cell as well as changes in neural 
inputs and in other islet hormones, notably somatostatin [150].  
  Previous studies [272, 472] have explored the effects of deleting the catalytic (α1 and α2) subunits 
of AMPK either individually or together in the β-cell  in mice using the rat insulin prompter-2 (RIP2) 
Cre [273]. Studies in islets isolated from α1/α2 null mice indicated that AMPK acts as a negative 
regulator of insulin secretion at the level of individual cells, consistent with findings in β-cell  lines 
[214, 228]. However, these mice became glucose intolerant and insulin secretion was impaired in 
vivo, demonstrating a requirement for AMPK for normal insulin release in vivo. Whilst the reasons 
for this discrepancy are not fully resolved, studies with the more β-cell selective Ins1Cre [427] 
suggested both confounding effects of AMPK deletion in key brain nuclei may be involved as well as 
changes in the expression of key β-cell genes involved in responsiveness to incretins, and the 
maintenance of normal β-cell identity.   
  More recently, the role of AMPK in the control of glucagon secretion has also been investigated.  
Using clonal αTC1-9 cells and pancreatic islets, it was found that forced over-expression of AMPK 
was able to activate glucagon release, whilst a dominant-negative form of the enzyme blocked 
release at low glucose concentrations [284]. The effect of AMPK (α1, α2 or both) deletion from the 
α-cell in vivo in mice has also been explored recently using a preproglucagon deletor strain (PPGCre) 
[454]. Deletion of AMPKα1 from these cells resulted in improvement of glucagon release whereas 
the effects of AMPKα2 deletion were minimal [453].  
  As discussed in chapter 4, LKB1, in addition to phosphorylating AMPK, is a tumour suppressor 
deleted in PJS. In chapter 4, we discovered that deletion of LKB1 from proglucagon-expressing cells, 
achieved by crossing animals bearing a glucagon promoter-driven Cre recombinase (iGluCre) to mice 
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with floxed LKB1alleles, leads to the development of large gastro-duodenal polyps, reminiscent of 
those seen in PJS [473]. Lineage tracing revealed that LKB1 ablation caused an epithelial-to-
mesenchymal transition (EMT) in LKB1 null proglucagon-expressing cells, and consequently the 
formation of a population of smooth muscle-like cells which expanded to form polyps.  
  This chapter was therefore designed with two goals in mind. Firstly, to determine whether the 
suppressive effect of LKB1 on EMT in L-cells or their progenitors is mediated by AMPK or via other 
AMPK-regulated kinases [204], and secondly to explore the role of AMPK in controlling GLP-1 
release. We addressed these questions by breeding iGluCre mice to animals bearing floxed AMPK α1 
and AMPK α2 alleles to generate mice lacking AMPK activity in the majority of proglucagon-
expressing cells in the body (GluAMPKKO). Whilst polyp development was not observed in these 
mice, AMPKα1/α2 deletion led to improved glucose tolerance when glucose was administered using 
oral gavage, but not through intraperitoneal injection. We show that the improvement in glucose 
tolerance reflects an increase in the number of L-cells, and up-regulated circulating GLP-1 levels. 
Thus, AMPK plays a role in the control of GLP-1 secretion from enteroendocrine cells of the gut, 
acting to improve glucose tolerance. 
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5.2 Results 
 
5.2.1 Deletion of AMPKα1α2 from preproglucagon-expressing cells does not lead 
to polyposis 
 
    GluAMPKKO mice were checked regularly for any sign of tumour development, and body mass 
was measured weekly (Figure 5.1d-e). Weights were measured weekly until 20 weeks of age in male 
and 17 weeks in female mice which is when mice were culled for isolation of islets or the harvesting 
of tissues. Weights in both male and female GluAMPKKO versus WT mice were unaltered. 
GluAMPKKO mice also appeared healthy and not bloated in appearance (data not shown), as was 
previously observed in GluLKB1KO mice (see chapter 4). When the intestine was explored upon post-
mortem no polyp growth was discovered in the null mice (Figure 5.1a-c). 
  To determine the level that AMPK was knocked-down in proglucagon secreting cells, pancreatic 
slices were stained for phosphorylated (P) AMPKα1 and α2 (red) and proglucagon (green) and the % 
of α-cells co-stained with both AMPK and pro-glucagon calculated (Figure 5.2a-b). Overall there 
appeared to be an approximately 2-fold decrease in P-AMPKα1α2 expression in α-cells (P<0.01, WT: 
59.6 ± 5.57%, KO: 35.1 ± 4.04%). AMPK expression was also quantified in proglucagon secreting L-
cells in the ileum (Figure 5.3a-b), as with pancreatic staining there appears to be a 2-fold decrease in 
AMPK expression in GluAMPKKO versus WT ileum sections (P<0.001, WT: 59.33 ± 2.95%, KO: 35.33 ± 
4.75%). To determine whether the iGlu Cre recombinase deletes in β-cells, pancreatic slices of WT 
and GluAMPKKO mice was co-stained for insulin (green) and AMPKα1α2 (red) and the % of co-
staining quantified. We found that expression of AMPK is similar in GluAMPKKO versus WT β-cells 
(NS, WT: 83.45 ± 5.13%, KO: 76.76 ± 2.07%, Figure 5.4a-b). Therefore, we are confident that any 
changes in insulin expression/secretion in these mice are not due to deletion of AMPK in the β-cell.  
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A. 
D. 
Figure 5.1 - GluAMPKKO mice did not display any weight loss or polyp development as found in 
GuLKB1KO mice  
Photographs of the lower abdomen of (A) WT, (B) GluAMPKKO and (C) GluLKB1KO (chapter 4) mice at 15-
20 weeks of age. Unlike GluLKB1KO mice, GluAMPKKO mice did not develop polyps in the duodenum that 
may have resulted in premature death of the mouse. Changes in body mass over time in (A) Male (4-20 
weeks) and (B) Female GluAMPKKO and WT mice (4-17 weeks). N=9-11 mice/genotype. Scale bar: 5mm.  
 
B. C. 
E. 
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Figure 5.2 - AMPK expression is down-regulated in ~30% α-cells 
(A) Immunofluorescent staining of pancreatic sections using anti-rabbit P-AMPKα1α2 (1:100; red) and anti-goat 
glucagon (1:100; green) antibodies of GluAMPKKO and WT mice, (B) % of cells co-stained for AMPK and 
glucagon was calculated to measure % AMPK knock-down in α-cells. N= 3 mice/genotype, **P<0.01 by unpaired 
Student’s t-test, data are expressed as means ± SEM. Scale bar: 50µm. 
WT GluAMPK KO 
Glucagon 
P-AMPKα1α2 
Glucagon/  
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B. 
A. 
WT GluAMPKKO 
Figure 5.3 - AMPK expression in enteroendocrine L-cells is down-regulated in GluAMPKKO versus WT mice 
(A) Immunohistochemical staining of ileum sections using P-AMPKα1α2 (red) and proglucagon (green) 
antibodies show co-staining between proglucagon and AMPK, (B) % of L-cells expressing AMPK in 
GluAMPKKO mice and their WT littermates. **P<0.001 by unpaired Student’s t-test. Data are expressed as 
means ± SEM, n= 3 mice/genotype. Scale bar: 50µm. 
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Insulin/AMPKα1α2
/DAPI 
Figure 5.4 - iGlu Cre driven recombination does not cause deletion of AMPK in pancreatic β-cells  
(A) Immunofluorescent staining of pancreatic slices co-stained for insulin (green) and AMPK (red) and (B) 
% of co-staining quantified to analyse the % of AMPK knocked-out in WT and GluAMPKKO β-cells. N=3 
mice/genotype, NS, by Student’s unpaired t-test, data are expressed as means ± SEM. Scale bars: 50µm. 
B. 
A. 
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5.2.2 Deletion of the AMPK α-subunits improves glucose tolerance after oral 
gavage but not after intraperitoneal injection 
 
Glycaemia was unchanged between male and female AMPKα1α2KO mice versus their WT 
littermates with all animals given free access to food (WT: 10.03 ± 0.45 mmol/L and KO: 9.7 ± 0.63 
mmol/L, Figure 5.5a-b).  
  The iGluCre promoter deletes selectively in proglucagon-expressing cells for example, 
enteroendocrine L-cells [403]. Therefore, OGTT was performed to assess any changes in glucose 
homeostasis in these mice in comparison to their WT littermates due to changes in the release of 
glucose lowering, gut secreting hormones such as GLP-1.  During OGTT, basal glycaemia was found 
to be unchanged in 10 week old GluAMPKKO versus WT mice in mice fasted overnight but 
significantly improved 30 mins. after glucose administration (P<0.01, WT: 17.3 ± 1.4.8 mmol/L and 
KO: 12.5 ± 0.70 mmol/L, Figure 5.6a).  Glucose tolerance was enhanced further in 15 week old male 
mice in GluAMPKKO versus WT mice (15 mins.; WT: 17.2 ± 0.65 mmol/L and KO: 13.8 ± 0.65 mmol/L 
(P<0.05), 30 mins.; WT: 18.3 ± 0.97 mmol/L and KO: 13.9 ±0.97mmol/L (P<0.01), and 45 mins.; WT: 
15.9 ± 1.02mmol/L and KO: 12.4 ± 0.69 mmol/L (P<0.01), Figure 5.6c). In comparison, glucose 
tolerance was unaltered in female GluAMPKKO versus WT mice at both 10 and 15 weeks of age 
when OGTTs were performed (Figure 5.6b, d).  
  In addition to OGTT, IPGTTs were performed on these mice at 20 weeks of age to examine if these 
improvements in glucose tolerance in these mice can also be seen after intraperitoneal injection of 
glucose. We found that, unlike oral administration of glucose, intraperitoneal injected glucose does 
not show alterations in glucose tolerance in GluAMPKKO versus WT (Figure 5.7a-b). 
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Figure 5.5 - Fed glycaemia is unchanged in GluAMPKKO versus WT mice 
Glycaemia was measured in (A) male and (B) female GluAMPKKO and WT mice when fed ad libitum and was 
found to be the same between these mice. NS, by Student’s unpaired t-test, data are expressed as means ± 
SEM, n=6-9 mice/genotype/sex. 
B. 
A. 
Male 
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Figure 5.6 - Glucose tolerance is improved in GluAMPKKO mice after oral administration of glucose 
Glucose was administered using oral gavage (1 g/kg) after mice were fasted overnight and blood glucose levels 
measured at 0, 15, 30, 45, 60, 90 and 120 mins. after glucose administration in (A-B) 10 week old male and 
female mice and (C-D) 15 week old male and female mice, AUC is also displayed in bottom right panels. N=5-9 
mice/genotype, *P<0.05, **P<0.01 by 2-way ANOVA and Student’s unpaired t-test. Data are expressed as 
means ± SEM. 
A. B. 
C. D. 
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Figure 5.7 - Glucose tolerance is unaffected in GluAMPKKO mice after intraperitoneal administration 
of glucose 
IPGTT’s were performed on 20 week old (A) male and (B) female mice, AUC displayed on the right. N=5-
9 mice/genotype, NS, by 2-way ANOVA and Student’s unpaired t-test, data are expressed as means ± 
SEM. 
A. 
B. 
Male 
Female 
 Chapter 5 - Deletion of AMPKα1 and α2 in proglucagon-expressing cells up-regulates GLP-1 levels 
and improves glucose homeostasis  
130 
 
5.2.3 AMPKα1α2 deletion in proglucagon expressing cells has no effect on insulin 
tolerance or circulating insulin levels 
 
  To determine whether deletion of the AMPK α-subunits in proglucagon-expressing cells has an 
effect on insulin tolerance, insulin tolerance tests (ITTs) were performed (Figure 5.8). ITTS were 
carried out on 10 and 15 week old male and female mice. These tests showed no changes in insulin 
tolerance in GluAMPKKO versus WT mice apart from at the 60 min. time point in 10 week old male 
mice (Figure 5.8a). Here, blood glucose was significantly higher in GluAMPKKO versus WT mice 
(P<0.01, WT: 7.12 ± 0.36mmol/L and KO: 10.62 ± 1.52mmol/L).  
  Insulin levels were measured in vivo by looking at insulin levels in the plasma of mice given free 
access to food, or after an overnight fast (Figure 5.9a-b). These measurements showed no changes in 
insulin levels between GluAMPKKO versus WT mice (NS, Fed; WT: 2.43 ± 0.18ng/ml and KO: 2.07 ± 
0.39ng/ml, Fasted; WT: 1.21 ± 0.46ng/ml and KO: 1.67 ± 0.06ng/ml). Plasma insulin levels were also 
measured 0, 15 and 30 mins. after glucose injection, and again, no alterations were found in insulin 
levels between GluAMPKKO mice and their WT littermates (NS, 0 mins. WT: 0.09 ± 0.006ng/ml, KO: 
0.10 ± 0.02ng/ml; 15 mins. WT: 0.18 ± 0.07ng/ml, KO: 0.19 ± 0.02ng/ml; 30 mins. WT: 0.22 ± 
0.08ng/ml, KO: 0.25 ± 0.07ng/ml, Figure 5.10).  
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Figure 5.8 - AMPKα1 and α2 deletion has no effect on glycaemia after insulin injection  
ITT’s were performed on (A-B) 10 week old male and female and (C-D) 15 week old male and female 
GluAMPKKO and WT mice after a 5 hour fast and injected with 0.75U/kg insulin, blood glucose was measured 
0, 15, 30, 45 and 60 mins. after insulin injection. N= 5-9 mice/sex/genotype, **P<0.01 by 2-way ANOVA data 
are expressed as means ± SEM. 
B. A. 
D. C. 
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Figure 5.9 - Plasma insulin levels are unaffected in GluAMPKKO mice when fed ad libitum or fasted 
overnight 
Plasma insulin levels were measured in GluAMPKKO and WT mice when (A) fed ad libitum and (B) fasted 
overnight. By Student’s unpaired t-test, N= 6 mice/genotype, data are expressed as means ± SEM. 
Figure 5.10 - The iGlu Cre transgene has no effect on β-cells function 
Plasma insulin levels were measured at 0, 15 and 30 mins. after glucose injection in WT versus 
GluAMPKKO mice. N= 3 mice/genotype, NS, by 2-way ANOVA, data are expressed as means ± SEM. 
B. A. 
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5.2.4 AMPKα1 and α2 deletion in proglucagon-expressing cells results in 
increased L-cell mass and circulating GLP-1 levels.  
 
  The improvement in oral (Figure 5a, c) but not intraperitoneal (Fig. 6a) glucose tolerance is 
suggestive of an improved incretin response in GluAMPKKO versus WT mice. To explore this 
possibility, L-cell mass and circulating GLP-1 levels were measured. Ileum sections of GluAMPKKO 
mice and their WT littermates were stained with a proglucagon staining antibody which allowed us 
to measure the percentage of proglucagon-expressing cells (Figure 5.11a-b). We found that L-cell 
mass was increased in GluAMPKKO versus WT mice (P<0.05, WT: 0.050 ± 0.006% and KO: 0.090 ± 
0.016%, Figure 5.11b) and cell number increased though not significantly (P= 0.06, WT: 0.0092 ± 
0.002µM-2, KO: 0.015 ± 0.002µM-2, Figure 5.11C). Epithelial cell number was unaltered in 
GluAMPKKO versus WT mice (NS, WT: 118.9 ± 4.33 KO: 121.2 ± 4.93).  
  Circulating GLP-1 secretion was measured by collecting plasma of GluAMPKKO mice and WT mice 
either when given free access to food or after overnight fast (Figure 5.12a-b). We found that plasma 
GLP-1 levels in GluAMPKKO mice both when fed and fasted were higher than in WT mice (P<0.01, 
Fed; WT:  15.69 ± 1.48pg/ml and KO: 21.99 ± 6.52pg/ml, Fasted; WT: 5.62 ± 0.80pg/ml and KO: 14.46 
± 1.87pg/ml).  
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Figure 5.11 - L-cell mass is increased in GluAMPKKO mice 
(A) Immunohistochemical analysis of an ileum section from GluAMPKKO versus WT male mouse; red 
staining represents proglucagon (GLP-1) staining in an enteroendocrine cell, dotted lines represent 
magnified section. (B) Percentage of proglucagon staining cells in the ileum. (C) L-cell count/area of gut, 
P=0.06 (D) Approximate endothelial cell count for the whole gut section. N= 3 mice/genotype (male), 
*P<0.5 by unpaired Student’s t-test. Data are expressed as means ± SEM. 
B. 
A. 
D. C. 
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Figure 5.12 - GLP-1 secretion in vivo is enhanced in GluAMPKKO mice 
GLP-1 levels were measured in the plasma of (A) fed and (B) fasted GluAMPKKO and WT mice, n= 6 
mice/genotype. **P<0.01 by unpaired Student’s t-test. Data are expressed as means ± SEM.  
A. B. 
D. C. 
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5.2.5 AMPKα1 and α2 deletion in proglucagon-expressing cells has no effect on α-
cell mass or glucagon secretion 
 
  To investigate whether AMPK plays a role in pancreatic α-cell growth or survival, pancreatic 
sections from male mice were co-stained with insulin and glucagon in order to measure pancreatic 
α- and β- cell mass as well as the α:β cell ratio (Figure 5.13a-d). Though the α:β cell ratio was found 
to be increased in GluAMPKKO mice in comparison to WT littermates (P<0.05 WT: 0.23 ± 0.02AU, 
KO: 0.33 ± 0.03AU, Figure 5.13d), no changes were found in overall α- or β-cell mass (NS α-cell WT: 
0.15 ± 0.02%, KO: 0.17 ± 0.03%; β-cell WT: 0.82 ± 0.10%, KO: 0.89 ± 0.17%, Figure 5.13b-c).   
  We determined whether deleting the AMPK α-subunits in pancreatic α-cells might affect glucagon 
levels in the blood by measuring plasma glucagon levels of GluAMPKKO and WT mice fed ad libitum 
or fasted overnight. This analysis revealed little difference in glucagon levels between the two 
mouse strains (NS, Fed WT: 64.0 ± 3.67pg/ml, KO: 71.7 ± 3.80pg/ml; Fasted WT: 28.3 ± 3.33pg/ml, 
KO: 23.7 ± 5.54pg/ml, Figure 5.14a-b). To further examine whether AMPKα1α2 deletion has an 
effect on pancreatic α-cells in vitro, glucagon secretion was investigated in isolated islets incubated 
in 0.5, 3 or 10mmol/L glucose (Figure 5.15). In both GluAMPKKO and WT mice, islets incubated in 
lower concentrations of glucose (0.5, 3mM) showed significantly higher levels of glucagon secretion 
compared to higher glucose concentrations (10mM, P<0.0001). However, deletion exerted no 
apparent effect on regulated glucagon secretion (0.5mM WT: 0.97 ± 0.13%, KO: 1.00 ± 0.22; 3mM 
WT: 0.40 ± 0.17%, KO: 0.37 ± 0.16%; 10mM WT: 0.13 ± 0.03%, KO: 0.10 ± 0.02%, Figure 5.15). 
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Figure 5.13 - α:β cell ratio increases in GluAMPKKO mice versus WT, whilst there is no effect on overall islet 
cell mass 
(A) Representative images of wax-embedded pancreatic slices of islets stained for insulin, glucagon and DAPI, 
(B) % α-cell mass of pancreatic sections, (C) % β-cell mass of pancreatic sections and (D) the α:β cell ratio of 
the pancreas. Data are expressed as means ± SEM, n=3 pancreata per condition, *P<0.05 by unpaired 
Student’s t-test. Scale bar: 50µm. 
A. 
B. C. D. 
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Figure 5.14 - Glucagon levels in the plasma is unaffected in GluAMPKKO mice in vivo 
Glucagon levels in the plasma of GluAMPKKO and WT mice was measured in (A) fed and (B) overnight 
fasted mice. Data are expressed as means ± SEM, n=6 mice/genotype, NS, by Student’s unpaired t-test. 
Figure 5.15 - Glucagon secretion in vitro is unaffected in GluAMPKKO mice 
12 size-matched islets of GluAMPKKO and WT mice were picked and incubated in 0.5mM, 3mM or 
10mM glucose and levels of glucagon secretion and total glucagon measured using radioimmunoassay. 
****P<0.0001 by 2-way ANOVA, n=6 mice/genotype. Data are expressed as means ± SEM. 
 A. B. 
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5.3 Discussion      
 
   The overall aims of this study were (1) to determine whether deletion of the AMPK α-subunits in 
enteroendocrine L-cells results in polyp formation as observed after LKB1 deletion in chapter 4 and 
(2) whether deleting AMPKα1α2 specifically in proglucagon-expressing cells improves GLP-1 
production and secretion. To do this we used the proglucagon specific Cre recombinase (iGlu Cre) 
crossed with mice bearing floxed alleles for AMPKα1α2 to generate GluAMPKKO mice and their WT 
littermates.  
5.3.1 Deletion of AMPKα1 and α2 does not stimulate polyposis  
 
  The first aim of this study was to determine whether deleting AMPKα1 and α2 subunits in 
proglucagon-expressing cells would phenocopy the effect of deleting LKB1 in these cells using the 
same iGluCre transgene [448] and produce large gastro-duodenal PJS like-polyps (chapter 4). In 
marked contrast to our earlier findings (chapter 4) [448], GluAMPKKO mice showed no signs of 
tumour development or premature death (Figure 5.1). This suggests that members of the AMPK-
related kinase (AMPK-RK) family [204], rather than canonical AMPK α1 or α2-containing complexes, 
are responsible for the suppression of polyposis from proglucagon-expressing cells [474] in the 
presence of LKB1. Possible candidates include Par1b/MARK2 [324], which controls cell polarity and is 
implicated in β-cell hyperplasia after LKB1 deletion [318, 319], as well as ARK5/SNARK [475, 476].   
5.3.2 Deletion of AMPKα1 and α2 in L-cells of the gut improves GLP-1 secretion 
resulting in these mice to become more glucose tolerant  
 
  GLP-1 plays an important role in GSIS by binding to GLP-1R on the pancreatic β-cell, enhancing 
adenylate cyclase activity and the downstream signalling pathways stimulating PKA and EPAC2, 
resulting in KATP channel closure and depolarisation which initiates insulin secretion [359, 458]. GLP-
1R KO models have been found to have impaired GSIS and GLP-1R is found to be miss-regulated in 
patients with Type 2 Diabetes [357, 462].   
  AMPK plays a role in insulin secretion as found in mice with AMPKα1 and -α2 selectively deleted in 
pancreatic β-cells [472]. AMPKα1α2 KO mice became hyperglycaemic and presented decreased 
levels of insulin secretion in vivo. In contrast, AMPKα1 and -α2 deletion in enteroendocrine L-cells 
improved glucose tolerance in male KO mice during OGTT (Figure 5.5). Interestingly, glucose 
tolerance during IPGTT did not seem to be affected in these KO mice (Figure 5.6), although it should 
be noted that the latter tests were performed in the same animals at a slightly later stage (at 20 
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versus 15 weeks of age). These findings suggest that the incretin response is selectively enhanced in 
the GluAMPKKO model. Providing direct evidence for this view GLP-1 release into the plasma was 
significantly increased in GluAMPKKO mice in both fed and fasted mice (Figure 5.12).  Surprisingly, 
however, this was not associated with any changes in detectable plasma insulin in fed or fasted 
states (Figure 5.9), nor in the increase in plasma insulin during IPGTT (Figure 5.7). These observations 
may suggest that the actions of GLP-1 on glucose tolerance may chiefly reflect local effects on 
neurons close to the site of release which then initiates an autocrine loop to regulate the production 
of hepatic glucose [477]. Of note, the latter study showed that metformin action in the gut acutely 
improved hepatic production of glucose in an AMPK-dependent manner. Whilst this did not 
modulate AMPK specifically within enterendocrine cells, the apparent contrast between the present 
study and our earlier findings [477] may thus suggest that metformin acts chiefly in the intestine on 
the a non-L-cell enteroendocrine population, largely localised in the duodenum, or that there are 
significant differences between the acute and chronic activation of AMPK on a “gut-brain-liver axis”. 
5.3.3 AMPKα1 and α2 deletion from pancreatic α-cells does not alter α-cell mass 
or glucagon secretion but increases L-cell mass 
 
  In the present study no changes in α- or β-cell mass were observed in GluAMPKKO mice, consistent 
with previous findings using the shorter glucagon promoter-Cre to drive deletion in these cells [453]. 
AMPK is a regulator of the mTOR complex (as mentioned in previous chapters), that goes on to 
phosphorylate the mTORC1 components Raptor and TSC2 [428] which are involved in the regulation 
of cell size [478] and proliferation.  Interestingly, a clear increase in total L-cell mass, expressed as a 
fraction of intestinal surface, was apparent (Figure 4a,b) alongside a strong tendency towards an 
increase, of similar magnitude, in the number of L-cells per unit area. Although further investigations 
are required to explore the mechanisms involved, these might conceivably include the activation of 
mTORC1 as a result of AMPK deletion. Additionally, Carbohydrate Response Element Binding Protein 
(ChREBP), a transcriptional regulator of proglucagon gene expression and carbohydrate metabolism 
in L-cells [479], is also inhibited by AMPK [480], and may further increase GLP-1 synthesis and 
secretion.   
  Consistent with previous findings [453]  in which both AMPK α1 and α2 were deleted in the α-cell 
using a shorter (1.6 kB) preproglucagon promoter [454] to drive Cre-expression, no evidence was 
obtained for changes in circulating glucagon levels after  deletion of AMPK activity. Of note, the 
longer proglucagon promoter used in our study deletes additionally in enteroendocrine L-cells as 
well as other proglucagon-expressing cells throughout the body (e.g. in the brain stem and olfactory 
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bulb) [481]. Thus, we show that deleting both AMPK α-subunits in pancreatic α-cells has little effect 
on glucagon release in response to low glucose levels in vitro or in vivo. Likewise, in GluAMPKKO 
mice, glucagon secretion was not enhanced in comparison to WT littermates during hypoglycaemia 
induced by insulin injection (Figure 5.8). It should be noted, however, that when AMPK α1, but not 
α2, was deleted selectively in the α-cell with the shorter proglucagon promoter-driven Cre, impaired 
glucagon secretion was observed both in vivo during hypoglycemic clamp and in vitro [482].  
Furthermore, AMPK activation was previously found to regulate glucagon secretion in vitro in a 
study using clonal αTC1-9 cells [284].  In the latter study, AMPK expression was stimulated using 
pharmacological agents such as metformin, and resulted in enhanced glucagon secretion at both 
high and low glucose concentrations. One possible explanation for the apparent discrepancy 
between the present and earlier studies is that complete inactivation of AMPK in the α-cell in vivo 
leads to robust compensatory changes that reset glucagon release back to wild-type levels as also 
observed in our previous study [482] after deletion of both AMPK α1 and α2 in the α-cell using the 
shorter Cre strain developed in [454]. 
 
5.4 Conclusions 
 
  Deletion of AMPKα1α2 in proglucagon secreting cells including pancreatic α-cells and 
enteroendocrine L-cells does not lead to polyposis seen after deletion of LKB1 in the same cell 
population [448], implicating non canonical members of the AMPK-RK family in EMT and polyposis. 
On the other hand, glucose tolerance after oral administration of glucose is improved, L-cell number 
increased and GLP-1 secretion enhanced. Our results suggest that AMPK limits expansion of the L-
cell population and GLP-1 release, processes which may provide a new therapeutic avenue for the 
treatment of Type 2 Diabetes.  
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Chapter 6 
  
Final Discussion 
 
6.1 Investigating the relevance of AMPK and LKB1 in glucose 
homeostasis using tissue-specific knock-out mice 
 
  The overall aim of this thesis has been to study the roles of the protein kinase LKB1 and one of its 
key down-stream kinases AMPK in regulated hormone secretion and the control of glucose 
homeostasis. Our main approach has been in the breeding and generation of mice deleted for either 
LKB1 or AMPK specifically in selected cell types. The role of LKB1 in the pancreatic β-cell has been 
previously studied in KO mice using relatively unrelated Cre recombination lines [318-320]. These 
earlier studies found that inhibiting LKB1 activity selectively in β-cells facilitates their expansion 
through hypertrophy and hyperplasia and improves glucose tolerance in vivo [318-320]. In chapter 3 
we use a novel strain of mice expressing a much more selective and efficient Cre recombinase (Ins1 
Cre), known to delete LKB1  floxed alleles in approximately 94% of β-cells without off-target effects 
in other tissues [400].   
  AMPK is thought to be an important target for the treatment of diabetes due to the role this kinase 
plays in the liver and muscle during the glucose-lowering treatment using metformin and 
thiazolidinedione [296]. AMPK has previously been studied in the pancreatic β-cell using tissue 
specific RIP-2 Cre deletion of both α-subunits of AMPK, as described above for LKB1 [483]. It was 
discovered through this approach that the regulation of AMPK in the β-cell is important for normal 
glucose homeostasis. 
  Information gathered on the roles of AMPK in the pancreatic α-cell is limited. Similarly, the role of 
both LKB1 and AMPK in the enteroendocrine L-cells and its contribution to the control of GLP-1 
secretion and glucose homeostasis has not been investigated previously. In this thesis, we bred mice 
floxed for LKB1 (chapter 4) or AMPK (chapter 5) with the proglucagon deleting iGlu Cre promoter to 
investigate the impact that these kinases have on L- and α-cells. 
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6.2 Roles of LKB1 in the pancreatic β-cell 
 
  In chapter 3 we build from previous studies exploring the effects of LKB1 deletion in the pancreatic 
β-cell by using the Ins1 Cre promoter. In these earlier studies, LKB1 was deleted in the β-cell of adult 
mice using the Pdx1 CreER [318, 319] or the RIP2 Cre transgene [320]. Encouragingly, our new 
findings using Ins1LKB1KO mice largely mirror these previous observations with glucose tolerance 
and in vivo insulin secretion becoming enhanced in the KO mice [427] as they are in the earlier 
models.  
  β-cell mass is ruled by the balance of four known parameters: proliferation, cell size, apoptosis and 
neogenesis [484]. Using the same methods as in [320], β-cell mass was measured in our mice and 
similar to the effect LKB1 deletion has in earlier models, β-cell size was increased. Although not 
tested directly in the current studies, this may be due to up-regulation of mTORC signalling, as 
discussed in chapter 3 and illustrated in figure 6.1.  
 
 
 
 
 
 
 
 
 
  Unexpectedly, in our Ins1LKB1KO mice in vitro insulin secretion was found to be unaltered (figure 
3.3), despite GSIS being markedly enhanced in vivo. Nonetheless, and perphaps arguing against the 
above model, deletion of both catalytic subunits of AMPK failed to phenocopy the action of LKB1 
deletion in this study [427]. This led us to further investigate the insulin secretion pathway 
components in the KO model to identify the signals responsible for the enhanced in vivo insulin 
secretion and glucose tolerance seen in these mice. Surprisingly, we found that LKB1 deletion in β-
Figure 6.1 - The proposed pathway for the modulation of β-cell size, utilising the LKB1-AMPK-
mTOR-rpS6 pathway 
In this pathway we show that LKB1 and AMPK are both detrimental to insulin content and β-cell 
size via the activation and consequent inhibition of the mTOR pathway. 
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cells causes a dramatic deterioration in glucose-induced cytosolic ATP/ADP and Ca2+ signalling as well 
as mitochondrial membrane potential (figures 5.4-5.8). 
  Similar findings were obtained in Pdx1 CreER [427], RIP2Cre [320] and the Ins1Cre strain LKB1 
deleted mice [430, 431]. In the latter mice, mitochondrial oxidation of glucose and the citrate cycle 
intermediate succinate was found to be defective in triggering GSIS [430] and ACC activation was 
enhanced [431]. From our work [427] and others [430, 431] we conclude that the improvement in 
glucose tolerance in LKB1-deficient mice is not simply a consequence of enhanced β-cell mass or 
insulin content. In tamoxifen-induced Pdx1 CreER LKB1 deleted strains, insulin content and β-cell 
mass were not found to be significantly increased to a degree that could explain the increase in 
insulin secretion [320, 427]. Instead an increase in GSIS in perifused islets suggested that insulin 
secretion is up-regulated in a cell-autonomous manner.  
    Given the observed defects in cytosolic Ca2+ and ATP/ADP signalling, we investigated 
mitochondrial and citrate cycle components in our Ins1LKB1KO mice using a metabolomic approach. 
Here, we found that certain citrate cycle intermediates such as succinate and citrate were present in 
lower levels in Ins1LKB1KO islets, as were glycerol and fatty acids (Figure 5.9). Mitochondrial 
membrane potential in β-cells from these mice was also found to be lowered (Figure 5.8). Similarly, 
β-cells deleted for LKB1 using tamoxifen-induced Pdx1 CreER deletion revealed mitochondrial 
defects. In the latter KO mice, it was proposed that leucine may be further metabolised increasing 
the concentration of glutamate which has been found to stimulate insulin secretion [177].  
Interestingly, transcriptomic analysis of islets from Ins1LKB1KO mice revealed up-regulation in genes 
involved in glutamate signalling, as discussed in chapter 3 [427]. Thus, we speculate that intracellular 
levels of glutamate increase in cells abolished for LKB1, stimulating a more effective GSIS and less 
ATP/ADP and Ca2+ is required to trigger insulin release (as shown in figure 3.15). Supporting this idea 
stimulation using the glutamate receptor agonist kainite resulted in a more pronounced increase in 
cytocolic Ca2+ ([Ca2+]cyt) and insulin secretion in Ins1LKB1KO islets in comparison to WT. Consistent 
with our results, Pdx1 CreER LKB1-deleted mice showed an up-regulation of glutamate levels in 
LKB1-deficient islets [430].  Taken together, these findings suggest that improved insulin secretion in 
LKB1 null β-cells is due to amplification of a glutamate induced-signalling pathway. An overview of 
LKB1 regulation in the β-cell is illustrated in figure 6.2.   
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6.3 Impact of LKB1 and AMPK deletion in enteroendocrine L-cells 
 
  Enteroendocrine L-cells make up a small but significant population of cells lining the intestinal walls 
within the gut (less than 1% of cells) that are essential for normal physiology and metabolism [403]. 
Through expression of proglucagon and PC-1; L-cells (and K-cells to a lesser extent) are responsible 
for the synthesis and release of the gut hormones, including GLP-1, GLP-2 and oxytomodulin [485]. 
These hormones target GLP-1R which are present on the pancreatic β-cell as well as in the CNS 
[486]. Given the role that the incretin hormone GLP-1 plays in glucose tolerance, appetite and 
energy expenditure, the GLP-1R is considered an important therapeutic target in the treatment of 
diabetes, as exemplified by the use of the analogue liraglutide and DPPIV inhibition [457]. In recent 
years, GLP-1 has been found to play a role in insulin secretion during food transit, initiating cAMP 
synthesis and downstream signalling of PKA and EPAC2, stimulating insulin secretion [359, 458]. 
Thus, GLP-1R agonists and inhibitors of GLP-1 now represent a front-line therapy for diabetes [487], 
and enhanced secretion of these hormones has also been implicated in the beneficial effects of 
bariatric surgery on diabetes [488]. Up until now, the roles of LKB1 and AMPK in enteroendocrine L-
cells have not been explored.  
  To investigate the role of these kinases in the control of GLP-1 production and secretion, mice were 
crossed with either LKB1 (chapter 4) or AMPKα1 and -α2 (chapter 5)  floxed mice and mice 
expressing Cre-recombinase under the control of the proglucagon promoter [403]. This resulted in 
mice that were deleted for AMPK or LKB1 in proglucagon-secreting cells, notably enteroendocrine L-
cells and pancreatic α-cells.  
6.3.1 Deletion of LKB1 in L-cells 
 
  LKB1, in addition to phosphorylating AMPK and its downstream kinases [204], acts as a tumour 
suppressor and is mutated in PJS, a syndrome characterised by the appearance of hamartomatous 
polyps in the gut (as discussed in chapter 1). Our findings in GluLKB1KO mice (chapter 4) show that 
LKB1 expression in regulating L-cells has little or no role in play in L-cell number or GLP-1 production 
and secretion. Thus, no changes were observed in incretin-induced glucose tolerance (Figure 4.5) or 
circulating GLP-1 (Figure 4.7) in GluLKB1KO mice.  
  However, Glu1LKB1KO mice were found to develop large gastro-duodenal polyps reminiscent of 
those seen in PJS [473] and previously in mice lacking a single LKB1 allele throughout the body [444]. 
These gastro-duodenal polyps eventually resulted in the death of the mice due to intestinal 
obstruction [448].  
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  Proglucagon-expressing cells are scattered throughout the gastrointestinal tract, the most 
concentrated area of these cells being within the colon and rectum [489]. Development of polyps 
within the gastro-duodenal junction was surprising as proglucagon-secreting cells are known to be 
sparse in this area. Encouragingly, similar findings were observed in three independent Glu-Cre 
founder lines [448]. Therefore, it is unlikely that these findings are due to some mis-expression of 
Cre due to random insertion events [448]. 
  LKB1 deletion in the intestinal epithelium has been shown previously to prevent terminal 
differentiation of secretory goblet cells. This resulted in an immature and less differentiated cell 
phenotype, suggesting that LKB1 plays a role in EMT in the intestinal epithelium [450]. During 
development, L-cells originate from common progenitor cells located at the base of the intestinal 
crypt, and neurogenin 3 commits the cells to their endocrine fate [490]. Though we are unable to 
make a definitive assignment of the progenitor cells from which the polyps develop after LKB1 
deletion, the rapid turn-over of mature L-cells and their inability to divide [491] make them unlikely 
candidates as the immediate precursors [448]. However, as discussed in [448] LKB1 deletion occurs 
before the loss of promoter activity and because relatively little proglucagon staining was observed 
within polyps we propose that offspring of immature LKB1 deleted cells undergo transition and 
become transformed to develop tumours. In studies performed in [448], GluLKB1KO mice expressing 
GFP demonstrate that a small proportion of proglucagon-expressing cells express the EMT marker 
vimentin. Proglucagon-expressing cells were found to undergo EMT by the 10th day post-partum 
[448]. Lineage tracing studies in our mice show that there is an increased number of cells within the 
duodenum  with mesenchymal characteristics and localisation [448] It seems likely that polyps 
develop from this population of smooth-muscle like cells (rather than mature L-cells).  
  It is unclear how mutations in LKB1 lead to tumour development. Our study suggests there is an 
increased susceptibility of proglucagon-expressing precursors to proliferate following deletion of 
LKB1. Thus, it is possible that this pool of LKB1 null cells provides a supply of precursors for polyp 
development and contributes to tumour growth [448].  However, the few studies that have looked 
at the role of endocrine cells towards PJS development are conflicting [335, 492]. Earlier suggestions 
for tumour development focussed on the inhibition of the mTOR pathway after LKB1 deletion (as 
mentioned above). In whole body LKB1-/+ mice rapamycin was shown to reduce tumour size [493]. 
However, in human PJS patients there is insufficient evidence to support the use of rapamycin as a 
preventative treatment [494]. An interesting follow-up to our study would be to investigate whether 
treatment of GluLKB1KO mice using oral rapamycin treatment will also reduce tumour size. In the 
context of manipulating LKB1 expression in the intestinal epithelium for the treatment of Type 2 
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Diabetes, due to the role this kinase plays in the initiation of tumorigenesis its use as a therapy 
should be approached with great caution.  
6.3.2 Deletion of AMPKα1 and α2 in L-cells 
 
  In our second study using the proglucagon iGlu Cre promoter, we crossed mice expressing this 
promoter with mice floxed for both AMPK α-subunits (chapter 5). Cre deleted GluAMPKKO mice 
show improved glucose tolerance after glucose was administered using oral gavage, but not after 
interperitonal injection. Providing a likely explanation for the improvements in glucose tolerance are 
the improvements in L-cell number and circulating GLP-1 levels that was found in this model 
(chapter 5). In future experiments, mTORC1 activation might be investigated to further explore the 
role of this critical kinase [429]. Another potential mediator is Carbohydrate Response Element 
Binding Protein (ChREBP) a transcriptional factor [495] inhibited by AMPK and which has recently 
been shown to regulate the output of GLP-1 from L-cells [496].  
  AMPK was previously found to play a role in insulin secretion. Thus, mice in which AMPKα1 and -α2 
was deleted selectively in pancreatic β-cells using the RIP2Cre transgene [483] became 
hyperglycaemic and insulin secretion was impaired. In contrast, glucose tolerance was improved in 
our GluAMPKKO mice during OGTT, but was not affected during IPGTT, whilst in vivo GLP-1 secretion 
was increased in these mice. Therefore, our findings indicate that the incretin response is impaired 
by AMPK expression in L-cells.  
  These observations may reflect an action of GLP-1 on enteric neurones close to its site of release 
that will then initiate an autocrine loop which regulates hepatic  glucose production as recently 
proposed [477]. However, in the latter study the acute action of metformin in the duodenum 
reduced hepatic glucose production via an AMPK-dependent mechanism. This contrast between 
these earlier studies [477] and our findings suggest that metformin may act chiefly on the non-L-cell 
enteroendocrine population of the gut (localised largely in the duodenum).  
  Initially, we bred our GluAMPKKO colony of mice to determine whether the suppressive effect of 
LKB1 on EMT in the enteroendocrine L-cells or their progenitors is mediated via AMPK or by other 
members of the AMPK-related kinase family [204]. These mice showed no signs of tumour 
development or premature death, suggesting that members of the AMPK-related kinase family, 
rather than canonical AMPK α1 or α2-containing complexes, are responsible for the suppression of 
polyposis from proglucagon secreting cells [474]. Possible candidates include Par1b/MARK2 which 
plays a role in the control of cell polarity and is involved in β-cell hyperplasia during LKB1 deletion 
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[318-320, 497] as well as NUAK1/SNARK [475] and NUAK2 [476]. An overview of LKB1 and AMPK 
regulation in L-cells is illustrated in Figure 6.2.   
 
6.4 Impact of AMPK and LKB1 in pancreatic α -cells 
 
  As discussed in previous chapters, glucagon, generated via the action of PC-2 and secreted from 
pancreatic α-cells, acts as the main anti-hypoglycaemic hormone in mammals [469]. Impaired 
release of this hormone is observed in patients suffering from Type 1 and long-standing Type 2 
Diabetes [498]. As well as deleting in enteroendocrine L-cells the iGlu Cre promoter leads to 
recombination of proglucagon-expressing cells of the pancreas, namely the α-cell.  
6.4.2 Deletion of LKB1 in α-cells 
 
  The role of LKB1 in the α-cell and the control of glucagon secretion have not previously been 
explored in vivo. In chapter 4, we show that deletion of LKB1 in the α-cell has no phenotypic effect 
on in vivo or in vitro glucagon secretion, α-cell mass or in insulin tolerance. In a previous study, the 
shorter PPG promoter (1.6kB) [454] was used to drive Cre expression, and crossed with mice floxed 
for LKB1. Unlike our GluLKB1KO mice, blood glucose was found to improve in PPG Cre: LKB1 floxed 
mice after overnight fast and fasting glucagon levels were increased enhanced. As with GluLKB1KO 
mice, α-cell size and number is unaffected in LKB1 deleted PPG Cre mice, despite up-regulation in 
glucagon secretion [482]. Unlike LKB1-deficient β-cells [318, 319, 427], attenuation of mTOR 
signalling by LKB1 appears to be absent from α-cells. Reasons for this are unclear.  
 
6.4.2 Deletion of AMPK in α-cells 
 
  As with our GluLKB1KO mice mentioned above, neither α- or β- cell mass were altered in 
GluAMPKKO mice (chapter 5). Consistent with our results, no changes in cell size or circulating 
glucagon levels were observed after deletion of AMPK using the PPG Cre promoter [482]. However, 
it should be noted that in AMPKα1- (though not α2-) deficient mice lacking AMPK selectively in α-
cells after recombination with the shorter proglucagon promoter-driven Cre [482] glucagon 
secretion was impaired both in vivo during hypoglycaemic clamp and in vitro. Thus, we find that 
deleting AMPK in both α-subunits in pancreatic α-cells has little effect on glucagon secretion in vitro 
or in vitro. This is in contrast to the effects of deleting AMPKα1 alone in these cells [453] and 
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suggests that the complete ablation of AMPK in pancreatic α-cells in vivo leads to robust 
compensatory changes that reset glucagon back to WT levels. An overview of LKB1 and AMPK 
regulation in α-cells is illustrated in Figure 6.2.   
  Of note, activation of AMPK was previously discovered to regulate glucagon secretion in vitro in a 
study that used clonal αTC1-9 cells [284]. Here, expression of AMPK was stimulated via 
pharmacological agents such as metformin, and this resulted in the enhancement of glucagon 
secretion at both high and low glucose concentrations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 – A brief overview of the roles LKB1 and AMPK play in the regulation of the pancreatic 
β-, α- and enteroendocrine L-cell 
GLP-1 is secretion from the L-cell plays a role in stimulating normal insulin secretion from the 
pancreatic β-cell. In the β- and L-cell, activation of LKB1 regulates normal proliferation and plays a 
role in inhibiting normal insulin secretion. Impairment of LKB1 in these cells results in enhanced cell 
growth and in the case of L-cells, polyp formation. Glucose stimulation results in inhibition of AMPK 
and further inhibition of GLP-1 and insulin secretion. Therefore, in AMPK deficient cells, glucose 
stimulation will enhance GLP-1 secretion, thus, improving glucose homeostasis. In the pancreatic α-
cell, glucose stimulation will prevent the secretion of glucagon from the cell.  
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6.5 Final conclusion 
 
  This thesis describes the impact of deleting LKB1 or AMPK selectively in the pancreatic α-cell and 
enteroendocrine L-cell as well as LKB1 selectively in the pancreatic β-cell. Through the generation of 
these three novel models we show that these kinases play an important role in the regulation of key 
gluco-regulatory hormones and regulation in glucose homeostasis. Although deletion of LKB1 in L-
cells exerted little effect on GSIS, this study provided new information on the origin of PJS as well as 
the role that LKB1 plays as a tumour suppressor. Moreover, the failure of AMPK deletion in L-cells 
(chapter 4) to recapitulate the effects of LKB1 deletion in these cells provides compelling evidence 
that alternative pathways and AMPK-related kinases probably mediate the effects of LKB1 in L-cells. 
Our findings support the view that LKB1, AMPK and/or their down-stream kinases may provide 
therapeutic targets in the pancreatic β-cell and enteroendocrine L-cell to treat some forms of 
diabetes.  
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Appendix 1 
Antibody List 
 
Primary Antibody 
Antibody Species   Procedure  Dilution Company  
          _____________ 
DsRed  anti rabbit  IHC   1:200  Clontech 
Glucagon anti goat  IHC   1:100  Dako 
Glucagon anti mouse  IHC   1:100  Sigma 
Glucagon anti rabbit  IHC/OPT  1:100  Santa Cruiz 
Insulin  anti guinea-pig  IHC/OPT  1:200  Dako 
P-AMPKα1/α2 anti rabbit  IHC   1:100  NEB Cell signalling 
 
 
Secondary Antibody 
Laser  Species   Procedure Dilution Company  
          _____________ 
488  donkey anti mouse IHC  1:1000  Life technologies 
488  donkey anti rabbit IHC/OPT 1:500  Life technologies 
488  goat anti guinea-pig IHC  1:1000  Invitrogen 
488  goat anti mouse IHC  1:1000  Invitrogen 
568  donkey anti goat IHC  1:1000  Life technologies 
568  goat anti guinea-pig IHC  1:1000  Invitrogen 
568  goat anti rabbit  IHC  1:1000  Invitrogen 
594  goat anti guinea-pig IHC/OPT 1:1000  Life technologies 
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Appendix 2 
 
PCR primers (for genotyping) and Tm 
 
Gene  Primer sequence      Tm  
          _____________ 
AMPKα1 Fwd: TATTGCTGCCATTAGGCTAC    53 
  Rev: GACCTGACAGAATAGGATATGCCCAACCTC 
AMPKα2 Fwd: GCTTAGCACGTTACCCTGGATGG    62 
  Rev: GTTATCAGCCCAACTAATTACAC 
β-actin  Fed: CGAGTCGCGTCCACCC     58 
  Rev: CATCCATGGCGAACTGGTG 
Cre  Fwd: TTCACTGGTTATGCGGCGG     60 
  Rev: GCCAGATTACGTATATCCTGGCAG 
FER  Fwd: ACCTTCAGACCTTGGCGTTGGAGG    60 
  Rev: ACCTTCAGACCTTGGCGTTGGAGG 
iGlu Cre  Fwd: ATGTCCAATTTACTGACCG     58 
  Rev: CGCCGCATAACCAGTGAAAC 
LKB1  Fwd: GGGCTTCCACCTGGTGCCAGCCTGT    60   
  Rev: GAGATGGGTACCAGGAGTTGGGGCT 
tdRFP  Fwd: CTGTTCCTGGGGCATGGC     58 
  Rev: CTACAGGAACAGGTGGTGG 
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Appendix 3 
 
Real time qPCR primers  
 
 
Gene  Primer sequence       
          _____________ 
Cyclophillin Fwd: AAGACTGAGTGGTTGGATGG 
  Rev: ATGGTGATCTTCTTGCTGGT 
Gcg  Fwd: CATTCACCAGCGACTACAGCAA 
  Rev: TCATCAACCACTGCACAAAATCT 
iCre  Fwd: GCCGAAATTGCCAGAATCAG 
  Rev: CAATGTGGATCAGCATTCTCC 
Ins1  Fwd: GAAGCGTGGCATTGTGGAT 
  Rev: TGGGCCTTAGTTGCAGTAGTTCT 
Ins2  Fwd: AGCCCTAAGTGATCCGCTACAA 
  Rev: CATGTTGAAACAATAACCTGGAAGA 
LKB1  Fwd: GCCGGGCAACCTGCTACT 
  Rev: CAACACCGAGGTCGGAGATC 
Nptx2  Fwd: GCTCCTTGCAAACCCTCAAG 
  Rev: GAGCACCTCTCGGAAGTCG 
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Appendix 4 
 
In vivo insulin secretion and glucose tolerance improves in 
Ins1LKB1KO mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4: Glucose tolerance and in vivo insulin secretion becomes enhanced in Ins1LKB1KO 
mice 
(A) Insulin tolerance tests (0.75U/Kg insulin) and (B) intraperitoneal glucose tolerance tests (3g/Kg) 
were performed and insulin secretion during IPGTT measured (C) in 10-12 week old Ins1LKB1KO and 
WT mice. N= 3-5 mice, *P<0.05, **P<0.01, ***P<0.001, using 2-way ANOVA. Data are expressed as 
mean ± SEM [427]. Experiments were performed by Marina Kone [427].  
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Appendix 5 
 
 Nptx2 expression is up-regulated in islets of Ins1LKB1KO mice  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Appendix 5 - Protein expression of Nptx2 is up-regulated in Ins1LKB1KO mice 
(A)IHC of pancreatic slices stained with insulin (green) and Nptx2 (red) and (B) density of Nptx2 in 
islets was significantly enhanced in Ins1LKB1KO versus WT pancreas. Scale bar = 50µm, n=6-7 
mice/genotype, *P<0.05 by unpaired t-test. Data are expressed as mean ± SEM [427]. Experiments 
were performed by Dr Marie-Sophie Nguyen-Tu [427].  
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Appendix 6 
 
Recombination in enteroendocrine L-cells was demonstrated by 
staining for RFP in GluLKB1KO mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RFP recombination in proglucagon-expressing cells and polyps 
IHC of frozen sections using an anti-RFP antibody of polyp, duodenum and colon of WT (M-P, Y-Zii), 
GluLKB1het (I-L, U-X) and GluLKB1KO mice (A-H, Q-T), brightfield, RFP, DAPI (nuclei localisation) and 
merged RFP/ DAPI images are shown. The insert in Zii shows an enlarged image of an RFP stained 
cell within a crypt. Experiments were performed by Dr Sagen Zac-Varghese [448]. 
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